Gene	Study of Origin	Sample ID	Cancer Type	Cancer Type Detailed	Protein Change	Annotation	Custom Driver	Custom Driver Tiers	Functional Impact	Mutation Type	Variant Type	Copy #	MS	VS	Center	Chromosome	Start Pos	End Pos	Ref	Var	HGVSg	HGVSc	Allele Freq (T)	Allele Freq (N)	Variant Reads	Ref Reads	Variant Reads (Normal)	Ref Reads (Normal)	# Mut in Sample	Exon	gnomAD	ClinVar	dbSNP	SIGNAL	Age at Diagnosis	Age At Specimen Acquisition	FLT3-ITD Allelic Ratio	ASXL1	Cause Of Death	CEBPA bi-allelic	Center ID	Cohort	Cumulative Chemo	Unique Regiments	No. Of Cumulative Regiments	Unique Treatment Stages	No. Of Unique Treatment Stages	Unique Treatment Types	No. Of Cumulative Treatments	Current Regimen	Current Stage	Disease Stage At Specimen Collection	Diagnosis At Inclusion	ELN2017	Ethnicity Category	FAB BLAST morphology	FLT3-ITD	De Novo	Relapsed	Transformed	Karyotype	Most Recent Treatment Duration	Most Recent Treatment Type	Diagnosis non AML, MDS, MPN	NPM1	Oncotree Code	Overall Survival (Months)	Overall Survival Status	Other Cytogenetics	Prior Non-Myeloid	Prior Malignancy Radiation	Type Non-Myeloid	Prior MDS	Prior MDS > Two Months	Prior MDS/MPN	Prior MDS/MPN >Two Months	Prior MPN	Prior MPN > Two Months	Race Category	Response Duration To Induction	Response To Induction	RUNX1	Number of Samples Per Patient	Sex	Somatic Status	Diagnosis MDS, MPN	Specific Diagnosis At Inclusion	Specimen Groups	Specimen Type	Surface Antigens Immunohistochemical Stains	Time Of Sample Collection, Relative To Inclusion	TMB (nonsynonymous)	TP53 Pathway	Treatment Type Induction	Used In Manuscript	Variant Summary
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2018_BA2950	Acute Myeloid Leukemia	AML with minimal differentiation	V581_E598dup	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608316	28608317	-	TCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACC	13:g.28608316_28608317insTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACC	ENST00000241453.7:c.1740_1793dup	0.08		14	156			6	14/24					44	47	1		Alive		6	Waves1+2	No	Radiation	1	Unknown	1	Targeted Therapy - Other	1	Radiation	Unknown	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	FALSE	FALSE	FALSE	46,XX[20]	14	Targeted Therapy - Other	FALSE	Negative	AML	40.47123287671233	0:LIVING	This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small precentage of tumor cells with chromosome abnormalities may not be detected due to the cells e	No	No		No	No	No	No	No	No	Black			RUNX1 (p.L98Pfs*40; 46.8%)	1	Female	UNMATCHED	FALSE	AML with minimal differentiation	Residual Disease|Post-Chemotherapy	Peripheral Blood	The blasts are positive for HLA-DR, CD34, CD117 (PARTIAL), CD13, CD(PARTIAL/DIM), CD33, TDT (DIM, SUBSET) and are negative for CD11b, CD14, CD64, MPO and all B and T cell markers. (Bone Marrow Immunophenotyping)	0	0.2			Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2022_BA2032	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							4	14/24					64	65	15.66666667		Dead-Disease		2	Waves1+2	Yes	Crenolanib|MEC, plexifor, GCSF|Sorafenib|7+3 (Cytarabine, Idarubicin) plus LBH|Clofarabine, Cytarabine	5	Salvage|Induction|Experimental|Re-induction	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Crenolanib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	FALSE	FALSE	FALSE	46,XX,t(3;11)(q21;p11.2),t(15;15)(q15;q22)[19]/46,XX,t(2;14)(q21;q11.2)[2]	124	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Positive	AML	14.958904109589042	1:DECEASED	nuc ish(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2 (5'MLL con 3'MLLx2)[198],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No		No	No	No	No	No	No		21	Refractory		1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood	CD7(partial +), CD15(partial +), CD33(bright +), CD34(partial +), CD45(+), and CD117(variably +). (80% population of variably-sized cells)	0	0.133333333		Standard Chemotherapy	Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2030_BA2336	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							4	14/24					73	73			Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|MiDAC|AC220 (Ambit)	3	Consolidation|Induction|Experimental	3	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	AC220 (Ambit)	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	FavorableOrIntermediate	NON-HISPANIC	M1	Positive	TRUE	FALSE	FALSE	46,XY[20]	30	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Positive	AML	13.972602739726028	1:DECEASED	normal	No	No		No	No	No	No	No	No	White	5	Complete Response		2	Male	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD11b, CD13, CD33, dim CD56, CD64, CD117, and dim MPO positive, CD34 negative, HLA-DR negative	1	0.1		Standard Chemotherapy	Yes	FLT3-ITD (Low Level)|NPM1
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2030_BA2708	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							5	14/24					73	74	0.923076923		Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|MiDAC|AC220 (Ambit)	3	Consolidation|Induction|Experimental	3	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	AC220 (Ambit)	Experimental	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M1	Positive	FALSE	TRUE	FALSE	46,XY[20]	30	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Positive	AML	13.972602739726028	1:DECEASED	normal	No	No		No	No	No	No	No	No	White	5	Complete Response		2	Male	UNMATCHED	FALSE	AML with mutated NPM1	Relapse|Post-Chemotherapy	Bone Marrow Aspirate	CD13, dim CD33, CD56, and CD117 positive	378	0.133333333		Standard Chemotherapy	No	NPM1
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2044_BA2277	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							16	14/24					72	72	0.639344262		Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Sorafenib|Ponatinib	3	Induction|Experimental	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Ponatinib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M1	Positive	FALSE	FALSE	FALSE	46,XX[5]	15	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Positive	AML	3.8794520547945206	1:DECEASED	Normal	No	No		No	No	No	No	No	No	White	10	Refractory		2	Female	MATCHED	FALSE	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Peripheral Blood		40	0.833333333		Standard Chemotherapy	No	CEBPA (p.E163*; MAF 40%)|FLT3-ITD (MAF 45%)|NPM1 (p.W288fs*12; MAF 32%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2044_BA2280	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							17	14/24					72	72			Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Sorafenib|Ponatinib	3	Induction|Experimental	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Ponatinib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M1	Positive	FALSE	FALSE	FALSE	46,XX[20]	15	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Positive	AML	3.8794520547945206	1:DECEASED	Normal	No	No		No	No	No	No	No	No	White	10	Refractory		2	Female	MATCHED	FALSE	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Peripheral Blood	CD13, CD33, CD38, partial CD56, partialCD64, CD117, dimCD123, and MPO	0	0.866666667		Standard Chemotherapy	Yes	CEBPA (p.E163*; MAF 39%)|FLT3-ITD (MAF 40%)|NPM1 (p.W288fs*12; MAF 40%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2047_BA2634	Acute Myeloid Leukemia	AML with maturation	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							24	14/24					74	75	1.941176471		Dead-Disease		3	Waves1+2	Yes	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Etoposide, Mitoxantrone	3	Hypomethylating/Low Dose Cytarabine|Salvage|Induction	3	Standard Chemotherapy	1	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial		M2	Positive	FALSE	FALSE	FALSE	46,XY,add(1)(p34),del(7)(q22),del(20)(q11.2)[20]	-1	Standard Chemotherapy	FALSE	Negative	AML	13.643835616438357	1:DECEASED	normal, no evidence of RUNX1T1/RUNX1 transloc or 11q23 or 16q22	No	No		No	No	No	No	No	No		-1	Refractory		1	Male	MATCHED	FALSE	AML with maturation	Residual Disease	Peripheral Blood	Increased CD34 positive myeloblasts, representing approximately 55% of the leukocytes	0	1.433333333		Standard Chemotherapy	Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2053_BA2673	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							5	14/24					70	70			Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|MiDAC|Quizartinib|Cytarabine, Methotrexate	4	Consolidation|Induction|Supportive/Palliative Care	3	Standard Chemotherapy|Intrathecal|Targeted Therapy - Other	3	Quizartinib	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	FavorableOrIntermediate	NON-HISPANIC	M1	Positive	TRUE	FALSE	FALSE	46,XX[20]	164	Targeted Therapy - Other	FALSE	Positive	AML	16.799999999999997	1:DECEASED	normal	No	No		No	No	No	No	No	No	White	6	Refractory		2	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Leukapheresis	CD13, CD33, dimCD45, CD56, partial CD117, MPO/positive	0	0.233333333		Standard Chemotherapy	Yes	FLT3-ITD|NPM1
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2053_BA2803	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							5	14/24					70	71			Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|MiDAC|Quizartinib|Cytarabine, Methotrexate	4	Consolidation|Induction|Supportive/Palliative Care	3	Standard Chemotherapy|Intrathecal|Targeted Therapy - Other	3	Quizartinib	Supportive/Palliative Care	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M1	Positive	FALSE	TRUE	FALSE	46,XX[20]	164	Targeted Therapy - Other	FALSE	Positive	AML	16.799999999999997	1:DECEASED	normal	No	No		No	No	No	No	No	No	White	6	Refractory		2	Female	UNMATCHED	FALSE	AML with mutated NPM1	Relapse|Post-Chemotherapy	Bone Marrow Aspirate	CD13, CD33, CD38, CD56, CD117, and MPO positive	337	0.2		Standard Chemotherapy	No	FLT3-ITD|NPM1
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2056_BA2292	Acute Myeloid Leukemia	Therapy-related myeloid neoplasms	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							12	14/24					69	70	1.222222222		Alive		5	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Azacitidine, Lenalidomide|Rituximab	3	Induction|Experimental	2	Standard Chemotherapy|Targeted Therapy - Other	2	Rituximab	Experimental	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial		M6a	Positive	FALSE	FALSE	TRUE	46,XY[18]	-1	Targeted Therapy - Other	FALSE	Negative	AML	14.926027397260274	0:LIVING	Normal	Yes	Yes	Squamous cell carcinoma	Yes	Yes	No	No	No	No		-1	Unknown		1	Male	MATCHED	FALSE	Therapy-related myeloid neoplasms	Post-Chemotherapy	Bone Marrow Aspirate		55	0.633333333		Standard Chemotherapy	No	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2059_BA2045	Acute Myeloid Leukemia	AML without maturation	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							5	14/24					71	72	0.923076923		Dead-Disease		1	Waves1+2	Yes	5+2 (Cytarabine, Idarubicin)|Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Hydroxyurea	5	Consolidation|Induction|Experimental|Re-induction|Supportive/Palliative Care	5	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	3	Hydroxyurea	Supportive/Palliative Care	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC	M1	Positive	FALSE	FALSE	FALSE	46,XY[20]	9	Supportive/Palliative Care	FALSE	Negative	AML	10.158904109589042	1:DECEASED	Normal	No	No		No	No	No	No	No	No	Unknown	6	Refractory	RUNX1 (p.Q283*; 51.5%)	3	Male	UNMATCHED	FALSE	AML without maturation	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	dim/partial CD7, CD13, CD33, CD34, variable CD38, CD58,variable CD117, CD123, and HLA-DR positive	297	0.266666667		Standard Chemotherapy	No	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2059_BA2831	Acute Myeloid Leukemia	AML without maturation	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							6	14/24					71	71	0.587301587		Dead-Disease		1	Waves1+2	Yes	5+2 (Cytarabine, Idarubicin)|Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Hydroxyurea	5	Consolidation|Induction|Experimental|Re-induction|Supportive/Palliative Care	5	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	3	Hydroxyurea	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	HISPANIC	M1	Positive	TRUE	FALSE	FALSE	46,XY[20]	9	Supportive/Palliative Care	FALSE	Negative	AML	10.158904109589042	1:DECEASED	Normal	No	No		No	No	No	No	No	No	Unknown	6	Refractory	RUNX1 (p.Q283*; 37.0%)|RUNX1 (p.M236Nfs*25; 20.0%)	3	Male	UNMATCHED	FALSE	AML without maturation	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD13, CD34, CD38, CD117, CD123, HLA-DR	0	0.3		Standard Chemotherapy	Yes	FLT3-ITD
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2059_BA2847	Acute Myeloid Leukemia	AML without maturation	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							6	14/24					71	71	0.886792453		Dead-Disease		1	Waves1+2	Yes	5+2 (Cytarabine, Idarubicin)|Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Hydroxyurea	5	Consolidation|Induction|Experimental|Re-induction|Supportive/Palliative Care	5	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	3	Hydroxyurea	Supportive/Palliative Care	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC	M1	Positive	FALSE	FALSE	FALSE	46,XY[20]	9	Supportive/Palliative Care	FALSE	Negative	AML	10.158904109589042	1:DECEASED	Normal	No	No		No	No	No	No	No	No	Unknown	6	Refractory	RUNX1 (p.Q283*; 40.7%)	3	Male	UNMATCHED	FALSE	AML without maturation	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	dim/partial CD7, CD13, CD34, CD38, CD58, CD117, CD123,and HLA-DR positive	262	0.3		Standard Chemotherapy	No	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2061_BA2762	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							9	14/24					22	22	0.666666667		Alive		2	Waves1+2	Yes	Fludarabine, Melphalan|Crenolanib|7+3 (Cytarabine, Idarubicin) plus Crenolanib	3	Allogeneic - Sibling|Induction|Experimental	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Fludarabine, Melphalan	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate			Positive	TRUE	FALSE	FALSE	46,XX[20]	-1	Bone Marrow Transplant	FALSE	Positive	AML	19.824657534246576	0:LIVING	nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con3'CBFBx2)[200]	No	No		No	No	No	No	No	No	White	39	Complete Response		1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD2(-), CD4(partial dim +), CD7(variably +), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(variably +), CD34(partial+), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(-), CD117(+), HLA-DR(partial +).	0	0.3		Standard Chemotherapy	Yes	FLT3-ITD (K602_W603INSCEYDLK; MAF 33.0%)|NPM1 (K292FS*6+; MFA 35.0%)|TCL1A (E54FS*28; MAF 44.0%)|WT1 (A382FS*4; MAF 40.0%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2065_BA2020	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							12	14/24					51	51			Alive		3	Waves1+2	Yes	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling|Consolidation|Induction	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	FavorableOrIntermediate		M4	Positive	TRUE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	FALSE	Positive	AML	25.05205479452055	0:LIVING	Normal	No	No		No	No	No	No	No	No		-1	Refractory		1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, partial CD15, CD33, CD117,  myeloperoxidase, and partial HLA-DR (atypical cells with dim CD45 - 45% of leukocytes) | CD13,  bright CD33, and bright CD64 (Monocytic (19% of leukocytes)) | CD13, CD33, and CD64, with  a left shift (increased percentage	0	0.533333333		Standard Chemotherapy	Yes	FLT3-ITD (c.1775_1816dup; MAF 3%)|IDH2 (R140Q; MAF 42.3%)|NPM1 (c.860_863dup; MAF 14.5%)|PTPN11 (c.1507G>A; MAF 4%)|PTPN11 (c.1508G>A; MAF 15.4%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2069_BA2932	Acute Myeloid Leukemia	AML without maturation	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							12	14/24					29	29			Alive		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy	1	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	IntermediateOrAdverse	NON-HISPANIC	M1	Positive	TRUE	FALSE	FALSE	46,XX[20]	-1	Standard Chemotherapy	FALSE	Negative	AML	78.34520547945205	0:LIVING	Normal	No	No		No	No	No	No	No	No	White	24	Complete Response		1	Female	MATCHED	FALSE	AML without maturation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim CD2, dim CD7, CD13, dim CD19, dim CD20,      CD33, partial CD34, variable CD38, dim CD64, CD117, CD123, and HLA-DR      positive.	0	0.4		Standard Chemotherapy	Yes	FLT3-ITD (MAF 50%)|MLL (PTD)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2071_BA2007	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							8	14/24					71	71			Dead-Disease		4	Waves1+2	Yes	Decitabine, Midostaurin	1	Induction	1	Standard Chemotherapy	1	Decitabine, Midostaurin	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	FavorableOrIntermediate			Positive	TRUE	FALSE	FALSE	46,XY[20]	-1	Standard Chemotherapy	FALSE	Positive	AML	4.175342465753425	1:DECEASED		No	No		No	No	No	No	No	No		-1	Refractory		1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD34+, EXPRESSING CD13, CD33,MPO, AND HLA-DR, WITH ABERRANT COEXPRESSION OF CD15 AND CD117, AND PARTIAL LOSS OF CD38	0	0.4		Standard Chemotherapy	Yes	FLT3-ITD|NPM1
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2077_BA2534	Acute Myeloid Leukemia	Therapy-related myeloid neoplasms	A627_T628insETGSSDNEYFYVDFREYEYDLKWEFPRENLEFGKNGMCQMFLQHFFSIGKSLKCTYSPFVFAGKVLGSGAFGKVMNA	OncoKB: Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608313	28608314	-	TCGGCGTTCATCACTTTTCCAAAAGCACCTGATCCTAGTACCTTCCCTGCAAAGACAAATGGTGAGTACGTGCATTTTAAAGATTTTCCAATGGAAAAGAAATGCTGCAGAAACATTTGGCACATTCCATTCTTACCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTC	13:g.28608313_28608314insTCGGCGTTCATCACTTTTCCAAAAGCACCTGATCCTAGTACCTTCCCTGCAAAGACAAATGGTGAGTACGTGCATTTTAAAGATTTTCCAATGGAAAAGAAATGCTGCAGAAACATTTGGCACATTCCATTCTTACCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTC	ENST00000241453.7:c.1880_1881insCGAGACCGGCTCCTCAGATAATGAGTACTTCTACGTTGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTTTGGTAAGAATGGAATGTGCCAAATGTTTCTGCAGCATTTCTTTTCCATTGGAAAATCTTTAAAATGCACGTACTCACCATTTGTCTTTGCAGGGAAGGTACTAGGATCAGGTGCTTTTGGAAAAGTGATGAACGC	0.21		57	209			25	14/24					71	72	0.315789474		Dead-Disease		3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|Hydroxyurea|Mitoxantrone	5	Hypomethylating/Low Dose Cytarabine|Induction|Re-induction|Supportive/Palliative Care	4	Standard Chemotherapy|Supportive/Palliative Care	2	Hydroxyurea	Supportive/Palliative Care	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	FALSE	FALSE	FALSE	46,XX,del(7)(q22q36)[18]/46,sl,t(1;10)(p13;q24)[2]	-1	Supportive/Palliative Care	FALSE	Negative	AML	9.205479452054794	1:DECEASED	- 3 copies of the MECOM locus at 3q26.2, suggestive of a  rearrangement or gain of this locus, in 156/200 (78.0  percent) cells scored.  - deletion 7q31 involving the D7S486 locus in 162/200 (81.0  percent) cells scored.	Yes	No	Follicular lymphoma	No	No	No	No	No	No		-1	Refractory		2	Female	MATCHED	FALSE	Therapy-related myeloid neoplasms	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate		249	1.366666667		Standard Chemotherapy	No	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2079_BA2735	Acute Myeloid Leukemia	AML with mutated NPM1	F612_G613insDVDFREYEYDLKWEFPRENLEF	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608284	28608285	-	CAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGT	13:g.28608284_28608285insCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGT	ENST00000241453.7:c.1772_1837dup	0.20		38	151			43	14/24					62	64	5.666666667		Dead-Unknown		2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Crenolanib|Clofarabine, Cytarabine|Busulfan, Cyclophosphamide	6	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Crenolanib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	FALSE	FALSE	FALSE	45,XY,der(12;16)(q10;p10)[2]/46,XY[18]	141	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Positive	AML	18.673972602739727	1:DECEASED	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2) [200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[31/200]	No	No		No	No	No	No	No	No		24	Complete Response		2	Male	MATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Post-Transplant|Residual Disease	Peripheral Blood		254	2.133333333		Standard Chemotherapy	No	CCND3 (P203S; MAF unlisted)|CHEK2 (T367fs*15; MAF unlisted)|DNMT3A (R882H; MAF unlisted)|FLT3-ITD|NPM1 (W288fs*10+; MAF unlisted)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2079_BA3029	Acute Myeloid Leukemia	AML with mutated NPM1	F612_G613insDVDFREYEYDLKWEFPRENLEF	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608284	28608285	-	CAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGT	13:g.28608284_28608285insCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGT	ENST00000241453.7:c.1772_1837dup	0.17		28	136			18	14/24					62	63	10.11111111		Dead-Unknown		2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Crenolanib|Clofarabine, Cytarabine|Busulfan, Cyclophosphamide	6	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Crenolanib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	FALSE	FALSE	FALSE	46,XY	141	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Positive	AML	18.673972602739727	1:DECEASED		No	No		No	No	No	No	No	No		24	Complete Response		2	Male	MATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood	CD2(-), CD4(dim +), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(variably +), CD16(-), CD33(bright +), CD34(-), CD36(-), CD38(+), CD45(moderately +), CD56(-), CD64 (partial +), CD117(variably +), HLA-DR(-), MPO(+), TdT(-).	0	0.966666667		Standard Chemotherapy	Yes	CCND3 (Foundation, P203S; MAF 8%)|CHEK2 (Foundation; T367fs*15; MAF 9%)|DNMT3A (Foundation, R882H; MAF 9%)|FLT3 (Foundation, Y591_V592INSVDFREYEYDLKWEFPRENLEFD; MAF 13%)|NPM1 (Foundation; W288fs*10+;MAF 8%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2090_BA2911	Acute Myeloid Leukemia	Therapy-related myeloid neoplasms	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							3	14/24					24	24			Dead-Disease		1	Waves1+2	Yes	AG-120|ATRA (Tretinoin)|HiDAC|3+7 (Cytarabine, Daunorubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|5+2 (Ara-C, Daunorubicin)	6	Consolidation|Salvage|Induction|Experimental|Re-induction	5	Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s)	3	AG-120	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC		Positive	FALSE	FALSE	FALSE		77	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Positive	AML	28.306849315068497	1:DECEASED	normal	Yes	No	Hodgkin Lymphoma	No	No	No	No	No	No	White	6	Complete Response		1	Female	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Leukapheresis	CD13, CD33, CD38, CD58, CD117 and CD123 positive.	0	0.1		Standard Chemotherapy	Yes	FLT3 (p.V592G; MAF 6%)|FLT3-ITD ((57 bp in-frame insertion); MAF 3% )|IDH1 (p.W288fs*12; MAF 50%)|NPM1 (p.W288fs*12; MAF 50% )
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2100_BA2705	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							6	14/24					39	40	0.923076923		Alive		5	Waves1+2	Yes	Unknown|GCLAC (GCSF, Clofarabine & Cytarabine)	2	Induction|Re-induction	2	Standard Chemotherapy	1	GCLAC (GCSF, Clofarabine & Cytarabine)	Re-induction	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	FALSE	FALSE	FALSE	46,XY[15]	-1	Standard Chemotherapy	FALSE	Positive	AML	2.695890410958904	0:LIVING	Negative	No	No		No	No	No	No	No	No	White	-1	UNKNOWN		1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Peripheral Blood	Positive (CD7, CD11b, CD13, CD33, dim CD34, CD38, dim CD45, CD117, HLA-DR)	0	0.133333333		Standard Chemotherapy	Yes	FLT3-ITD (ITD (39bp ins); VAF 39%)|NPM1 (c.859_860insTCTG; p.W288fs)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2107_BA2839	Acute Myeloid Leukemia	AML with myelodysplasia-related changes	Y597_E598insDPVTGSSDNEYFYVDFREY	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608315	28608316	-	GGGATCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCAC	13:g.28608315_28608316insGGGATCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCAC	ENST00000241453.7:c.1793_1794insTCCCGTGACCGGCTCCTCAGATAATGAGTACTTCTACGTTGATTTCAGAGAATATGA	0.16		19	102			9	14/24					44	44	0.960784314		Dead-Disease		2	Waves1+2	No		0		0		0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse			Positive	FALSE	FALSE	TRUE	47,XY,+21[19]/46,XY[1]		None	FALSE	Negative	AML	0.1972602739726027	1:DECEASED	nuc ish(RUNX1T1x2,RUNX1x3)[140/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML, RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No		Yes	Yes	No	No	No	No	White			RUNX1 (p.E223*; 64.8%)	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(-­), CD7(dim + to -­), CD11b(-­), CD13(+), CD14(-­), CD15 (partial +), CD33(bright +), CD34(partial +), CD36(-­), CD38(variably +), CD45(+), CD56(-­), CD64(partial +), CD117(+), HLA-­DR(variably +)	0	0.433333333			Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2122_BA2024	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							8	14/24					48	48			Dead-Disease		1	Waves1+2	Yes	ADE (Cytarabine, Daunorubicin & Etoposide)	1	Induction	1	Standard Chemotherapy	1	ADE (Cytarabine, Daunorubicin & Etoposide)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	FavorableOrIntermediate	NON-HISPANIC		Positive	TRUE	FALSE	FALSE	46,XY[20]	7	Standard Chemotherapy	FALSE	Positive	AML	1.084931506849315	1:DECEASED	Normal	No	No		No	No	No	No	No	No	White	7	Unknown		1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD33, CD117 positive, negative for CD34 and HLA-DR	0	0.266666667		Standard Chemotherapy	Yes	FLT3-ITD (MAF 33%)|IDH2 (p.R140Q; MAF 40%)|NPM1 (p.W288fs*12; MAF 40%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2131_BA2590	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							6	14/24					55	55	1		Dead-Disease		5	Both	Yes	Midostaurin|Fludarabine, Cyclophosphamide, Thiotepa, TBI|7+3 (Cytarabine, Idarubicin) plus Enasidenib	3	Induction|Double Umbilical Cord Blood Transplant (DUCBT)|Maintenance	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Midostaurin	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate			Positive	TRUE	FALSE	FALSE	46,XY[19]	44	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Positive	AML	9.271232876712329	1:DECEASED	Normal	No	No		No	No	No	No	No	No		-1	Complete Response		1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Negative (CD19, CD22, Cyt CD3, CD7, CD56, CD11b, CD13, CD14, CD34, CD64, CD117, TdT) | Positive (CD38, Cyt CD79a, CD15, CD33, MPO) | Dim (CD45, HLA-DR)	0	0.233333333		Standard Chemotherapy	No	FLT3 (c.1811_1812insl8; p.E604_P605insYDLKWE; MAF 32%)|IDH1 (c.395G>A; p.R132H; 44%)|NPM1 (c.863_864insTCTG; p.W288fs; MAF 42%)|SRSF2 (c.284_307del; p.P95_R102del; MAF 45%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2133_BA2675	Acute Myeloid Leukemia	AML without maturation	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							2	14/24					10	10			Alive	mono	1	Waves1+2	Yes	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine|Unknown|MiDAC	4	Unknown|Induction|Re-induction	3	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Other	4	Unknown	Unknown	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	IntermediateOrAdverse	NON-HISPANIC	M2	Positive	TRUE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	FALSE	Negative	AML	68.87671232876713	0:LIVING		No	No		No	No	No	No	No	No	White	10	Refractory		1	Male	UNMATCHED	FALSE	AML without maturation	Initial Acute Leukemia Diagnosis	Peripheral Blood	variable CD7, dim CD11b, CD13, CD33, partial CD34, dim CD64, CD117, CD123, HLA-DR, and dim MPO positive	0	0.066666667		Standard Chemotherapy	Yes	CEBPA (p.R142fs*19; MAF 52%)|FLT3-ITD (MAF 48%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2144_BA2902	Acute Myeloid Leukemia	AML with mutated NPM1	W603_E604insASSDNEYFYVDFREYEYDLKW	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608306	28608307	-	TGCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGA	13:g.28608306_28608307insTGCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGA	ENST00000241453.7:c.1810_1811insCATCCTCAGATAATGAGTACTTCTACGTTGATTTCAGAGAATATGAATATGATCTCAAATGGG	0.34		40	76			16	14/24					83	83	1.083333333		Dead-Disease		4	Waves1+2	Yes	Azacitidine|Decitabine, Midostaurin	2	Hypomethylating/Low Dose Cytarabine|Induction	2	Standard Chemotherapy	1	Decitabine, Midostaurin	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate			Positive	FALSE	FALSE	TRUE	46,XY[13]	-1	Standard Chemotherapy	FALSE	Positive	AML	1.5452054794520547	1:DECEASED		No	No		No	No	Yes	Yes	No	No		-1	Refractory		1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	ABNORMAL CD34-NEGATIVE BLAST POPULATION, 65%, EXPRESSING MYELOPEROXIDASE, CD117, CD13, CD33, AND CD56, AND SHOWING PARTIAL EXPRESSION OF CD38, CD64(DIM), CD11c(DIM), CD4(DIM) AND HLA-DR	1	0.8		Standard Chemotherapy	Yes	FLT3-ITD|NPM1
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2147_BA2181	Acute Myeloid Leukemia	AML with myelodysplasia-related changes	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							16	14/24					70	70	1.222222222		Alive		3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse			Positive	TRUE	FALSE	FALSE	46,XX,del(7)(q22q36)[11]/46,XX[2]	-1	Bone Marrow Transplant	FALSE	Negative	AML	26.202739726027396	0:LIVING		No	No		No	No	No	No	No	No		-1	Complete Response	RUNX1 (p.R162S; 96.2%)	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD34, dim CD45, partial CD117, HLA-DR, and minimal (3%) myeloperoxidase	0	0.766666667		Standard Chemotherapy	Yes	DNMT3A (c.2645G>A; MAF 41.8%)|FLT3-ITD (c.1797delins22; MAF 19%)|IDH1 (c.394C>T; MAF 46.7%)|RUNX1 (c.486G>C; MAF 89.5%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2150_BA2620	Acute Myeloid Leukemia	AML with myelodysplasia-related changes	X581_X581insVTGSSDNEYFYVDFREYEYDLKWEFPRENLEFGKNR	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608313	28608314	-	CTATTCTTACCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTC	13:g.28608313_28608314insCTATTCTTACCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTC	ENST00000241453.7:c.1837+8_1837+9insAGGACCGGCTCCTCAGATAATGAGTACTTCTACGTTGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTTTGGTAAGAAT	0.32		69	149			15	14/24					65	65		ASXL1 (p.R549Pfs*2; 42.0%)	Alive		1	Waves1+2	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC	3	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC		Positive	TRUE	FALSE	FALSE		0	Bone Marrow Transplant	FALSE	Negative	AML	79.75890410958904	0:LIVING		No	No		No	No	No	No	No	No	White	6	Complete Response		1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD7, minor subset CD11b, CD13, minor subset CD14,      dim CD33, CD34, CD38, CD58, minor subset CD64, CD117, CD123, HLA-DR, subset      myeloperoxidase positive	0	0.766666667		Standard Chemotherapy	Yes	FLT3-ITD (MAF 45%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2157_BA2452	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							6	14/24					34	36	0.960784314		Dead-Unknown		1	Both	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	4	Consolidation|Salvage|Induction|Re-induction	4	Standard Chemotherapy	1	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M4	Positive	FALSE	FALSE	FALSE	46,XY,add(17)(p13)[19]/46,XY[1]	43	Standard Chemotherapy	FALSE	Positive	AML	19.56164383561644	1:DECEASED	Normal	No	No		No	No	No	No	No	No	White	6	Complete Response		1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	partial CD7, CD13, CD33, CD38, dim CD45, dimCD58, CD117, CD123, and HLA-DR	574	0.233333333		Standard Chemotherapy	No	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2164_BA2916	Acute Myeloid Leukemia	AML with mutated NPM1	V579_L601dup	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608322	28608323	-	AGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGTACC	13:g.28608322_28608323insAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGTACC	ENST00000241453.7:c.1734_1802dup	0.29		51	125			5	14/24					65	65	1.272727273		Dead-Unknown		1	Waves1+2	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|Quizartinib|Methotrexate	5	Consolidation|Induction|Experimental|CNS|Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Kinase Inhibitor(s)	4	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M5	Positive	FALSE	FALSE	TRUE	46,XX[20]	-1	Bone Marrow Transplant	FALSE	Positive	AML	12.723287671232876	1:DECEASED	normal	No	No		Yes	Yes	No	No	No	No	White	5	Complete Response		2	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD7, CD11b, CD13, CD33, variable CD34, dim CD64, CD117, CD123, HLA-DR and MPO positive	0	0.2		Standard Chemotherapy	Yes	FLT3-ITD|NPM1
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2164_BA3035	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							6	14/24					65	66	0.785714286		Dead-Unknown		1	Waves1+2	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|Quizartinib|Methotrexate	5	Consolidation|Induction|Experimental|CNS|Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Kinase Inhibitor(s)	4	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NOS	Positive	FALSE	FALSE	TRUE	46,XX,t(1;15)(p32;q15)[19]/46,XX[1]	-1	Bone Marrow Transplant	FALSE	Positive	AML	12.723287671232876	1:DECEASED	normal	No	No		Yes	Yes	No	No	No	No	White	5	Complete Response		2	Female	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	CD7, CD13, CD33, partial CD34, CD38, dim CD45, CD58, CD71, CD117, CD123, and HLA-DR-positive	151	0.3		Standard Chemotherapy	No	FLT3-ITD|NPM1 (Insertion mutation detected in a minority of cells )
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2169_BA2756	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							11	14/24					69	69			Dead-Disease		4	Waves1+2	Yes	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine, Midostaurin|FLAG-IDA, Gemtuzumab|MEC, Lenalidomide	4	Salvage|Induction|Re-induction	3	Standard Chemotherapy	1	MEC, Lenalidomide	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	FALSE	FALSE	FALSE	46,XY[22]	5	Standard Chemotherapy	FALSE	Negative	AML	9.994520547945205	1:DECEASED		No	No		No	No	No	No	No	No		79	Refractory		2	Male	MATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate		0	0.6		Standard Chemotherapy	Yes	FLT3-ITD|IDH1
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2178_BA2843	Acute Myeloid Leukemia	AML with minimal differentiation	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							15	14/24					84	84	0.851851852		Dead-Disease		4	Waves1+2	Yes	Decitabine, Midostaurin	1	Induction	1	Standard Chemotherapy	1	Decitabine, Midostaurin	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse		M0	Positive	TRUE	FALSE	FALSE	46,XY[20]	-1	Standard Chemotherapy	FALSE	Negative	AML	2.202739726027397	1:DECEASED		No	No		No	No	No	No	No	No		-1	Refractory		1	Male	MATCHED	FALSE	AML with minimal differentiation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD34, CD38, CD117, CD13, CD4, HLA-DR, AND TDT	0	0.633333333		Standard Chemotherapy	Yes	FLT3-ITD
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2181_BA2240	Acute Myeloid Leukemia	AML with mutated NPM1	E573_D593dup	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608339	28608340	-	ATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGTACCATCTGTAGCTGGCTTTC	13:g.28608339_28608340insATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGTACCATCTGTAGCTGGCTTTC	ENST00000241453.7:c.1717_1779dup	0.41		133	195			3	14/24					61	61	9		Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Sorafenib|Hydroxyurea	5	Consolidation|Induction|Experimental|Re-induction	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Sorafenib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC		Positive	FALSE	FALSE	FALSE		61	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Positive	AML	8.646575342465754	1:DECEASED		No	No		No	No	No	No	No	No	White	7	Complete Response		2	Female	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood		0	0.1		Standard Chemotherapy	Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2181_BA2613	Acute Myeloid Leukemia	AML with mutated NPM1	E573_D593dup	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608339	28608340	-	ATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGTACCATCTGTAGCTGGCTTTC	13:g.28608339_28608340insATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGTACCATCTGTAGCTGGCTTTC	ENST00000241453.7:c.1717_1779dup	0.42		101	138			3	14/24					61	61			Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Sorafenib|Hydroxyurea	5	Consolidation|Induction|Experimental|Re-induction	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Sorafenib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC		Positive	FALSE	FALSE	FALSE	46,XX[19]	61	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Positive	AML	8.646575342465754	1:DECEASED	Normal	No	No		No	No	No	No	No	No	White	7	Complete Response		2	Female	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood	CD7, CD13, CD33, partial CD34, partial CD64, CD117, CD123, HLA-DR and partial MPO+	9	0.1		Standard Chemotherapy	No	DNMT3A (p.P777S; MAF 90%)|FLT3-ITD (MAF 75%)|IDH1 (p.R132H; MAF 45%)|NPM1 (p.W288fs*12; MAF 40%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2201_BA2097	Acute Myeloid Leukemia	AML with myelodysplasia-related changes	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							18	14/24					77	77	0.612903226		Alive		4	Waves1+2	Yes	Azacitidine, Sorafenib|Decitabine, Midostaurin	2	Induction|Re-induction	2	Standard Chemotherapy	1	Azacitidine, Sorafenib	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse			Positive	FALSE	FALSE	TRUE	46,XY[20]	-1	Standard Chemotherapy	FALSE	Negative	AML	9.468493150684932	0:LIVING	CD15, AND PARTIAL CD56 -7/DEL(7q) TRISOMY #8MLL GENE REARRANGEMENTDEL(20q)	No	No		No	No	Yes	Yes	No	No	White	165	Refractory		2	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	ABNORMAL CD34+ BLAST POPULATION EXPRESSING ABERRANT CD7,CD4, AND CD2, AND CD38, CD10, CD22, CD11C, HLA-DR, CD117,CD13, CD33,CD15, AND PARTIAL CD56	0	0.866666667		Standard Chemotherapy	Yes	FLT3-ITD
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2201_BA2925	Acute Myeloid Leukemia	AML with myelodysplasia-related changes	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							12	14/24					77	77			Alive		4	Waves1+2	Yes	Azacitidine, Sorafenib|Decitabine, Midostaurin	2	Induction|Re-induction	2	Standard Chemotherapy	1	Azacitidine, Sorafenib	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	IntermediateOrAdverse			Positive	FALSE	FALSE	TRUE	46,XY[20]	-1	Standard Chemotherapy	FALSE	Negative	AML	9.468493150684932	0:LIVING	CD15, AND PARTIAL CD56 -7/DEL(7q) TRISOMY #8MLL GENE REARRANGEMENTDEL(20q)	No	No		No	No	Yes	Yes	No	No	White	165	Refractory		2	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	ABNORMAL CD34+ BLAST POPULATION EXPRESSING ABERRANT CD7,CD4, AND CD2, AND CD38, CD10, CD22, CD11C, HLA-DR, CD117,CD13, CD33,CD15, AND PARTIAL CD56	0	0.633333333		Standard Chemotherapy	No	FLT3-ITD
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2203_BA2552	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							4	14/24					67	69	0.666666667		Dead-Unknown		6	Waves1+2	Yes	AG-120|7+3 (Cytarabine, Idarubicin)|Cytarabine|Decitabine|ME (Etoposide, Mitoxantrone)|Fludarabine, Melphalan, ATG	6	Consolidation|Salvage|Induction|Experimental|Post-Transplant Relapse|Allogeneic - Matched Unrelated Donor	6	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	3	Cytarabine	Post-Transplant Relapse	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC		Positive	FALSE	TRUE	FALSE		3	Standard Chemotherapy	FALSE	Positive	AML	31.035616438356165	1:DECEASED		No	No		No	No	No	No	No	No	White	6	Complete Response		1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Relapse|Post-Chemotherapy|Post-Transplant	Peripheral Blood		0	0.133333333		Standard Chemotherapy	Yes	IDH1 (p.R132S, MAF 46%)|NPM1 (p.W288Cfs*12, MAF 57%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2206_BA2813	Acute Myeloid Leukemia	AML with mutated NPM1	M578_E598dup	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608324	28608325	-	TTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGTACCAT	13:g.28608324_28608325insTTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGTACCAT	ENST00000241453.7:c.1732_1794dup	0.19		29	126			16	14/24					64	64	0.428571429		Alive		5	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Fludarabine, Cyclophosphamide, Thiotepa, TBI	2	Induction|Double Umbilical Cord Blood Transplant (DUCBT)	2	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable			Positive	FALSE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	FALSE	Positive	AML	20.90958904109589	0:LIVING	Normal	Yes	No	Prostate Cancer	No	No	No	No	No	No	White	41	Complete Response		1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Positive (The large majority of cells (around 90%) are an abnormal population of myeloblasts. The myeloblasts are positive for CD33, CD13, HLA-DR, and CD117, and show uniform aberrant expression of CD7. A subset of the blasts are positive for myeloperoxid	0	0.866666667		Standard Chemotherapy	Yes	DNMT3A (c.2645G>A; p.R882H)|FLT3-ITD (FLT3-ITD 63bp insertion)|NPM1 (c.859_860insTCTG; p.W288fs)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2209_BA2764	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							3	14/24					77	79			Alive		7	Waves1+2	Yes	Decitabine	1	Induction	1	Standard Chemotherapy	1	Decitabine	Induction	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	FALSE	FALSE	FALSE		-1	Standard Chemotherapy	FALSE	Positive	AML	16.43835616438356	0:LIVING	Translocation between the long arm of chromosome 3 and short arm of chromosome 12.	No	No		No	No	No	No	No	No	White	-1	Complete Response		1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy	Bone Marrow Aspirate		0	0.066666667		Standard Chemotherapy	No	FLT3-ITD|NPM1
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2224_BA3099	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							3	14/24					52	53	13.28571429		Dead-Disease		1	Waves3+4	Yes	MiDAC|Idarubicin and Cytarabine|FLAG-IDA plus Midostaurin|Azacitidine, Midostaurin, Ponatinib|7+3 (Cytarabine, Idarubicin) plus Dasatinib	5	Consolidation|Salvage|Induction|Maintenance	4	Standard Chemotherapy	1	Idarubicin and Cytarabine	Salvage	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M5	Positive	FALSE	TRUE	FALSE	46,X,t(X;7)(q21;q32)[20]	3	Standard Chemotherapy	FALSE	Positive	AML	18.378082191780823	1:DECEASED	Normal	No	No		No	No	No	No	No	No	White	-1	Complete Response		3	Female	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Relapse	Peripheral Blood	variable CD7, CD13, CD33, partial CD34, CD38, CD58,  CD117, CD123 and HLA-DR  (Immunophenotypic shift is noted from the prior leukemic blast  population.)	383	0.1		Standard Chemotherapy	No	DNMT3A (p.R882C; MAF 46%)|FLT3-ITD (MAF ~90%)|NPM1 (p.W288fs*12; MAF 44%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2225_BA2206	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							26	14/24					46	47			Alive		4	Waves1+2	Yes	HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|SWOG S1203 (7+3 +/- Vorinostat)|MEC, Lenalidomide|Etoposide, Cytarabine	5	Consolidation|Salvage|Induction|Re-induction	4	Standard Chemotherapy	1	GCLAC (GCSF, Clofarabine & Cytarabine)	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M4	Positive	FALSE	FALSE	FALSE	46,XY[20]	-1	Standard Chemotherapy	FALSE	Positive	AML	28.734246575342468	0:LIVING	Normal	No	No		No	No	No	No	No	No	White	6	Complete Response		2	Male	MATCHED	FALSE	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	CD7, CD13, CD33, partial CD34, CD117 and dim CD123+	375	1.3		Standard Chemotherapy	No	DNMT3A (p.R882C; MAF 47%)|DNMT3A (p.V778M; MAF 48% )|FLT3-ITD (MAF ~3-4%)|IDH1 (p.R132C; MAF 47%)|NPM1 (p.W288fs*9; MAF 50%)|NRAS (p.G13D; MAF 17%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2232_BA2744	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							5	14/24					76	76	0.176470588		Dead-Unknown		1	Waves1+2	No	Hydroxyurea	1	Supportive/Palliative Care	1	Supportive/Palliative Care	1	Hydroxyurea	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M1	Positive	FALSE	FALSE	TRUE	46,XY[20]	7	Supportive/Palliative Care	FALSE	Positive	AML	0.263013698630137	1:DECEASED	Normal	No	No		No	No	Yes	Yes	No	No	White				1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Leukapheresis	CD13, CD33, CD38, variable CD56, CD58, CD117 and MPO positive	0	0.166666667			Yes	FLT3-ITD (MAF 45%)|NPM1 (p.W288fs*12; MAF 50%)|TET2 (p.W564*; MAF 50%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2238_BA2249	Acute Myeloid Leukemia	AML with mutated NPM1	P606_R607insSSSDNEYFYVDFREYEYDLKWEFP	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608307	28608308	-	CTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAG	13:g.28608307_28608308insCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAG	ENST00000241453.7:c.1749_1820dup	0.40		55	83			20	14/24					53	54	9		Dead-Disease		1	Waves1+2	Yes	HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea	4	Induction|Experimental|Re-induction|Maintenance	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Sorafenib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC		Positive	FALSE	FALSE	FALSE	46,XY,t(7;17)(q22;q21)[3]/46,XY,t(2;4)(q33;q25),del(9)(q2?1;q3?2),add(17)(q21)[cp3]/46,XY,t(1;2)(q31;p25),inv(9)(q3?1q34)[2]/46,XY,t(13;14)(q14;q32)[cp2]/46,XY,add(3)(p24)[1]/46,XY[3]	49	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Positive	AML	5.523287671232877	1:DECEASED	normal	No	No		No	No	No	No	No	No	White	6	Refractory		4	Male	MATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood	dimCD7, CD13, dimCD11b, CD33, variable CD34, CD58,  CD117, CD123, and HLA-DR positive	63	1.1		Standard Chemotherapy	No	DNMT3A (p.R882C; MAF 45%)|FLT3-D835 (p.D835H; MAF 15%)|FLT3-ITD (MAF 78%)|NPM1 (p.W288fs*12; MAF 40%)|TET2 (p.Q548*; MAF 45%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2238_BA2579	Acute Myeloid Leukemia	AML with mutated NPM1	P606_R607insSSSDNEYFYVDFREYEYDLKWEFP	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608307	28608308	-	CTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAG	13:g.28608307_28608308insCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAG	ENST00000241453.7:c.1749_1820dup	0.06		9	148			2	14/24					53	54			Dead-Disease		1	Waves1+2	Yes	HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea	4	Induction|Experimental|Re-induction|Maintenance	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Sorafenib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC		Positive	FALSE	FALSE	FALSE	46,XY[12]	49	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Positive	AML	5.523287671232877	1:DECEASED	normal	No	No		No	No	No	No	No	No	White	6	Refractory		4	Male	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood	dim variable CD7, dim CD11b, CD13, CD33, CD34, CD58, CD117, and CD123	30	0		Standard Chemotherapy	No	DNMT3A (p.R882C; MAF 6%)|FLT3-ITD (MAF 15-20%)|NPM1 (p.W288fs*12; MAF 6%)|TET2 (p.Q548*, MAF 6%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2238_BA2829	Acute Myeloid Leukemia	AML with mutated NPM1	P606_R607insSSSDNEYFYVDFREYEYDLKWEFP	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608307	28608308	-	CTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAG	13:g.28608307_28608308insCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAG	ENST00000241453.7:c.1749_1820dup	0.35		82	154			20	14/24					53	54			Dead-Disease		1	Waves1+2	Yes	HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea	4	Induction|Experimental|Re-induction|Maintenance	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Sorafenib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC		Positive	FALSE	FALSE	FALSE	46,XY,add(3)(p24)[cp4]/46,XY[14]	49	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Positive	AML	5.523287671232877	1:DECEASED	normal	No	No		No	No	No	No	No	No	White	6	Refractory		4	Male	MATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood	CD117 (Initial diagnosis on 7/27/2015 BMBX: CD7, dim CD11b, CD13, CD33, partial CD34, CD58, CD117, CD123, dim MPO, and HLA-DR positive)	7	1		Standard Chemotherapy	Yes	CBL (p.I423N; MAF <0.5%)|DNMT3A (p.R882C; MAF 0.9%)|FLT3-ITD (MAF 2.9)|NPM1 (p.W288fs*12; MAF 0.7%)|TET2 (p.Q548*; MAF 0.7%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2238_BA2979	Acute Myeloid Leukemia	AML with mutated NPM1	P606_R607insSSSDNEYFYVDFREYEYDLKWEFP	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608307	28608308	-	CTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAG	13:g.28608307_28608308insCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAG	ENST00000241453.7:c.1749_1820dup	0.53		150	131			17	14/24					53	54	19		Dead-Disease		1	Waves1+2	Yes	HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea	4	Induction|Experimental|Re-induction|Maintenance	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Sorafenib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC		Positive	FALSE	FALSE	FALSE	46,XY,t(7;17)(q22;q21)[3]/46,XY,t(2;4)(q33;q25),del(9)(q2?1;q3?2),add(17)(q21)[cp3]/46,XY,t(1;2)(q31;p25),inv(9)(q3?1q34)[2]/46,XY,t(13;14)(q14;q32)[cp2]/46,XY,add(3)(p24)[1]/46,XY[3]	49	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Positive	AML	5.523287671232877	1:DECEASED	normal	No	No		No	No	No	No	No	No	White	6	Refractory		4	Male	MATCHED	FALSE	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Peripheral Blood		75	0.9		Standard Chemotherapy	No	DNMT3A (p.R882C; MAF 45%)|FLT3-D835 (p.D835H; MAF 15%)|FLT3-ITD (MAF 78%)|NPM1 (p.W288fs*12; MAF 40%)|TET2 (p.Q548*; MAF 45%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2239_BA3006	Acute Myeloid Leukemia	AML with mutated NPM1	S586_K615dup	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608301	28608302	-	TTACCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCT	13:g.28608301_28608302insTTACCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCT	ENST00000241453.7:c.1755_1837+4dup	0.50		153	154			11	14/24					33	33	4		Dead-Treatment		3	Waves1+2	Yes	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|HAM (Cytarabine, Mitoxantrone)	4	Allogeneic - Sibling|Consolidation|Induction|Re-induction	4	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate		M2	Positive	TRUE	FALSE	FALSE	46,XX[7]	-1	Bone Marrow Transplant	FALSE	Positive	AML	14.432876712328767	1:DECEASED		No	No		No	No	No	No	No	No		-1	Refractory		1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	increased CD117 positive, partial CD34 positive myeloblasts,   representing approximately 91% of the leukocytes, consistent with acute myeloid leukemia	0	0.533333333		Standard Chemotherapy	Yes	FLT3-ITD|NPM1
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2245_BA2640	Acute Myeloid Leukemia	AML with myelodysplasia-related changes	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							15	14/24					52	54	1		Dead-Disease		2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|AG-221|HAM (Mitoxantrone, Cytarabine) plus Crenolanib|Fludarabine, Melphalan, ATG	5	Consolidation|Salvage|Induction|Experimental|Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	3	Fludarabine, Melphalan, ATG	Allogeneic - Matched Unrelated Donor	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	FALSE	TRUE	FALSE	89<4n>,XXY,-Y,-7,-12,+13,+13,-17,-21[2]/46,XY[18]	-1	Bone Marrow Transplant	FALSE	Negative	AML	40.66849315068493	1:DECEASED	nuc ish(RUNX1T1x4,RUNX1x3)[33/200],(5'MLL,3'MLL)x4(5'MLL con 3'MLLx4)[41/200],(PMLx4,RARAx3~4)[31/200],(5'CBFB,3'CBFB)x4(5'CBFB con 3'CBFBx4)[27/200]	No	No		No	No	No	No	No	No	Unknown	15	Refractory		2	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Relapse	Bone Marrow Aspirate		506	0.733333333		Standard Chemotherapy	No	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2254_BA2600	Acute Myeloid Leukemia	AML with myelodysplasia-related changes	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							26	14/24					64	64	1		Alive		4	Waves1+2	Yes	Fludarabine, BCNU, Melphalan|Decitabine, Midostaurin	2	Allogeneic - Sibling|Induction	2	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, BCNU, Melphalan	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse		M4	Positive	TRUE	FALSE	FALSE	46,XX,t(2;3)(p13;q25~26)[2]/46,idem,i(14)(q10)[18]	-1	Bone Marrow Transplant	FALSE	Negative	AML	33.56712328767124	0:LIVING		No	No		No	No	No	No	No	No		249	Complete Response	RUNX1 (p.P430S; 60.0%)|RUNX1 (p.R166*; 41.2%)	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD34, partial CD117, CD38, CD33, partial CD13,partial CD11C, CD4, partial CD14, partial CD64, partial CD2, and HLA-DR	0	1.433333333		Standard Chemotherapy	Yes	FLT3-ITD
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2255_BA2704	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							4	14/24					61	61	0.851851852		Dead-Disease		1	Waves1+2	Yes	Hydroxyurea	1	Induction	1	Standard Chemotherapy	1	Hydroxyurea	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M1	Positive	TRUE	FALSE	FALSE	46,XX[20]	8	Standard Chemotherapy	FALSE	Positive	AML	0.263013698630137	1:DECEASED	Normal	No	No		No	No	No	No	No	No	White	8	Unknown		1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	partial CD13, CD33, dim/partial CD56, CD58, dim CD117, CD123 and MPO	3	0.133333333		Standard Chemotherapy	Yes	FLT3-ITD (MAF ~50%)|IDH2 (p.R140Q; MAF ~50%)|NPM1 (p.W288fs*12; MAF ~50%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2261_BA2910	Acute Myeloid Leukemia	AML with mutated NPM1	K614_V615insYEYDLKWEFPRENLEFGKNGMCQMFLQHFFSIGKSLKCTYSPFVFAGK	OncoKB: Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608268	28608269	-	TTCCCTGCAAAGACAAATGGTGAGTACGTGCATTTTAAAGATTTTCCAATGGAAAAGAAATGCTGCAGAAACATTTGGCACATTCCATTCTTACCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATAT	13:g.28608268_28608269insTTCCCTGCAAAGACAAATGGTGAGTACGTGCATTTTAAAGATTTTCCAATGGAAAAGAAATGCTGCAGAAACATTTGGCACATTCCATTCTTACCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATAT	ENST00000241453.7:c.1788_1841dup	0.23		24	82			17	14/24					79	79	0.470588235		Dead-Disease		2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Crenolanib	2	Induction|Experimental	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Crenolanib	Experimental	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	FALSE	TRUE	FALSE		14	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Positive	AML	4.076712328767123	1:DECEASED		No	No		No	No	No	No	No	No		4	Complete Response		1	Female	MATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Relapse	Peripheral Blood		0	0.966666667		Standard Chemotherapy	Yes	FLT3-ITD (High level (>50%))|NPM1 (Positive for insertion mutation in exon 12)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2264_BA2397	Acute Myeloid Leukemia	AML with mutated NPM1	V579_L601dup	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608321	28608322	-	GAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGTAC	13:g.28608321_28608322insGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGTAC	ENST00000241453.7:c.1735_1803dup	0.15		14	79			5	14/24					59	59					7	Waves1+2	No		0		0		0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	MissingKaryo			Positive	TRUE	FALSE	FALSE			None	FALSE	Positive	AML	0.0			No	No		No	No	No	No	No	No					1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	Atypical monocytes (are about 91.5%). They are CD45+, CD33+, HLADR++.CD13+, CD14+. CD15++, CD64++, CD116++, CD11b+++,CD11c++,CD38+ and CD34(-),CD117(-). A small population of monoclonal B-cells, CD19+, CD5+(<1%)	0	0.233333333			Yes	DNMT3A (p.Arg882His)|FLT3-ITD (p.Val579_Leu601dup)|NPM1 (p.Trp288Cysfs*12)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2284_BA2450	Acute Myeloid Leukemia	AML with mutated NPM1	F612_G613insAGSSDNEYFYVDFREYEYDLKWEFPRENLEF	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608311	28608312	-	CAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGG	13:g.28608311_28608312insCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGG	ENST00000241453.7:c.1745_1837dup	0.28		35	92			13	14/24					46	46	0.25		Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea	5	Consolidation|Salvage|Induction|Supportive/Palliative Care	4	Standard Chemotherapy|Supportive/Palliative Care	2	Sunitinib	Consolidation	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC		Positive	FALSE	FALSE	FALSE		2	Standard Chemotherapy	FALSE	Positive	AML	8.843835616438355	1:DECEASED	metaphases positive for 45XX monosomy chromosome 17,20/22 metaphases positive for 46XX diploid	No	No		No	No	No	No	No	No	White	32	Complete Response		3	Female	MATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood		0	0.533333333		Standard Chemotherapy	Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2284_BA2824	Acute Myeloid Leukemia	AML with mutated NPM1	F612_G613insAGSSDNEYFYVDFREYEYDLKWEFPRENLEF	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608311	28608312	-	CAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGG	13:g.28608311_28608312insCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGG	ENST00000241453.7:c.1745_1837dup	0.34		31	61			14	14/24					46	47	0.515151515		Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea	5	Consolidation|Salvage|Induction|Supportive/Palliative Care	4	Standard Chemotherapy|Supportive/Palliative Care	2	Sunitinib	Consolidation	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC		Positive	FALSE	FALSE	FALSE		2	Standard Chemotherapy	FALSE	Positive	AML	8.843835616438355	1:DECEASED	Positive	No	No		No	No	No	No	No	No	White	32	Complete Response		3	Female	MATCHED	FALSE	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Peripheral Blood	variable CD7, CD13, dim CD33, partial CD34, CD38,dim CD58, partial and variable CD117 and CD123 positive	23	0.633333333		Standard Chemotherapy	No	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2285_BA2806	Acute Myeloid Leukemia	AML with mutated NPM1	Y599delins*	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608317	28608318	-	ATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCT	13:g.28608317_28608318insATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCT	ENST00000241453.7:c.1740_1796dup	0.19		33	137			6	14/24					42	42	0.960784314	ASXL1 (p.G645Vfs*58; 8.0%)	Alive		2	Waves1+2	Yes	Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Bu/Cy/ATG	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse			Positive	TRUE	FALSE	FALSE		-1	Bone Marrow Transplant	FALSE	Positive	AML	33.4027397260274	0:LIVING		No	No		No	No	No	No	No	No	Unknown	5	Complete Response		1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	partialCD4, partial/dimCD7, partialCDllb, CD13, partialCD15, partialCD22, partialCD25, brightCD33, partialCD34, CD38, CD45, CD117, partialCD123, HLA-DR, partialMPO, partialTdT	0	0.166666667		Standard Chemotherapy	Yes	FLT3-ITD|NPM1
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2291_BA2201	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							10	14/24					68	68			Dead-Other		1	Waves1+2	Yes	HiDAC|3+7 (Cytarabine, Daunorubicin)|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	FavorableOrIntermediate	NON-HISPANIC	M5	Positive	TRUE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	FALSE	Positive	AML	28.306849315068497	1:DECEASED	Normal	No	No		No	No	No	No	No	No	White	23	Complete Response		1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Variable CD13, variable CD14, CD33, variable CD64, CD117, CD123, and partial HLA-DR positive	0	0.4		Standard Chemotherapy	Yes	FLT3-ITD (MAF 91%)|IKZF1 (p.Q156H; MAF 45%)|NPM1 (p.W288fs*; MAF 49%)|SF3B1 (p.K666Q; MAF 50%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2297_BA2168	Acute Myeloid Leukemia	AML with myelodysplasia-related changes	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							1	14/24					47	48	3.166666667		Dead-Unknown		2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling|Consolidation|Salvage|Induction	4	Standard Chemotherapy|Bone Marrow Transplant	2	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	FALSE	TRUE	FALSE	46,XX	-1	Standard Chemotherapy	FALSE	Negative	AML	19.134246575342466	1:DECEASED	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[198],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No		No	No	No	No	No	No	Unknown	-1	Refractory		1	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Post-Transplant|Relapse	Peripheral Blood	CD2(-), CD4(partial +), CD7(-), CD11b(partial +), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(bright +), CD34(partial +), CD36(-), CD38(variably +), CD45(variably +), CD56(partial +), CD64(-), CD117(partial +), HLA-DR(partial dim +)	0	0		Standard Chemotherapy	Yes	FLT3-ITD
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2300_BA2808	Acute Myeloid Leukemia	AML with myelodysplasia-related changes	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							12	14/24					56	56	0.388888889		Dead-Unknown		4	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Induction|Re-induction	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse			Positive	TRUE	FALSE	FALSE	40~43,XY,add(1)(p36),-2,-4,-5,-8,-12,-14,-15,-16,-17,?add(17)(p13),der(19)?t(8;19)(q11.2;p13),-20,-22,+7mar[cp18]	-1	Bone Marrow Transplant	FALSE	Negative	AML	6.50958904109589	1:DECEASED		No	No		No	No	No	No	No	No		27	Complete Response		1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD34, CD38 (dim), CD13, CD33 (dim),CD64 (partial), CD11c, CD4 (partial), CD15, CD117, HLA-DR, and MPO(partial).	0	0.633333333		Standard Chemotherapy	Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2305_BA2110	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							7	14/24					65	65			Dead-Disease		1	Waves1+2	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|Fludarabine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|MiDAC	5	Consolidation|Salvage|Induction|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	FavorableOrIntermediate	NON-HISPANIC	M4	Positive	TRUE	FALSE	FALSE	46,XX[20]	4	Standard Chemotherapy	FALSE	Positive	AML	14.432876712328767	1:DECEASED	Normal	No	No		No	No	No	No	No	No	White	6	Complete Response		1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD11b, partial CD13, partial CD14, dim CD15, partial      CD16, CD33, CD38, CD58, CD64, partial CD123 and HLA-DR positive	0	0.266666667		Standard Chemotherapy	Yes	DNMT3A ( p.R882H; MAF 50%)|FLT3-ITD (MAF 10%)|FLT3-N676K (MAF 12%)|NPM1 (p.W288fs*12; MAF 50%)|PTPN11 (p.F71L; MAF 14%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2307_BA2414	Acute Myeloid Leukemia	Therapy-related myeloid neoplasms	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							10	14/24					50	50	0.818181818		Dead-Unknown		5	Waves1+2	Yes	GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI	2	Induction|Double Umbilical Cord Blood Transplant (DUCBT)	2	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse			Positive	FALSE	FALSE	FALSE	46,XY,add(1)(p11),del(5)(q15q33),del(7)(q22q36),der(11)t(1;11)(p31;p12-14)[20]	-1	Bone Marrow Transplant	FALSE	Negative	AML	6.608219178082191	1:DECEASED	Loss of 5q31 sequences for 99% of total cells | Loss of 7q31 sequences for 96% of total cells	Yes	No	Hodgkin Lymphoma	No	No	No	No	No	No	White	-1	Complete Response		1	Male	MATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	Positive: CD38, CD56, CD13, CD34, CD45, CD117, HLA-DR | Partially positive: CD7, CD11b, CD33, CD64 | Negative: CD19, CD22, Cyt CD79a, Cyt CD3, CD14, CD15, MPO, TdT	0	0.366666667		Standard Chemotherapy	Yes	BCOR (C.3067T>C; p.F1023L)|FLT3-ITD|NOTCH1 (c.7625G>A; p.S2542N)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2319_BA2027	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							12	14/24					70	70	4		Dead-Disease		4	Waves1+2	Yes	Hydroxyurea	1	Supportive/Palliative Care	1	Standard Chemotherapy	1	Hydroxyurea	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate			Positive	FALSE	FALSE	FALSE		1	Standard Chemotherapy	FALSE	Positive	AML	0.1315068493150685	1:DECEASED	Negative	Yes	No	Prostate Cancer	No	No	No	No	No	No	White	1			1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	Positive (increased CD34 positive blasts (50-60%), CD71 Decreased erythroid cells (less than 5%), CD61 Few scattered megakaryocytes, E-cadherin; Scattered immature erythroid precursors, CD117: Increased immature myeloid cells and blasts (70-80%), CD3: Sca	0	0.466666667		Standard Chemotherapy	Yes	DNMT3A (p.R882H; MAF 50%)|NPM1 (p.W288fs*12;MAF 40%)|SOCS1 (p.Q210H; MAF 50%)|TET2 (p.S460F; MAF 45%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2321_BA2171	Acute Myeloid Leukemia	AML with mutated NPM1	P606_R607insSLTGSSDNEYFYVDFREYEYDLKWEFP	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608314	28608315	-	AGCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCA	13:g.28608314_28608315insAGCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCA	ENST00000241453.7:c.1820_1821insCTTGACCGGCTCCTCAGATAATGAGTACTTCTACGTTGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAG	0.40		93	141			8	14/24					73	73	0.428571429		Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	UNKNOWN	M1	Positive	TRUE	FALSE	FALSE	46,XX[20]	3	Standard Chemotherapy	FALSE	Positive	AML	0.1315068493150685	1:DECEASED	Normal	No	No		No	No	No	No	No	No	Unknown	3	Unknown		1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD38, CD58, dim CD64, CD117, CD123, and MPO	0	0.266666667		Standard Chemotherapy	Yes	DNMT3A (p.R326P; MAF 50%)|FLT3-ITD (MAF 46%)|IDH2 (p.R140Q; MAF 40%)|NPM1 (p.W288fs*12; MAF 40%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2327_BA2970	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							11	14/24					63	63	9	ASXL1 (p.W898*; 42.1%)	Dead-Disease		2	Waves1+2	No	Ruxolitinib|Hydroxyurea	2	Supportive/Palliative Care	1	Supportive/Palliative Care	1	Hydroxyurea	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC		Positive	FALSE	FALSE	TRUE	46,XY[20]	103	Supportive/Palliative Care	FALSE	Positive	AML	0.263013698630137	1:DECEASED	nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[199], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No		No	No	No	No	Yes	Yes	Black				1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	CD34(+), CD7(partial +), CD13(+), CD33(+), CD38(partial +), CD45(moderately +), CD56 (+), CD117(+), HLA-DR(variably +), other myeloid and lymphoid antigens(-).	0	0.4			Yes	ASXL1 (Foundation; W898*; MAF 47%)|KRAS (Foundation; A59T mutation; MAF 47%)|KRAS (Foundation; G13C; MAF 3%)|SUZ12 (Foundation; W617*; MAF 49%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2338_BA2933	Acute Myeloid Leukemia	AML with maturation	X585_X585insSDNEYFYVDFREYEYDLKWEFPRENLEFGKKVP	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608302	28608303	-	GCACCTTCTTACCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTG	13:g.28608302_28608303insGCACCTTCTTACCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTG	ENST00000241453.7:c.1837+7_1837+8insGGTGCCAGATAATGAGTACTTCTACGTTGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTTTGGTAAGAA	0.10		18	162			28	14/24					61	61		ASXL1 (p.E635Rfs*15; 20.2%)	Dead-Disease		3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse		M2	Positive	TRUE	FALSE	FALSE	46,XY[20]	-1	Standard Chemotherapy	FALSE	Negative	AML	1.3808219178082193	1:DECEASED	Normal	No	No		No	No	No	No	No	No		-1	Refractory	RUNX1 (p.R166Q; 41.5%)|RUNX1 (p.R162K; 47.6%)	2	Male	MATCHED	FALSE	AML with maturation	Initial Acute Leukemia Diagnosis	Peripheral Blood	partial  weak CD4 (20% positive), CD13, partial weak CD11b (60%  positive), partial weak CD15 (20% positive), CD34, CD117,  myeloperoxidase, and partial HLA-DR (60% positive)	0	1.566666667		Standard Chemotherapy	Yes	ASXL1 (p.Glu635Argfs*15; MAF 9%)|CSF3R (p.Tyr779*; MAF 5.4%)|IDH2 (p.Arg140Gln; 37.7%)|PHF6 (p.Arg319*; MAF 88.6%)|RUNX1 (p.Arg162Lys; MAF 43%)|RUNX1 (p.Arg166Gln; MAF 35.3%)|SMC1A (p.Arg790Gln; 9.2%)|U2AF1 (p.Gln157Pro; MAF 51.3%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2342_BA2139	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							3	14/24					48	48	0.785714286		Alive		3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|TBI, VP-16	4	Consolidation|Induction|CNS|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	3	TBI, VP-16	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate		M5b	Positive	TRUE	FALSE	FALSE	46,XX	-1	Bone Marrow Transplant	FALSE	Positive	AML	30.871232876712327	0:LIVING		No	No		No	No	No	No	No	No		-1	Complete Response		1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	Large population of atypical monocytic cells (weaker than  normal CD33, partial loss of CD13) including  promonocytes/monoblasts representing approximately 50% of  the leukocytes suggestive of acute monoblastic or monocytic  leukemia. | Large population o	0	0.1		Standard Chemotherapy	Yes	DNMT3A (p.Arg882Cys; MAF 47.1%)|FLT3-ITD|NPM1 (p.Trp288fs (NM_002520.6); MAF 27.9%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2350_BA2459	Acute Myeloid Leukemia	AML without maturation	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							18	14/24					55	55	0.234567901		Alive		2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate		M1	Positive	TRUE	FALSE	FALSE	92<4n>,XXYY[13]/46,XY[7]	8	Standard Chemotherapy	FALSE	Negative	AML	1.4794520547945205	0:LIVING	The AML FISH panel analysis showed evidence of extra copies of the RUNX1T1 (8q24) and RUNX1 (21q22) genes in 95.5%, extra copies of the PML (15q24) and RARA (17q21.1) genes in 95.5%, and extra copies of the CBFB (16q22) gene in 96% of the cells examined.)	No	No		No	No	No	No	No	No		8	Unknown		1	Male	MATCHED	FALSE	AML without maturation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(-), CD4(partial dim +), CD7(-), CD11b (variably +), CD13(variably +), CD14(predominantly -), CD15(predominantly -/few scattered +), CD16(-), CD20(small subset +), CD33(partial +), CD34(variably +), CD36(small subset +), CD38(variably +), CD45(variably	0	0.966666667		Standard Chemotherapy	Yes	IDH1 (p.R132C; MAF unlisted)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2371_BA2200	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							3	14/24					59	59			Dead-Disease		3	Waves1+2	Yes	Azacitidine, Sorafenib|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)	3	Consolidation|Induction|Re-induction	3	Standard Chemotherapy	1	Azacitidine, Sorafenib	Re-induction	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	FALSE	TRUE	FALSE	46,XY,t(3;4)(p21;q25)[3]/46,XY[17]	-1	Standard Chemotherapy	FALSE	Positive	AML	8.416438356164385	1:DECEASED		No	No		No	No	No	No	No	No		-1	Complete Response		1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Relapse|Post-Chemotherapy	Bone Marrow Aspirate	CD4, CD7, CD11b, CD13,  CD33, partial CD34, CD117, HLA-DR, partial weak TdT and  partial CD64	0	0.1		Standard Chemotherapy	Yes	DNMT3A (c.2251T>C; MAF 36.9% (33.1% on 3/13/15))|FLT3-ITD (c.1759_1800dup; MAF 24% (39% on 3/13/15))|NPM1 (c.860_863dup; MAF 9.9% (24% on 3/13/15))
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2374_BA3021	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							6	14/24					56	60	4.555555556		Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|3+7 (Cytarabine, Daunorubicin)|Azacitidine|3+3 plus Sorafenib|Clofarabine|Clofarabine, Cytarabine	8	Consolidation|Salvage|Induction|Re-induction	4	Standard Chemotherapy	1	Cytarabine	Consolidation	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NOS	Positive	FALSE	TRUE	FALSE	46,XY[4]	64	Standard Chemotherapy	FALSE	Positive	AML	57.04109589041096	1:DECEASED	Normal	No	No		No	No	No	No	No	No	Asian	6	Complete Response		2	Male	UNMATCHED	FALSE	AML with mutated NPM1	Relapse|Post-Chemotherapy	Bone Marrow Aspirate	CD13, CD33, partial CD56, CD58, CD64, dim CD117, CD123and partial/dim cMPO positive	309	0.233333333		Standard Chemotherapy	Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2380_BA2435	Acute Myeloid Leukemia	AML with minimal differentiation	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							11	14/24					70	71	1.083333333		Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Quizartinib|Idarubicin and Cytarabine	4	Consolidation|Induction|Experimental	3	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Quizartinib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M0	Positive	FALSE	FALSE	FALSE	46,XY[20]	155	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Positive	AML	13.150684931506849	1:DECEASED	normal	No	No		No	No	No	No	No	No	White	7	Complete Response		2	Male	UNMATCHED	FALSE	AML with minimal differentiation	Post-Chemotherapy|Residual Disease	Peripheral Blood	CD34, CD38, CD58, CD117, dimCD123,  HLA-DR, TDT	185	0.333333333		Standard Chemotherapy	No	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2393_BA2662	Acute Myeloid Leukemia	AML with mutated NPM1	T582_D600dup	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608312	28608313	-	ATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGT	13:g.28608312_28608313insATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGT	ENST00000241453.7:c.1744_1800dup	0.05		9	166			6	14/24					65	65			Alive		1	Waves1+2	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea	4	Consolidation|Unknown|Induction|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant|Other	3	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	FavorableOrIntermediate	NON-HISPANIC	M5	Positive	TRUE	FALSE	FALSE	46,XX[20]	-1	Bone Marrow Transplant	FALSE	Positive	AML	64.5041095890411	0:LIVING	Normal	No	No		No	No	No	No	No	No	White	6	Complete Response		1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate		0	0.233333333		Standard Chemotherapy	Yes	CEBPA (p.K298Q; MAF 25%)|DNMT3A (p.R882C; MAF 44%)|FLT3-ITD (MAF 25%)|IDH2 (p.R140Q; MAF 18%)|NPM1 (p.W288fs*12; MAF 46%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2396_BA2315	Acute Myeloid Leukemia	AML with mutated NPM1	G613delinsVISENMNMISNGSFQEKI*	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608280	28608281	-	AACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCA	13:g.28608280_28608281insAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCA	ENST00000241453.7:c.1778_1837dup	0.10		14	120			7	14/24					53	53			Alive		4	Waves1+2	Yes	HiDAC|7+3 (Cytarabine, Idarubicin)|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	FavorableOrIntermediate			Positive	TRUE	FALSE	FALSE	46,XY[7]	-1	Bone Marrow Transplant	FALSE	Positive	AML	41.16164383561644	0:LIVING		No	No		No	No	No	No	No	No		7	Complete Response		1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD117,HLA-DR, CD13 and CD33.  Blasts also show partial expression of CD34, CD7, CD11c, CD38, CD15, dim CD64, and dim CD4	0	0.333333333		Standard Chemotherapy	Yes	FLT3-ITD|NPM1
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2409_BA2695	Acute Myeloid Leukemia	Therapy-related myeloid neoplasms	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							3	14/24					67	68	1.325581395		Dead-Disease		2	Waves1+2	Yes	AG-120|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Hydroxyurea	4	Salvage|Experimental|Supportive/Palliative Care	3	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other|Bone Marrow Transplant	4	Sorafenib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	FALSE	FALSE	FALSE	47,XX,+11[5]/48,idem,+19[15]	-1	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Negative	AML	14.761643835616438	1:DECEASED	nuc ish(DXZ1x2)[181]//(DXZ1,DYZ3)x1[19] nuc ish(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[176/200],(PML,RARA)x2[196], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	Yes	No	Acute Myeloid Leukemia	No	No	No	No	No	No					2	Female	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Post-Chemotherapy|Post-DLI|Post-Transplant|Residual Disease	Peripheral Blood		254	0.133333333	TP53 (p.R283C; 45.1%)		No	FLT3-ITD|IDH1 (R132G)|IDH1 (p.R132G; MAF 51%)|KMT2A (MLL-PTD (exons 2-10))|TP53 (p.R283C; MAF 49%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2420_BA3004	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							11	14/24					76	76			Dead-Disease		1	Waves1+2	Yes	5+2 (Cytarabine, Idarubicin)|Decitabine	2	Induction|Re-induction	2	Standard Chemotherapy	1	5+2 (Cytarabine, Idarubicin)	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M1	Positive	TRUE	FALSE	FALSE	46,XX[22]	4	Standard Chemotherapy	FALSE	Positive	AML	0.8547945205479452	1:DECEASED	Normal	No	No		No	No	No	No	No	No	White	8	Refractory		1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dimCD13, CD33, CD45, CD56, dimCD117 and MPO positive	0	0.4		Standard Chemotherapy	Yes	ASXL1 (p.G966delG; MAF 50%)|DNMT3A (p.R736H; MAF 45%)|FLT3-ITD (MAF 20%)|NPM1 (p.W288fs*12; MAF 35%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2424_BA2035	Acute Myeloid Leukemia	AML without maturation	F590_N609dup	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608289	28608290	-	TTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAG	13:g.28608289_28608290insTTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAG	ENST00000241453.7:c.1767_1826dup	0.06		6	103			4	14/24					61	61			Alive		1	Waves1+2	Yes	Fludarabine, Melphalan|3+7 (Cytarabine, Daunorubicin)|MiDAC|Midostaurin|Hydroxyurea	5	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Maintenance	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Midostaurin	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M1	Positive	TRUE	FALSE	FALSE		284	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Negative	AML	71.73698630136987	0:LIVING	Normal	No	No		No	No	No	No	No	No	White	6	Complete Response		1	Male	UNMATCHED	FALSE	AML without maturation	Initial Acute Leukemia Diagnosis	Peripheral Blood	dim CD33, CD34, CD38, dim CD45, CD117, and MPO	0	0.166666667		Standard Chemotherapy	Yes	DNMT3A (p.R882H; MAF ~50%)|FLT3-ITD (MAF 40%)|IDH1 (p.R132S; MAF ~50%)|SRSF2 (p.P95L; MAF ~40% )
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2431_BA2776	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							3	14/24					61	61	9		Dead-Disease		1	Waves1+2	No	Hydroxyurea	1	Supportive/Palliative Care	1	Supportive/Palliative Care	1	Hydroxyurea	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M1	Positive	FALSE	FALSE	TRUE	46,XX[20]	-1	Supportive/Palliative Care	FALSE	Positive	AML	10.389041095890411	1:DECEASED	Normal	No	No		No	No	No	No	Yes	Yes	White				1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD13, CD33, CD38, CD56, CD58, CD117, CD123 and dim MPO positive	0	0.066666667			Yes	FLT3-ITD (30 bp insertion; MAF 70%)|NPM1 (p.W288fs*12; MAF 45%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2433_BA2521	Acute Myeloid Leukemia	AML with mutated NPM1	K602_W603insCPDNEYFYVDFREYEYDLK	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608300	28608301	-	AGGACATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATC	13:g.28608300_28608301insAGGACATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATC	ENST00000241453.7:c.1808_1809insTCCTGATAATGAGTACTTCTACGTTGATTTCAGAGAATATGAATATGATCTCAAATG	0.11		19	147			5	14/24					44	44	2.333333333		Dead-Disease		1	Both	Yes	Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Hydroxyurea|Busulfan, Cyclophosphamide|7+3 (Cytarabine, Idarubicin) plus Dasatinib	6	Allogeneic - Sibling|Induction|Experimental|Re-induction|Post-Transplant Relapse	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Azacitidine	Post-Transplant Relapse	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M5	Positive	TRUE	FALSE	FALSE	46,XX[20]	81	Standard Chemotherapy	FALSE	Positive	AML	10.487671232876712	1:DECEASED	Normal	No	No		No	No	No	No	No	No	White	28	Complete Response i		1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, subset CD34, variable CD117, CD123, HLA-DR, and variable MPO positive - Monocytic/blast equivalent immunophenotype: CD11b, CD13, subset CD14, variable CD16, CD33, CD64, dim CD123, and HLA-DR positive	0	0.166666667		Standard Chemotherapy	No	DNMT3A (p.R882H; MAF 48%)|FLT3-ITD (MAF 70%)|NPM1 (p.W288fs*12; MAF 46%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2451_BA2335	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							5	14/24					60	60	0.5625		Dead-Treatment		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Hydroxyurea|Quizartinib|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling|Induction|Experimental	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Busulfan, Cyclophosphamide	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M2	Positive	TRUE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	FALSE	Positive	AML	3.9123287671232876	1:DECEASED	normal	No	No		No	No	No	No	No	No	White	5	Refractory		1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD7, CD13, CD33, CD34, CD117, CD123, and HLA-DR-positive	0	0.166666667		Standard Chemotherapy	Yes	FLT3-ITD|NPM1 (exon 12 insertion W288fs*1)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2455_BA2893	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							4	14/24					59	59	1		Dead-Disease		3	Waves1+2	Yes	Azacitidine, Sorafenib|Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|7+3 (Cytarabine, Idarubicin)|HiDAC	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant	2	Azacitidine, Sorafenib	Hypomethylating/Low Dose Cytarabine	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate			Positive	TRUE	FALSE	FALSE	46,XX[20]	-1	Standard Chemotherapy	FALSE	Positive	AML	8.35068493150685	1:DECEASED	Normal	No	No		No	No	No	No	No	No		-1	Complete Response		1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Large population of CD117 positive myeloblasts (predominantly CD34 negative, HLA-DR negative), representing approximately 71% of the leukocytes consistent with acute myeloid leukemia.	0	0.133333333		Standard Chemotherapy	Yes	NPM1
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2466_BA2921	Acute Myeloid Leukemia	AML with myelodysplasia-related changes	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							5	14/24					70	71	0.01010101		Dead-Disease		2	Both	Yes	7+3 (Cytarabine, Idarubicin)|Azacitidine	2	Hypomethylating/Low Dose Cytarabine|Induction	2	Standard Chemotherapy|Supportive/Palliative Care	2	Azacitidine	Hypomethylating/Low Dose Cytarabine	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC		Positive	FALSE	FALSE	FALSE	46,XY,del(7)(q22q36)[7]/47,idem,+22[cp12]/46,XY[1]	-1	Supportive/Palliative Care	FALSE	Negative	AML	6.378082191780822	1:DECEASED	nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1x2,D7S522x1)[187/200], (D8Z2,D20S108)x2[199],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No		No	No	No	No	No	No	White	-1	Refractory		1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood		0	0.2		Standard Chemotherapy	No	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2471_BA2211	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							8	14/24					65	65	1		Dead-Disease		1	Waves1+2	Yes	Azacitidine|7+3 (Cytarabine, Idarubicin) plus Sorafenib	2	Consolidation|Induction	2	Standard Chemotherapy	1	Azacitidine	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M1	Positive	TRUE	FALSE	FALSE	46,XX[20]	34	Standard Chemotherapy	FALSE	Positive	AML	4.668493150684932	1:DECEASED	normal	No	No		No	No	No	No	No	No	White	17	Complete Response i		1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD38, CD56, CD58, partial CD64, CD117, CD123, and MPO positive	0	0.3		Standard Chemotherapy	Yes	FLT3-ITD (MAF 50%)|NPM1 (p.W288fs*12; MAF 45%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2475_BA3192	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							10	14/24					66	67			Alive		6	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	FALSE	FALSE	FALSE	49,XY,+4,+8,+14[9]/49,sl,del(4)(q21q31.1)[11]	63	Standard Chemotherapy	FALSE	Positive	AML	9.863013698630137	0:LIVING		No	No		No	No	No	No	No	No	White	23	Complete Response		2	Male	MATCHED	FALSE	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	POSITIVE FOR CD117, HLA-DR, CD13, CD33, CD14 AND MPO AND NEGATIVE FOR CD34, CD11B, CD64, CD10 AND TDT. (Bone Marrow Immunophenotype)	80	0.5		Standard Chemotherapy	No	DNMT3A (c.2645G>A; p.R882H MAF 42%)|FLT3-ITD|KIT (c.2447A>T; p.D816V MAF 81%)|NPM1 ((NPM1) c.860_863dupTCTG; p.W288Cfs*12  MAF 51%)|SETBP1 (c.3209C>T; p.P1070L MAF 46%)|TET2 (c.3638T>G; p.V1213G MAF 87%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2476_BA2005	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							4	14/24					27	31	1.173913043		Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, TBI|Sorafenib|Hydroxyurea|Decitabine	6	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Sorafenib	Experimental	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M1	Positive	FALSE	TRUE	FALSE	46,XX,del(6)(q13q23)[18]/46,XY[2]	99	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Positive	AML	48.0986301369863	1:DECEASED	Missing 6q21 signal while having two copies each of the 6 centromere signal and the MYB (6q23) signal (40%)	Yes	No	Juvenile pilocytic astrocytoma	No	No	No	No	No	No	White	2	Complete Response		5	Female	UNMATCHED	FALSE	AML with mutated NPM1	Relapse|Post-Transplant|Post-Chemotherapy	Bone Marrow Aspirate	partial CD7, variable CD13, CD33, partial CD34,CD38, CD58, CD117, CD123, and partial HLA-DR positive	1339	0.066666667		Standard Chemotherapy	No	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2476_BA2102	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							3	14/24					27	27	0.960784314		Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, TBI|Sorafenib|Hydroxyurea|Decitabine	6	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Sorafenib	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M1	Positive	FALSE	FALSE	FALSE	46,XX[20]	99	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Positive	AML	48.0986301369863	1:DECEASED	Normal	Yes	No	Juvenile pilocytic astrocytoma	No	No	No	No	No	No	White	2	Complete Response		5	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD7, CD13, CD33, partial CD34, dim CD45, CD117, CD123, HLA-DR and MPO positive	0	0.033333333		Standard Chemotherapy	Yes	CEBPA|FLT3-ITD|NPM1
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2476_BA2555	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							3	14/24					27	31			Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, TBI|Sorafenib|Hydroxyurea|Decitabine	6	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Sorafenib	Experimental	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M1	Positive	FALSE	TRUE	FALSE	46,XX,del(6)(q13q23)[15]/46,XY[5]	99	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Positive	AML	48.0986301369863	1:DECEASED	6q deletion (79%)	Yes	No	Juvenile pilocytic astrocytoma	No	No	No	No	No	No	White	2	Complete Response		5	Female	UNMATCHED	FALSE	AML with mutated NPM1	Relapse|Post-Transplant|Post-Chemotherapy	Peripheral Blood		1465	0.066666667		Standard Chemotherapy	No	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2476_BA3074	Acute Myeloid Leukemia	AML with mutated NPM1	F612_G613insVREYEYDLKWEFPRENLEF	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608275	28608276	-	CAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGA	13:g.28608275_28608276insCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGA	ENST00000241453.7:c.1781_1837dup	0.06		7	114			4	14/24					27	31	2.03030303		Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, TBI|Sorafenib|Hydroxyurea|Decitabine	6	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Sorafenib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M1	Positive	FALSE	FALSE	FALSE	46,XX,del(6)(q13q23)[18]/46,XY[2]	99	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Positive	AML	48.0986301369863	1:DECEASED	Missing 6q21 signal while having two copies each of the 6 centromere signal and the MYB (6q23) signal (40%)	Yes	No	Juvenile pilocytic astrocytoma	No	No	No	No	No	No	White	2	Complete Response		5	Female	UNMATCHED	FALSE	AML with mutated NPM1	Post-Transplant|Residual Disease	Peripheral Blood		1354	0.1		Standard Chemotherapy	No	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2479_BA2012	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							6	14/24					60	61	2.448275862		Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Quizartinib	5	Salvage|Consolidation|Induction|Experimental|Supportive/Palliative Care	5	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	3	Etoposide, Mitoxantrone	Supportive/Palliative Care	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NOS	Positive	FALSE	TRUE	FALSE	46,XX[20]	0	Supportive/Palliative Care	FALSE	Positive	AML	12.953424657534246	1:DECEASED	normal	No	No		No	No	No	No	No	No	White	6	Complete Response		3	Female	UNMATCHED	FALSE	AML with mutated NPM1	Relapse	Bone Marrow Aspirate	partial CD7, CD13, CD33, partial CD34, partial dim CD64, CD117, and CD123 positive	0	0.233333333		Standard Chemotherapy	Yes	FLT3-ITD|NPM1
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2479_BA2352	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							6	14/24					60	61	7.333333333		Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Quizartinib	5	Salvage|Consolidation|Induction|Experimental|Supportive/Palliative Care	5	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	3	Etoposide, Mitoxantrone	Supportive/Palliative Care	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NOS	Positive	FALSE	FALSE	FALSE	46,XX[20]	0	Supportive/Palliative Care	FALSE	Positive	AML	12.953424657534246	1:DECEASED	normal	No	No		No	No	No	No	No	No	White	6	Complete Response		3	Female	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood	partial CD7, CD13, CD33, partial CD34, CD58, CD64, CD117, and CD123 positive	138	0.266666667		Standard Chemotherapy	No	FLT3-ITD|NPM1
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2479_BA2630	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							6	14/24					60	61	19		Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Quizartinib	5	Salvage|Consolidation|Induction|Experimental|Supportive/Palliative Care	5	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	3	Etoposide, Mitoxantrone	Supportive/Palliative Care	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NOS	Positive	FALSE	FALSE	FALSE	46,XX[20]	0	Supportive/Palliative Care	FALSE	Positive	AML	12.953424657534246	1:DECEASED	normal	No	No		No	No	No	No	No	No	White	6	Complete Response		3	Female	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood		181	0.233333333		Standard Chemotherapy	No	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2485_BA2100	Acute Myeloid Leukemia	AML with myelodysplasia-related changes	Y599_D600insAGSSDNEYFYVDFREYEY	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608309	28608310	-	CGCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCC	13:g.28608309_28608310insCGCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCC	ENST00000241453.7:c.1798_1799insCGGGCTCCTCAGATAATGAGTACTTCTACGTTGATTTCAGAGAATATGAATATG	0.18		30	138			17	14/24					73	74	1.222222222		Dead-Unknown		2	Waves1+2	Yes	Cytarabine, Fludarabine, Sorafenib|Crenolanib|Azacitidine|Sorafenib|Decitabine, Sorafenib |Clofarabine, Cytarabine|Sapacitabine (CYC682-06)	7	Hypomethylating/Low Dose Cytarabine|Salvage|Unknown|Induction|Experimental|Re-induction	6	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Crenolanib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	FALSE	FALSE	TRUE	46,XY,+1,dic(1;15)(q12;p11.2)[2]/46,XY[18]	33	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Negative	AML	21.632876712328766	1:DECEASED	18].nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2 [200],(RUNX1T1,RUNX1)x2[198],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	Yes	No	Prostate Cancer	Yes	Yes	No	No	No	No	Unknown	39	Refractory	RUNX1 (p.R201Q; 47.2%)	2	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood	CD4(partial dim +), CD7(-), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD20(-), CD22(-), CD33(variably +), CD34(+), CD36(-), CD38(variably +), CD45 (variably +), CD56(-), CD64(-), CD79a(-) | CD117(variably +), HLA-DR (variably +), MPO	0	0.766666667		Standard Chemotherapy	Yes	FLT3-ITD (NOT FOUNDATION NO MAF AVAILABLE)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2485_BA2953	Acute Myeloid Leukemia	AML with myelodysplasia-related changes	Y599_D600insAGSSDNEYFYVDFREYEY	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608309	28608310	-	CGCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCC	13:g.28608309_28608310insCGCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCC	ENST00000241453.7:c.1798_1799insCGGGCTCCTCAGATAATGAGTACTTCTACGTTGATTTCAGAGAATATGAATATG	0.15		21	118			11	14/24					73	74	3		Dead-Unknown		2	Waves1+2	Yes	Cytarabine, Fludarabine, Sorafenib|Crenolanib|Azacitidine|Sorafenib|Decitabine, Sorafenib |Clofarabine, Cytarabine|Sapacitabine (CYC682-06)	7	Hypomethylating/Low Dose Cytarabine|Salvage|Unknown|Induction|Experimental|Re-induction	6	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Crenolanib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	FALSE	FALSE	TRUE	46,XY	33	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Negative	AML	21.632876712328766	1:DECEASED	nuc ish(D5S721,D5S23,EGR1)x2[198],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[198],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]	Yes	No	Prostate Cancer	Yes	Yes	No	No	No	No	Unknown	39	Refractory	RUNX1 (p.R201Q; 51.8%)	2	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	CD2(-), CD4(-), CD7(-), CD8(-), CD10(-), CD11b(partial +), CD13(+), CD14(-), CD15(-), CD16(-), CD19(-), CD20(-), CD22(-), CD33(variable and bright +), CD34(variably +) (Within this population, there is a small subset of cells (1.7% of total events) that i	37	0.5		Standard Chemotherapy	No	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2491_BA2003	Acute Myeloid Leukemia	AML with mutated NPM1	M578_E596dup	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608324	28608325	-	TTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGTACCAT	13:g.28608324_28608325insTTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGTACCAT	ENST00000241453.7:c.1732_1788dup	0.24		68	210			4	14/24					57	58	2.125		Dead-Disease		3	Both	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	FALSE	FALSE	FALSE	46,XX[20]	-1	Standard Chemotherapy	FALSE	Positive	AML	8.449315068493151	1:DECEASED	Normal	No	No		No	No	No	No	No	No		-1	Unknown		1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Peripheral Blood		215	0.133333333		Standard Chemotherapy	No	FLT3-ITD|NPM1
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2493_BA2563	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							15	14/24					61	61	0.063829787		Alive		3	Waves1+2	Yes	Busulfan, Fludarabine|IDAC plus Midostaurin|7+3 (Cytarabine, Daunorubicin) plus Sorafenib	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable			Positive	TRUE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	FALSE	Positive	AML	13.084931506849315	0:LIVING	Normal	No	No		No	No	No	No	No	No	White	-1	Complete Response		1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate		0	0.6		Standard Chemotherapy	Yes	DNMT3A (p.Arg326Cys; MAF 44.5%)|FLT3-ITD (p.Phe594_Asp600dup; MAF 45%)|NPM1 (p.Trp288fs; MAF 20.7%)|TET2 (p.Ala911fs; MAF 40.6%)|TET2 (p.His1036fs; MAF 39.4%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2495_BA2410	Acute Myeloid Leukemia	AML with mutated NPM1	V582_L620dup	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608314	28608315	-	GGCACATTCCATTCTTACCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCA	13:g.28608314_28608315insGGCACATTCCATTCTTACCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCA	ENST00000241453.7:c.1742_1837+18dup	0.18		30	140			13	14/24					57	57			Dead-Treatment		2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin) plus Crenolanib	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin) plus Crenolanib	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable			Positive	TRUE	FALSE	FALSE	46,XX[20]	-1	Standard Chemotherapy	FALSE	Positive	AML	2.663013698630137	1:DECEASED	Normal	No	No		No	No	No	No	No	No		-1	Complete Response i		1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	It reveals 0.23% CD34 (+) myeloid blasts with the following immunophenotype: CD2(-), CD7(-), CD13(+), CD15(-/few +), CD33 (bright +), CD36(few +), CD38(partial +), CD45(+), CD64(-), CD117(+), HLA-DR(-), MPO (partial +). (A limited/targeted immunophenotypi	0	0.633333333		Standard Chemotherapy	Yes	ASXL1 (E981G; MAF 49%)|DNMT3A (F290fs*24; MAF 40%)|FLT3-ITD (MAF 18%)|JAK2 (N322I; MAF 51%)|NPM1 (W288fs*10+; MAF 38%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2501_BA2359	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							19	14/24					56	56			Dead-Treatment		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	FavorableOrIntermediate	NON-HISPANIC	M1	Positive	FALSE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	FALSE	Positive	AML	8.12054794520548	1:DECEASED	normal	Yes	No	Other malignant neoplasm without specification of site	No	No	No	No	No	No	White	7	Complete Response		1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD11b, CD13, CD33, CD38, CD58, CD64, dim CD117, CD123, MPO+	0	1		Standard Chemotherapy	Yes	DNMT3A (p.N879D; MAF 50%)|FLT3-ITD (MAF 50%)|NPM1 (W228fs*12; MAF 50%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2522_BA2746	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							6	14/24					56	56	0.111111111		Dead-Disease		5	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI	4	Consolidation|Salvage|Induction|Double Umbilical Cord Blood Transplant (DUCBT)	4	Standard Chemotherapy|Bone Marrow Transplant	2	GCLAC (GCSF, Clofarabine & Cytarabine)	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	HISPANIC		Positive	TRUE	FALSE	FALSE	46,XX[19]	-1	Standard Chemotherapy	FALSE	Positive	AML	10.61917808219178	1:DECEASED	Normal	No	No		No	No	No	No	No	No		27	Complete Response		2	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Positive (Approximately 55% of assayed cells are an abnormal population of immature monocytic cells (consistent with monoblasts and promonocytes). Approximately 30% of assayed cells are mature monocytes. Both the immature and mature monocytic cells show u	0	0.166666667		Standard Chemotherapy	Yes	ASXL1 (c.1954G>A; p.G652S)|DNMT3A (c.2644C>T; p.R882C)|FLT3 (c.2503G>T; p.D835Y)|FLT3-ITD (FLT3-ITD 21 bp insertion)|NPM1 (c.859_860insTCTG; p.W288fs)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2522_BA3075	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							6	14/24					56	56	7.333333333		Dead-Disease		5	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI	4	Consolidation|Salvage|Induction|Double Umbilical Cord Blood Transplant (DUCBT)	4	Standard Chemotherapy|Bone Marrow Transplant	2	GCLAC (GCSF, Clofarabine & Cytarabine)	Salvage	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC		Positive	FALSE	TRUE	FALSE	46,XX[19]	-1	Standard Chemotherapy	FALSE	Positive	AML	10.61917808219178	1:DECEASED	Normal	No	No		No	No	No	No	No	No		27	Complete Response		2	Female	UNMATCHED	FALSE	AML with mutated NPM1	Post-Transplant|Relapse	Bone Marrow Aspirate		224	0.2		Standard Chemotherapy	No	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2523_BA2232	Acute Myeloid Leukemia	Therapy-related myeloid neoplasms	F612_G613insADNEYFYVDFREYEYDLKWEFPRENLEF	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608302	28608303	-	CAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTG	13:g.28608302_28608303insCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTG	ENST00000241453.7:c.1754_1837dup	0.21		38	141			15	14/24					74	74	0.111111111		Dead-Disease		2	Waves1+2	Yes	Crenolanib|HAM (Mitoxantrone, Cytarabine) plus Crenolanib|Azacitidine, Pracinostat	3	Induction|Maintenance	2	Standard Chemotherapy|Targeted Therapy - Other	2	Crenolanib	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC		Positive	FALSE	FALSE	FALSE	46,XY,t(6;9)(p23;q34)[18]/46,XY[2]	433	Targeted Therapy - Other	FALSE	Negative	AML	32.97534246575343	1:DECEASED	DEK-NUP214 fusion; MAF unavailable	Yes	Yes	Prostate Cancer	No	No	No	No	No	No	White	-1	Complete Response		2	Male	MATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(-), CD4(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33(bright +), CD34 (partial +), CD36(equivocal), CD38(variably +), CD45(+), CD56(-), CD64(partial dim +), CD117(+), HLA-DR(partial +), TdT (-), MPO(-).	0	0.633333333		Standard Chemotherapy	Yes	DNMT3A (F827fs*4; MAF 35%)|FLT3 (S585_D586ins28; MAF 14% )|ZRSR2 (D242fs*13; MAF 25%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2523_BA3145	Acute Myeloid Leukemia	Therapy-related myeloid neoplasms	F612_G613insADNEYFYVDFREYEYDLKWEFPRENLEF	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608302	28608303	-	CAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTG	13:g.28608302_28608303insCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTG	ENST00000241453.7:c.1754_1837dup	0.41		136	195			5	14/24					74	77		ASXL1 (p.G645Vfs*58; 10.5%)	Dead-Disease		2	Waves3+4	Yes	Crenolanib|HAM (Mitoxantrone, Cytarabine) plus Crenolanib|Azacitidine, Pracinostat	3	Induction|Maintenance	2	Standard Chemotherapy|Targeted Therapy - Other	2	Crenolanib	Maintenance	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC		Positive	FALSE	FALSE	FALSE	47,XY,t(6;9)(p23;q34),+8[13]/48,idem,+13[4]/46,XY[3]	433	Targeted Therapy - Other	FALSE	Negative	AML	32.97534246575343	1:DECEASED	DEK-NUP214 fusion; MAF unavailable (DEK-NUP214 fusion; MAF unavailable) | nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[198], (RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[17/200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2	Yes	Yes	Prostate Cancer	No	No	No	No	No	No	White	-1	Complete Response		2	Male	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Post-Chemotherapy|Residual Disease	Peripheral Blood		979	0.2		Standard Chemotherapy	No	DNMT3A (F827fs*4)|FLT3-ITD
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2540_BA2254	Acute Myeloid Leukemia	AML with mutated NPM1	L601_K602insLQVTGSSDNEYFYVDFREYEYDL	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608320	28608321	-	GGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGTA	13:g.28608320_28608321insGGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGTA	ENST00000241453.7:c.1803_1804insCTACAGGTGACCGGCTCCTCAGATAATGAGTACTTCTACGTTGATTTCAGAGAATATGAATATGATCTC	0.30		62	143			15	14/24					56	56			Alive		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction|Re-induction	3	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	FavorableOrIntermediate	HISPANIC	M1	Positive	TRUE	FALSE	FALSE	46,XY[20]	111	Standard Chemotherapy	FALSE	Positive	AML	45.66575342465754	0:LIVING	Normal	No	No		No	No	No	No	No	No	Multiracial	6	Refractory		2	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD13, CD33, CD38, partial CD56 (7%), CD58, CD117, CD123, and partial MPO positive	0	0.733333333		Standard Chemotherapy	Yes	FLT3-ITD (Internal tandem duplication; MAF: 40%)|IDH2 (p.R140Q; MAF: 50%)|NPM1 (p.W288fs*9; MAF: 40%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2542_BA2820	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							7	14/24					73	73	1		Dead-Disease		1	Waves1+2	Yes	S0919 Trial (Pravastatin, Idarubicin, Cytarabine)|Hydroxyurea	2	Induction	1	Standard Chemotherapy	1	S0919 Trial (Pravastatin, Idarubicin, Cytarabine)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M4	Positive	FALSE	FALSE	TRUE	46,XY[20]	21	Standard Chemotherapy	FALSE	Positive	AML	0.9205479452054794	1:DECEASED	normal	Yes	No	Prostate Cancer	No	No	Yes	Yes	No	No	White	167	unknown		1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Positive (Myeloid blast immunophenotype: CD13, CD33, dim CD64, CD117, CD123 (+) Monocytic/monoblastic immunophenotype: bright CD11b, CD13, bright CD14, CD33, bright CD64, HLA-DR (+))	0	0.233333333		Standard Chemotherapy	Yes	DNMT3A (p.R882H; MAF 42%)|EP300 (p.N674D; MAF 50%)|EP300 (p.V2140I; MAF 50%)|FLT3-ITD (MAF ~48%)|MLL2 (p.M3398V; MAF 51%)|NPM1 (p.W288fs*12; MAF 43%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2543_BA2525	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							6	14/24					72	72	0.538461538		Dead-Disease		4	Waves1+2	Yes	Azacitidine, Lenalidomide|Temozolomide, Vorinostat	2	Induction|Re-induction	2	Standard Chemotherapy	1	Temozolomide, Vorinostat	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse			Positive	TRUE	FALSE	FALSE	46,XX,del(5)(q31q35),inv(7)(p15q32),del(12)(q?15)[2]/45~46,idem,add(3)(q27),-9,-del(12)(q?15),+add(12)(q13),-16,-17,+mar1,+mar2x2[cp16]/46,XX[2]	-1	Standard Chemotherapy	FALSE	Positive	AML	13.80821917808219	1:DECEASED		No	No		No	No	No	No	No	No		-1	Refractory		1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood		0	0.133333333	TP53	Standard Chemotherapy	Yes	TP53
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2555_BA2284	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							15	14/24					44	44	0.851851852		Alive		2	Waves1+2	Yes	HiDAC|7+3 (Cytarabine, Idarubicin) plus Crenolanib|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate			Positive	TRUE	FALSE	FALSE	45,XX,der(13;14)(q10;q10)?c[20]	-1	Bone Marrow Transplant	FALSE	Positive	AML	12.131506849315068	0:LIVING	nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No		No	No	No	No	No	No	White	-1	Complete Response		1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate		0	0.733333333		Standard Chemotherapy	Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2556_BA2401	Acute Myeloid Leukemia	AML with maturation	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							3	14/24					69	69	0.075268817		Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Sorafenib|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC|IMGN779 (Immunogen Trial)|Fludarabine, Cyclophosphamide, Thiotepa, TBI|ALRN-6924|Azacitidine, Midostaurin, Ponatinib	8	Salvage|Induction|Experimental|Re-induction	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other	3	IMGN779 (Immunogen Trial)	Salvage	Remission	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M2	Positive	FALSE	FALSE	FALSE	46,XX[20]	-1	Targeted Therapy - Other	FALSE	Negative	AML	18.575342465753423	1:DECEASED	normal	Yes	No	Breast Cancer	No	No	No	No	No	No	White	6	Refractory		2	Female	UNMATCHED	FALSE	AML with maturation	Post-Chemotherapy	Bone Marrow Aspirate	Positive (CD13, dim CD33, CD34, CD38, CD58 and CD123+)	46	0.1		Standard Chemotherapy	No	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2556_BA2721	Acute Myeloid Leukemia	AML with maturation	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							5	14/24					69	69	1		Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Sorafenib|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC|IMGN779 (Immunogen Trial)|Fludarabine, Cyclophosphamide, Thiotepa, TBI|ALRN-6924|Azacitidine, Midostaurin, Ponatinib	8	Salvage|Induction|Experimental|Re-induction	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other	3	IMGN779 (Immunogen Trial)	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Positive	FALSE	FALSE	FALSE	46,XX[20]	-1	Targeted Therapy - Other	FALSE	Negative	AML	18.575342465753423	1:DECEASED	normal	Yes	No	Breast Cancer	No	No	No	No	No	No	White	6	Refractory	RUNX1 (p.A187T; MAF 42%)	2	Female	UNMATCHED	FALSE	AML with maturation	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD13, CD34, CD58, CD117, partial MPO and HLA-DR +	0	0.166666667		Standard Chemotherapy	Yes	CREBBP (p.S893L; MAF 41%)|FLT3-ITD (MAF 47%)|RUNX1 (p.A187T; MAF 42%)|SF3B1 (p.K700E; MAF 51%)|TET2 (p.K751fs*61; MAF 44%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2570_BA2303	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							4	14/24					39	39	5.666666667		Alive		3	Both	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC + Midostaurin|Fludarabine, TBI	3	Allogeneic - Sibling|Consolidation|Induction	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, TBI	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate			Positive	FALSE	FALSE	FALSE	46,XX[20]	-1	Bone Marrow Transplant	FALSE	Positive	AML	9.731506849315068	0:LIVING		Yes	No	Cervical Cancer	No	No	No	No	No	No		-1	Complete Response		1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	Large pop. of promonocytes/monoblasts representing approx 57% of total leukocytes and increased atypicalCD117 pos, partial CD34 pos myeloblasts (partial CD7 pos) representing approx 6% of leukocytes consistent w/AMLw/monocytic differentiation.	0	0.166666667		Standard Chemotherapy	No	DNMT3A (p.Arg882His; MAF 41.8%)|FLT3 (p.Tyr572Cys; MAF 1.2%)|FLT3 (p.Val581_Arg595dup; MAF 22%)|FLT3-ITD|NPM1 (p.Trp288fs; MAF 21.2%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2578_BA3043	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							3	14/24					51	51			Dead-Disease		1	Waves1+2	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant	2	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	FavorableOrIntermediate	NON-HISPANIC	M4	Positive	TRUE	FALSE	FALSE	46,XX[20]	3	Standard Chemotherapy	FALSE	Positive	AML	7.265753424657534	1:DECEASED	Normal	No	No		No	No	No	No	No	No	White	6	Complete Response		1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	dim/partial CD7, variable CD13, CD33, dim/partial     CD64,     CD117, CD123, HLA-DR and cMPO positive	0	0.1		Standard Chemotherapy	Yes	DNMT3A (p.R882H; MAF 50%)|FLT3-ITD (exon 14 )|NPM1 (p.W288fs*12; MAF 40%)|WT1 (rs16754; no MAF available)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2579_BA3045	Acute Myeloid Leukemia	AML with myelodysplasia-related changes	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							5	14/24					46	47	0.538461538		Dead-Disease		2	Waves1+2	Yes	Azacitidine, Sorafenib|7+3 (Cytarabine, Idarubicin)|HiDAC|Crenolanib|PLX3397|Fludarabine, Cyclophosphamide, Thiotepa, TBI|AC220 (Ambit)	7	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT)	6	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Crenolanib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	FALSE	FALSE	FALSE	46,X,t(X;11)(p22.1;q13),add(7)(p22),add(17)(q21)[cp3]/45,X,-X,add(1)(q21),add(2)(q37),add(5)(q35),add(7)[cp3]/46,XX[4]	-1	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Negative	AML	15.747945205479454	1:DECEASED	Normal	No	No		No	No	No	No	No	No		9	Complete Response i		1	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Post-Transplant|Residual Disease	Peripheral Blood	CD2(dim +), CD7(-), CD13(partial dim +), CD14(-), CD15(partial +), CD33(+), CD34(+), CD38(partial +), CD45(moderately +), CD117(partial +), HLA-DR(variably +)	0	0.2		Standard Chemotherapy	Yes	FLT3-D835 (NOT FOUNDATION NO MAF AVAILABLE)|FLT3-ITD (NOT FOUNDATION NO MAF AVAILABLE)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2581_BA3047	Acute Myeloid Leukemia	AML with mutated NPM1	D586_F612dup	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608299	28608300	-	CAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTAT	13:g.28608299_28608300insCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTAT	ENST00000241453.7:c.1757_1837dup	0.28		55	141			4	14/24					63	63	0.538461538		Dead-Disease		1	Waves1+2	Yes	Fludarabine, Melphalan|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Allogeneic - Sibling|Salvage|Induction|Supportive/Palliative Care	4	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	3	Decitabine	Supportive/Palliative Care	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M4	Positive	FALSE	TRUE	TRUE	49,XX,+X,+8,+10[13]/46,XY[7]	-1	Supportive/Palliative Care	FALSE	Positive	AML	5.523287671232877	1:DECEASED	Trisomy 8 (24%)	No	No		No	No	Yes	Yes	No	No	White	-1	Refractory		1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Relapse|Post-Transplant|Post-Chemotherapy	Bone Marrow Aspirate	dim CD13, CD33, CD34, CD117, CD123, and dim HLADR	0	0.133333333		Standard Chemotherapy	Yes	DNMT3A (p.R882H; MAF 30%)|FLT3-ITD (Weakly positive; MAF 1.3%)|JAK3 (p.V722I; MAF 50%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2584_BA3053	Acute Myeloid Leukemia	AML with mutated NPM1	X592_X592insVDFREYEYDLKWEFPRENLEFGF	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608281	28608282	-	AACCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAA	13:g.28608281_28608282insAACCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAA	ENST00000241453.7:c.1837+2_1837+3insTTTGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTTTGGT	0.07		11	147			3	14/24					63	64	0.785714286		Dead-Disease		3	Waves1+2	Yes	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Sorafenib	5	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Sorafenib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial		M1	Positive	FALSE	FALSE	FALSE	46,XY[6]	-1	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Positive	AML	12.986301369863014	1:DECEASED		No	No		No	No	No	No	No	No		-1	Complete Response		1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Residual Disease|Post-Chemotherapy|Post-Transplant	Peripheral Blood		0	0.1		Standard Chemotherapy	Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2590_BA3065	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							4	14/24					69	72			Alive		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Sorafenib|MiDAC|Treo/Flu/TBI (Treosulfan, Fludarabine, Total Body Irradiation)	7	Allogeneic - Sibling|Consolidation|Unknown|Induction|Re-induction|Maintenance|Supportive/Palliative Care	7	DLI|Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	4	Sorafenib	Maintenance	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC		Positive	FALSE	TRUE	FALSE	46,XY[18]	-1	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Positive	AML	101.1945205479452	0:LIVING	Normal	No	No		No	No	No	No	No	No	White	32	Complete Response		1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Post-Transplant|Relapse|Post-Chemotherapy	Peripheral Blood	Immunophenotype: dim CD13, CD33, CD117, CD123 and MPO positive.	0	0.166666667		Standard Chemotherapy	Yes	CEBPA (p.A240fs*83 (7 bp insertion with frameshift); MAF 19%)|CREBBP (p.P1150S; MAF 18%)|FLT3-ITD (MAF 56%)|IDH2 (p.R140Q; MAF 29%)|NPM1 (p.W288fs*12; MAF 29%)|SRSF2 (p.P95L; MAF 22%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2594_BA3385	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							4	14/24					50	50	0.492537313		Dead-Disease		1	Waves3+4	Yes	HiDAC|7+3 (Cytarabine, Daunorubicin) plus Crenolanib|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M4	Positive	TRUE	FALSE	FALSE	46,XX[20]	-1	Bone Marrow Transplant	FALSE	Positive	AML	8.67945205479452	1:DECEASED	Normal	No	No		No	No	No	No	No	No	White	6	Complete Response		1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Myeloid blasts immunophenotype:  CD7, partial CD13, CD33, partial CD34, CD117, HLA-DR and MPO | Monoblasts immunophenotype: dim CD4, CD11b, partial CD13, CD14, CD15, bright CD33, CD64, HLA-DR	0	0.133333333		Standard Chemotherapy	Yes	DNMT3A (p.S714C; VAF 43%)|FLT3-ITD (p.E596delinsQVTGSSDNEYFYVDFRE (48-nucleotide internal tandem duplication); VAR 0.79; VAF 44%)|NPM1 (p.W288fs*12; VAF 44%)|WT1 (p.S381fs*4; VAF 43%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2602_BA3335	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							7	14/24					56	56			Alive		5	Waves3+4	Yes	Venetoclax (ABT-199), Azacitidine	1	Induction	1	Standard Chemotherapy	1	Venetoclax (ABT-199), Azacitidine	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	FavorableOrIntermediate			Positive	TRUE	FALSE	FALSE	46,XX[22]	30	Standard Chemotherapy	FALSE	Positive	AML	16.898630136986302	0:LIVING	Normal	No	No		No	No	No	No	No	No	White	30	Refractory		1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood		0	0.266666667		Standard Chemotherapy	Yes	DNMT3A (P38SRfs*22; VAF 22%)|FLT3-ITD|GATA2 (T354_T355 insF; VAF 15%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2613_BA3435	Acute Myeloid Leukemia	AML without maturation	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							7	14/24					79	79	0.111111111	ASXL1 (p.G646Wfs*12; 30.2%)	Dead-Disease		1	Waves3+4	Yes	Decitabine|Azacitidine, BI 836858 (anti-CD33)	2	Salvage|Induction	2	Standard Chemotherapy	1	Decitabine	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M1	Positive	TRUE	FALSE	FALSE	47,XY,+8[18]/46,XY[2]	37	Standard Chemotherapy	FALSE	Negative	AML	4.438356164383562	1:DECEASED	CEP8 and RUNX1T1 (8q21.3): ~90% of cells had an extra signal for chromosome 8 probes, consistent with trisomy 8, as seen on metaphase analysis.	No	No		No	No	No	No	No	No	White	50	Refractory	RUNX1 (p.T246Hfs*15; 25.0%)	1	Male	MATCHED	FALSE	AML without maturation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	partial CD13, partial CD33, CD34, CD117, CD123, partial HLA-DR, and partial MPO	0	0.266666667		Standard Chemotherapy	Yes	FLT3-ITD (MAF 16%)|IDH1 (p.R132C; MAF 46%)|JAK2 (p.V617F; MAF 12%)|RUNX1 (p.T246fs*15; MAF 50%)|U2AF1 (p.Q157P; MAF 48%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2626_BA3095	Acute Myeloid Leukemia	AML without maturation	V615_L616insTGSSDNEYFYVDFREYEYDLKWEFPRENLEFGKNGMCQMFLQHFFSIGKSLKCTYSPFVFAGKV	OncoKB: Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608313	28608314	-	ACCTTCCCTGCAAAGACAAATGGTGAGTACGTGCATTTTAAAGATTTTCCAATGGAAAAGAAATGCTGCAGAAACATTTGGCACATTCCATTCTTACCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTC	13:g.28608313_28608314insACCTTCCCTGCAAAGACAAATGGTGAGTACGTGCATTTTAAAGATTTTCCAATGGAAAAGAAATGCTGCAGAAACATTTGGCACATTCCATTCTTACCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTC	ENST00000241453.7:c.1743_1844dup	0.26		58	164			6	14/24					27	27	0.818181818		Alive		1	Waves3+4	Yes	Ruxolitinib|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Busulfan, Cyclophosphamide|Ibrutinib	7	Consolidation|Induction|Re-induction|Maintenance|Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Ruxolitinib	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M1	Positive	TRUE	FALSE	FALSE	47,XX,+8[19]/46,XX[1]	-1	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Negative	AML	49.70958904109589	0:LIVING	RUNX1T1 (8q21.3):   93% of cells had three signals for RUNX1T1 (8q21.3)  consistent with trisomy 8 as seen on metaphase analysis.	No	No		No	No	No	No	No	No	White	6	Refractory		1	Female	MATCHED	FALSE	AML without maturation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim CD7, CD13, CD33, dimCD34, dimCD64, dim CD117, CD123, and dim HLA-DR+	0	0.233333333		Standard Chemotherapy	Yes	FLT3-ITD (MAF 50% )
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2639_BA3275	Acute Myeloid Leukemia	Acute Myeloid Leukemia	X591_X591insYVDFREYEYDLKWEFPRENLEFGVD	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608284	28608285	-	CCACACCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGT	13:g.28608284_28608285insCCACACCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGT	ENST00000241453.7:c.1837+2_1837+3insGTGGACGTTGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTTTGGT	0.15		47	272			4	14/24							0.388888889				3	Waves3+4	No		0		0		0	NONE	NONE	Unknown	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	unknown	unknown	unknown			None	FALSE	Negative	AML	0.0			No	No		No	No	No	No	No	No					1	Male	UNMATCHED	FALSE	Unknown	Unknown	Peripheral Blood		0	0.2			Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2645_BA3286	Acute Myeloid Leukemia	AML without maturation	X582_X582insTGSSDNEYFYVDFREYEYDLKWEFPRENLEFGKNGMCQMALSEA	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608311	28608312	-	CCTCACTCAACGCCATTTGGCACATTCCATTCTTACCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGG	13:g.28608311_28608312insCCTCACTCAACGCCATTTGGCACATTCCATTCTTACCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGG	ENST00000241453.7:c.1837+23_1837+24insGCGTTGAGTGAGGCCGGCTCCTCAGATAATGAGTACTTCTACGTTGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTTTGGTAAGAATGGAATGTGCCAAATG	0.21		55	206			4	14/24					45	45	0.298701299		Alive		1	Waves3+4	Yes	7+3 (Cytarabine, Daunorubicin) plus Sorafenib|HIDAC + Sorafenib|7+3 (Cytarabine, Idarubicin) plus Sorafenib	3	Consolidation|Induction|Re-induction	3	Standard Chemotherapy	1	HIDAC + Sorafenib	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M1	Positive	TRUE	FALSE	FALSE	46,XX[20]	-1	Standard Chemotherapy	FALSE	Negative	AML	3.419178082191781	0:LIVING	Normal	No	No		No	No	No	No	No	No	Declined	6	Complete Response		2	Female	MATCHED	FALSE	AML without maturation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dimCD7, dimCD13, CD33, CD34, CD38, variable CD64, dimCD117, CD123, HLA-DR, and MPO positive	0	0.1		Standard Chemotherapy	Yes	FLT3-ITD (123 bp insertion; MAF 50%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2648_BA3280	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							9	14/24					51	51	0.136363636		Alive		5	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable			Positive	TRUE	FALSE	FALSE	46,XY[20]	-1	Standard Chemotherapy	FALSE	Positive	AML	2.695890410958904	0:LIVING		No	No		No	No	No	No	No	No	White	-1	Complete Response		1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	positive for CD117, CD13, CD33, and HLA-DR. Roughly half of the blasts were positive for CD34, roughly half of the blasts showed aberrant dim expression of CD7, and roughly half of the cells showed aberrant dim expression of CD19.	0	0.433333333		Standard Chemotherapy	Yes	ASXL1|CEBPA|FLT3-ITD|NPM1|NRAS|PTPN11|STAG2
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2650_BA3227	Acute Myeloid Leukemia	AML with mutated NPM1	L576_K602dup	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608329	28608330	-	ATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGTACCATCTGTA	13:g.28608329_28608330insATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGTACCATCTGTA	ENST00000241453.7:c.1727_1807dup	0.15		80	465			3	14/24					70	70	0.149425287		Alive		1	Waves3+4	Yes	MIDAC, Midostaurin|7+3 (Cytarabine, Idarubicin) plus Midostaurin|Methotrexate|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	4	Allogeneic - Sibling|Consolidation|Induction	3	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	3	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M1	Positive	TRUE	FALSE	FALSE	46,XX[20]	-1	Bone Marrow Transplant	FALSE	Positive	AML	39.057534246575344	0:LIVING	Normal	No	No		No	No	No	No	No	No	White	6	Refractory		1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim CD13, CD33, CD38, CD117, and MPO +	0	0.1		Standard Chemotherapy	Yes	ATM (p.K1454N; VAF 49%)|BCL6 (p.A321V; VAF 49%)|FLT3-ITD (Allelic ratio: 0.32)|IDH2 (p.R140Q; VAF 49%)|NOTCH2 (p.P2377L; VAF 48%)|NPM1 (p.W288fs*12; VAF 69%)|NRAS (p.A59T; VAS 3%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2654_BA3386	Acute Myeloid Leukemia	AML with mutated NPM1	E596_F612dup	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608269	28608270	-	CAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATT	13:g.28608269_28608270insCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATT	ENST00000241453.7:c.1787_1837dup	0.09		19	193			4	14/24					63	63	32.33333333		Alive		1	Waves3+4	Yes	Fludarabine, Melphalan|Gilteritinib or Placebo|MIDAC, Midostaurin|7+3 (Cytarabine, Idarubicin) plus Midostaurin|Methotrexate	5	Consolidation|Induction|CNS|Maintenance|Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Kinase Inhibitor(s)	4	Gilteritinib or Placebo	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M1	Positive	TRUE	FALSE	FALSE	46,XX[20]	734	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Positive	AML	34.38904109589041	0:LIVING		No	No		No	No	No	No	No	No	White	6	Refractory		1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Leukapheresis	dim CD7, partial CD11b, dim CD13, variable CD25, CD33, partial CD34, CD117, HLA-DR, and MPO positive	0	0.133333333		Standard Chemotherapy	Yes	DNMT3A (p.G543C; VAF 49%)|FLT3-ITD (VAF 76%; VAR 13.3)|NPM1 (p.W288fs*12; VAF 45%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2656_BA3151	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							10	14/24					53	53	0.666666667		Alive		2	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|Decitabine	2	Induction|Maintenance	2	Standard Chemotherapy	1	Decitabine	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse			Positive	FALSE	FALSE	TRUE	45,XX,del(3)(p13p26),-5[cp3]/48,idem,+8,der(9;12)(q10;q10),+19,+21,idic(21)(p11.2)x2,+mar[cp5]/50,idem,+8,der(9)t(5;9)(p13;p13),+19,+21,+21,idic(21)x2,+mar[cp8]/50,idem,del(9)(p13p22),der(9)t(5;9),+19,+21,+21,idic(21)x2,+mar[cp4]	-1	Standard Chemotherapy	FALSE	Positive	AML	4.997260273972603	0:LIVING		No	No		No	No	No	No	Yes	Yes	White	-1	Refractory		1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate		0	0.4	TP53 (p.Y220H; 63.6%)	Standard Chemotherapy	Yes	TP53
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2659_BA3421	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							5	14/24					52	52	0.724137931		Alive		5	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin) plus Midostaurin|Midostaurin|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Induction|Maintenance	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Midostaurin	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate			Positive	TRUE	FALSE	FALSE		13	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Positive	AML	5.950684931506849	0:LIVING	Normal/Negative Rearrangement	No	No		No	No	No	No	No	No	White	-1	Complete Response		1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate		0	0.133333333		Standard Chemotherapy	Yes	DNMT3A (MAF 47%)|FLT3-ITD (2 on separate alleles: p.E604_F605insYDLKWE, MAF 19%; p.L601_K602ins18, MAF 9%)|NPM1 (MAF 44%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2672_BA3266	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							4	14/24					83	83	0.587301587		Dead-Disease		1	Waves3+4	No		0		0		0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M2	Positive	TRUE	FALSE	FALSE	46,XX[20]		None	FALSE	Positive	AML	0.9205479452054794	1:DECEASED		No	No		No	No	No	No	No	No	White				1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim CD4, CD7, partial CD9, CD13, CD25, CD33, partial CD34, CD38, CD117, CD123, HLA-DR and MPO-positive	0	0.166666667			Yes	BRAF (p.S87N; VAF 52%)|DNMT3A (p.R882C; VAF 47%)|FLT3-ITD (Allelic ratio: 0.464; VAF 31.7%)|IDH1 (p.R132H; VAF 32%)|IDH2 (p.R140Q; VAF 3%)|NPM1 (p.W288fs*12; VAF 42%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2676_BA3189	Acute Myeloid Leukemia	AML with maturation	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							1	14/24					20	20	1		Alive		1	Waves3+4	Yes	Cytarabine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|7+3 (Cytarabine, Daunorubicin) plus Midostaurin|Busulfan, Cyclophosphamide	5	Allogeneic - Sibling|Induction|Re-induction|Maintenance	4	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Kinase Inhibitor(s)	4	Sorafenib	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Positive	TRUE	FALSE	FALSE	46,XY,del(2)(q11.2q21)[3]	317	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Negative	AML	44.580821917808215	0:LIVING	Normal	No	No		No	No	No	No	No	No	White	6	Refractory		1	Male	UNMATCHED	FALSE	AML with maturation	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD13, CD33, CD34, CD38, CD58, dim CD64, CD117,  variable MPO	0	0		Standard Chemotherapy	Yes	FLT3-ITD (p.E608delinsDPVDFREYEYDLKWEFPRE; p.E598delinsDLSYVDFREYE;  ratio: ~1.0; Two visible FLT3 ITD insertions, one  of ~ 10 amino acids (predominating, with a high mutant allele ratio) and  one of ~18 amino acids (smaller sub-clone).)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2677_BA3289	Acute Myeloid Leukemia	AML with minimal differentiation	W603_E604insGVTGSSDNEYFYVDFREYEYDLKW	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608315	28608316	-	TCCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCAC	13:g.28608315_28608316insTCCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCAC	ENST00000241453.7:c.1810_1811insGAGTGACCGGCTCCTCAGATAATGAGTACTTCTACGTTGATTTCAGAGAATATGAATATGATCTCAAATGGG	0.21		40	152			9	14/24					61	61	0.587301587		Alive		5	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|Midostaurin|Fludarabine, Cyclophosphamide, Thiotepa, TBI	3	Induction|Double Umbilical Cord Blood Transplant (DUCBT)|Supportive/Palliative Care	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse		M0	Positive	TRUE	FALSE	FALSE		-1	Bone Marrow Transplant	FALSE	Negative	AML	5.819178082191781	0:LIVING	Normal	No	No		No	No	No	No	No	No	White	-1	Complete Response		1	Male	MATCHED	FALSE	AML with minimal differentiation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate		0	0.266666667		Standard Chemotherapy	Yes	DNMT3A|FLT3-ITD|TET2
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2679_BA3454	Acute Myeloid Leukemia	AML with mutated NPM1	N609_L610insFDFREYEYDLKWEFPREN	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608280	28608281	-	AAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCA	13:g.28608280_28608281insAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCA	ENST00000241453.7:c.1776_1829dup	0.04		9	196			3	14/24					82	82	0.960784314		Dead-Disease		1	Waves3+4	No		0		0		0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M2	Positive	TRUE	FALSE	FALSE	46,XX[20]		None	FALSE	Positive	AML	0.4602739726027397	1:DECEASED	Normal	No	No		No	No	No	No	No	No	White				1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD13, CD33, CD117, and MPO	0	0.1			Yes	DNMT3A (p.R882C; VAF 48%)|FLT3-ITD (VAF 44%; Allelic ratio 0.77)|NPM1 (p.W288fs*12; VAF 48%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2685_BA3293	Acute Myeloid Leukemia	AML with mutated NPM1	D593_L610dup	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608277	28608278	-	TCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAA	13:g.28608277_28608278insTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAA	ENST00000241453.7:c.1779_1832dup	0.09		21	205			3	14/24					53	55	11.5		Dead-Disease		1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	3	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Mismatched Unrelated Donor	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M4	Positive	FALSE	TRUE	FALSE	46,XX[20]	-1	Bone Marrow Transplant	FALSE	Positive	AML	27.452054794520546	1:DECEASED		Yes	No	Cervical Cancer	No	No	No	No	No	No	White	6	Complete Response		1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Relapse|Post-Chemotherapy|Post-Transplant	Leukapheresis	variable CD11b, CD13, CD33, dim CD123, partial HLA-DR, dim/partial MPO	0	0.1		Standard Chemotherapy	Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2692_BA3083	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							8	14/24						57	5.666666667				3	Waves3+4	No		0		0		0	NONE	NONE	Unknown	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	unknown	unknown	unknown			None	FALSE	Positive	AML	0.0			No	No		No	No	No	No	No	No					1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Unknown	Peripheral Blood		0	0.366666667			Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2697_BA3211	Acute Myeloid Leukemia	AML with myelodysplasia-related changes	X583_X583insGSSDNEYFYVDFREYEYDLKWEFPRENLEFGKNGRS	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608308	28608309	-	TTCTTCCATTCTTACCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGC	13:g.28608308_28608309insTTCTTCCATTCTTACCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGC	ENST00000241453.7:c.1837+12_1837+13insGAAGCTCCTCAGATAATGAGTACTTCTACGTTGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTTTGGTAAGAATGGAA	0.26		147	413			8	14/24					69	69	0.176470588		Dead-Disease		1	Waves3+4	Yes	Gilteritinib (ASP2215)|Azacitidine|RVD (Bortezomib, Dexamethasone, Lenalidomide)|7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin	4	Salvage|Induction|Maintenance	3	Standard Chemotherapy|Targeted Therapy - Other	2	Gilteritinib (ASP2215)	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M0	Positive	FALSE	FALSE	TRUE	46,XY,del(20)(q11.2)[cp20]	-1	Targeted Therapy - Other	FALSE	Negative	AML	2.4986301369863013	1:DECEASED	CEP 3:  16/100 cells (16%) had three signals, reflecting trisomy 3.	No	No		Yes	Yes	No	No	No	No	White	6	Refractory	RUNX1 (p.R346Pfs*254; 37.7%)|RUNX1 (p.X269_splice; 43.5%)	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	CD43+ and dim CD45+ with dim CD13, dim CD33, dim CD38, partial CD11b, variable HLA-DR, and partial, dim CD117	0	0.333333333		Standard Chemotherapy	Yes	FLT3-ITD (allelic ratio 0.84; VAF 45.7%)|KMT2A (PTD (exon 11/exon 3))|RUNX1 (splice site; VAF 43%)|U2AF1 (p.S34F; VAF 44%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2699_BA3352	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							12	14/24					73	73	1.222222222		Dead-Disease		2	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate			Positive	TRUE	FALSE	FALSE	46,XY[20]	-1	Standard Chemotherapy	FALSE	Positive	AML	0.7232876712328767	1:DECEASED	Normal	No	No		No	No	No	No	No	No	White	-1	Refractory		1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD34(-), CD13(predominantly -), CD33(+), CD38(partial +), CD45(dim +), CD56(variably +), CD64(partial dim +), CD117(+),HLA-DR(-), MPO(+), TdT(-), other myeloid and lymphoid antigens(predominantly -).	0	0.466666667		Standard Chemotherapy	Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2706_BA3125	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							5	14/24					59	59	0.162790698		Alive		1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin) plus Midostaurin	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin) plus Midostaurin	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M4	Positive	TRUE	FALSE	FALSE	46,XY[20]	20	Standard Chemotherapy	FALSE	Positive	AML	1.0191780821917809	0:LIVING		No	No		No	No	No	No	No	No	Black	20	Unknown		1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Leukapheresis	Myloid blast population, about 25%: variable CD13, CD33, partial CD34, CD38, CD117, CD123, HLA-DR and dim MPO | Monoblast population, about 50%: Dim CD9, bright CD11b, variable CD13, CD16, CD33, CD38, CD56, CD64, HLA-DR	0	0.2		Standard Chemotherapy	Yes	BIRC6 (p.S3135C; VAF 52%)|BRCA2 (p.P59A; VAF 48%)|CDKN2C (p.D64N; VAF 51%)|DNAH5 (p.G2668R; VAF 48%)|DNMT3A (p.R882H; VAF 48%)|EFTUD1 (p.S504Y; VAF 49%)|FLT3-ITD (p.E598delinsDYVDFREYE (24-nucleotide ITD); VAR 0.082; VAF 5.2%)|FLT3-ITD (p.P606delinsPFREYE
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2714_BA3232	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							7	14/24					36	36	0.265822785		Dead-Disease		1	Waves3+4	Yes	Azacitidine, Sorafenib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|SY-1425 (Tamibarotene) plus Daratumumab|7+3 (Cytarabine, Idarubicin) plus Midostaurin|Busulfan, Cyclophosphamide|Cytarabine, Methotrexate	6	Allogeneic - Sibling|Induction|Experimental|Re-induction|Maintenance	5	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Other	4	SY-1425 (Tamibarotene) plus Daratumumab	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M4	Positive	TRUE	FALSE	FALSE	46,XX[20]	28	Targeted Therapy - Other	FALSE	Positive	AML	12.164383561643836	1:DECEASED	Normal	No	No		No	No	No	No	No	No	White	-1	Complete Response		1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim CD7, partial CD11b, variable CD13, CD33, CD64,  CD117, dim CD123, dim HLA-DR and partial MPO positive	0	0.3		Standard Chemotherapy	Yes	BCOR (p.V89D; MAF 54%)|DNMT3A (p.R882H; MAF 51%)|FLT3-ITD (MAF 15%)|NPM1 (p.W288fs*12; MAF 48%)|NRAS (p.G12S; MAF 20%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2717_BA3228	Acute Myeloid Leukemia	AML with myelodysplasia-related changes	L601_K602insREVTGSSDNEYFYVDFREYEYDL	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608317	28608318	-	CCCTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCT	13:g.28608317_28608318insCCCTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCT	ENST00000241453.7:c.1804_1805insGGGAGGTGACCGGCTCCTCAGATAATGAGTACTTCTACGTTGATTTCAGAGAATATGAATATGATCTCA	0.06		15	230			6	14/24					68	69			Alive		1	Waves3+4	Yes	Azacitidine|7+3 (Cytarabine, Idarubicin) plus Midostaurin|Cytarabine, Midostaurin	3	Induction|Re-induction|Supportive/Palliative Care	3	Standard Chemotherapy	1	Cytarabine, Midostaurin	Re-induction	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC		Positive	FALSE	FALSE	TRUE	46,XX,i(14)(q10)[8]/46,XX[12]	-1	Standard Chemotherapy	FALSE	Negative	AML	16.24109589041096	0:LIVING	IGH (14q32) breakapart probe set, as listed  below.  4/200 interphase cells had three intact signals, but one abnormal  metaphase was found, which had an IGH signal on either end of the  i(14)(q10).	No	No		No	No	Yes	Yes	No	No	White	11	Refractory	RUNX1 (p.R320*; 49.8%)	1	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood		0	0.266666667		Standard Chemotherapy	Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2725_BA3255	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							14	14/24					55	55	3		Dead-Disease		1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC + Midostaurin|Decitabine, Sorafenib |Busulfan, Cyclophosphamide	4	Allogeneic - Sibling|Consolidation|Salvage|Induction	4	Standard Chemotherapy|Bone Marrow Transplant	2	Decitabine, Sorafenib	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M0	Positive	TRUE	FALSE	FALSE	46,XY[20]	61	Standard Chemotherapy	FALSE	Positive	AML	8.942465753424658	1:DECEASED	Normal	No	No		No	No	No	No	No	No	White	6	Complete Response		1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim partial CD4, dim partial CD7, dim CD11b, CD13, CD33,  partial CD34, CD38, CD58, dim CD71, CD117, CD123 and HLA-DR+	0	0.6		Standard Chemotherapy	Yes	DNMT3A (Splice site (start of intron 18; likely pathogenic); MAF 47%)|FLT3-ITD (p.E598delinsDYVDFREYE; MAF 60%)|NPM1 (p.W290fs*10; MAF 45%)|WT1 (p.D464N; MAF 46%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2733_BA3135	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							4	14/24					63	63	0.315789474		Alive		8	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable		M1	Positive	TRUE	FALSE	FALSE		7	Standard Chemotherapy	FALSE	Positive	AML	1.5780821917808217	0:LIVING		No	No		No	No	No	No	No	No	Black	7	Complete Response		1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	dim CD56 | dim CD15 | dim CD123	0	0.133333333		Standard Chemotherapy	Yes	FLT3-ITD
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2734_BA3226	Acute Myeloid Leukemia	Therapy-related myeloid neoplasms	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							3	14/24					75	75	0.960784314		Dead-Disease		1	Waves3+4	Yes		0		0		0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M2	Positive	FALSE	FALSE	FALSE	46,XX[20]		None	FALSE	Positive	AML	1.2164383561643834	1:DECEASED	Normal	Yes	Yes	Breast Cancer	No	No	No	No	No	No	White				1	Female	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	dim CD11b, CD13, CD33, partial CD34, partial CD38, dim CD45, partial CD64, CD58, partial CD117, CD123 and partial MPO positive	0	0.066666667			Yes	FLT3-ITD (MAF 44%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2738_BA3197	Acute Myeloid Leukemia	AML with mutated NPM1	T582_E604dup	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608312	28608313	-	CTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGT	13:g.28608312_28608313insCTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGT	ENST00000241453.7:c.1744_1812dup	0.22		59	211			3	14/24					47	47	0.785714286		Dead-Disease		1	Waves3+4	No		0		0		0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M1	Positive	TRUE	FALSE	FALSE			None	FALSE	Positive	AML	0.3287671232876712	1:DECEASED	PML/RARA: Negative	No	No		No	No	No	No	No	No	White				1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	partial CD13, CD33, CD38, partial CD56, CD58, CD117,  CD123, and MPO positive	0	0.1			Yes	FLT3-ITD (p.F605delinsTGSSDNEYFYVDFREYEYDLKWEF; MAF 46%)|IDH1 (p.R132G; MAF 47%)|NOTCH1 (p.E1555V; MAF 51%)|NPM1 (p.W288fs*12; MAF 50%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2741_BA3328	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							9	14/24					63	63	0.754385965		Dead-Treatment		1	Waves3+4	Yes	Fludarabine, Melphalan|HiDAC|7+3 (Cytarabine, Idarubicin) plus Midostaurin	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M1	Positive	TRUE	FALSE	FALSE	46,XX[15]	-1	Bone Marrow Transplant	FALSE	Positive	AML	5.49041095890411	1:DECEASED	Normal	No	No		No	No	No	No	No	No	White	6	Complete Response		1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	dim CD13, CD33, CD38, partial CD56, CD58, CD64, dim CD117, CD123 and MPO+	0	0.333333333		Standard Chemotherapy	Yes	DNMT3A (p.R326L; MAF 47%)|FLT3-ITD (MAF 43%; mutant allelic ratio 0.74)|IDH2 (p.R140Q; MAF 47%)|NPM1 (p.W288fs*12; MAF 48%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2749_BA3375	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							5	14/24					63	63	0.754385965		Dead-Treatment		1	Waves3+4	Yes	Fludarabine, Melphalan|MiDAC|7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M1	Positive	TRUE	FALSE	FALSE		-1	Bone Marrow Transplant	FALSE	Positive	AML	5.6219178082191785	1:DECEASED	Normal	No	No		No	No	No	No	No	No	White	7	Complete Response		1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	dim CD13, CD33, CD117 and MPO-positive	1	0.2		Standard Chemotherapy	Yes	CHD2 (p.P1353L; VAF 50%)|CHEK2 (p.T410fs*15; VAF 51%)|FLT3 (p.N676K; VAF 4%)|FLT3-ITD (p.F594delinsLPSDNEYFYVDF (33-nucleotide internal tandem duplication); allelic ratio 0.85; VAF 46%)|IDH1 (p.R132S; VAF 47%)|KMT2A (p.F798L; VAF 49%)|NPM1 (p.W288fs*12; V
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2770_BA3180	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							8	14/24					27	27	0.886792453		Alive		5	Waves3+4	Yes	Fludarabine, Cyclophosphamide, Thiotepa, TBI|7+3 (Cytarabine, Idarubicin) plus Azacitidine	2	Induction|Double Umbilical Cord Blood Transplant (DUCBT)	2	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate			Positive	TRUE	FALSE	FALSE		-1	Bone Marrow Transplant	FALSE	Positive	AML	3.8136986301369866	0:LIVING		No	No		No	No	No	No	No	No	White	-1	Complete Response		1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate		0	0.333333333		Standard Chemotherapy	Yes	FLT3-ITD|IDH2
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2776_BA3146	Acute Myeloid Leukemia	AML with mutated NPM1	V581_E611dup	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608315	28608316	-	CTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCAC	13:g.28608315_28608316insCTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCAC	ENST00000241453.7:c.1741_1833dup	0.27		152	415			5	14/24					42	42	0.176470588		Dead-Treatment		1	Waves3+4	Yes	HIDAC + Gemtuzumab Ozogamicin|7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Consolidation|Induction	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Positive	TRUE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	FALSE	Positive	AML	4.602739726027397	1:DECEASED	Normal	No	No		No	No	No	No	No	No	White	6	Complete Response		1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD7, CD13, CD25, CD33, partial CD34, CD117, dim CD123, HLA-DR, and MPO.	0	0.166666667		Standard Chemotherapy	Yes	DNMT3A (p.R882H; VAF 45%)|FLT3-ITD (allelic ratio 0.85; VAF 45.9%)|NPM1 (p.W288fs*12; VAF 69%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2777_BA3230	Acute Myeloid Leukemia	AML with maturation	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							5	14/24					71	71	0.694915254	ASXL1 (p.E635Rfs*15; 22.0%)	Dead-Disease		1	Waves3+4	Yes	Decitabine	1	Induction	1	Standard Chemotherapy	1	Decitabine	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Positive	TRUE	FALSE	FALSE	46,XX,del(12)(p12p13)[23]	-1	Standard Chemotherapy	FALSE	Negative	AML	10.816438356164383	1:DECEASED	Normal	No	No		No	No	No	No	No	No	White	-1	UNKNOWN		1	Female	UNMATCHED	FALSE	AML with maturation	Initial Acute Leukemia Diagnosis	Peripheral Blood	dim CD5, CD13, dim CD33, CD34, variable CD38, CD58, CD117, dim CD123 and HLA-DR positive	0	0.2		Standard Chemotherapy	Yes	CREBBP (W1745*; MAF ~50%)|FLT3-ITD (MAF ~50%)|SF3B1 (p.K666M; MAF ~50%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2781_BA3376	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							2	14/24					58	58	1.040816327		Alive		1	Waves3+4	Yes	Gilteritinib or Placebo|HiDAC + Midostaurin|7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin|Busulfan, Cyclophosphamide	4	Allogeneic - Sibling|Consolidation|Induction|Maintenance	4	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	3	Gilteritinib or Placebo	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M1	Positive	TRUE	FALSE	FALSE	46,XX[20]	-1	Targeted Therapy - Other	FALSE	Positive	AML	26.400000000000002	0:LIVING	Normal	No	No		No	No	No	No	No	No	White	6	Complete Response		1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD11b, CD13, CD33, variable CD34, CD38, CD117, CD123, and MPO positive	0	0.033333333		Standard Chemotherapy	Yes	CEBPA (p.G242S; VAF 47%)|FLT3-ITD (allelic ratio 1.03; VAF 51%)|NPM1 (p.W290fs*10; VAF 49%)|SYNE1 (p.A2715G; VAF 50%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2783_BA3175	Acute Myeloid Leukemia	AML with myelodysplasia-related changes	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							8	14/24					62	63	0.234567901		Dead-Disease		1	Waves3+4	Yes	Decitabine, anti-PD1, anti-TIM3|7+3 (Cytarabine, Idarubicin)|JNJ-40346527 (CSF1R inhibitor)|Mitoxantrone|FLAG, Midostaurin	5	Salvage|Induction|Re-induction	3	Standard Chemotherapy|Targeted Therapy - Other	2	Mitoxantrone	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC		Positive	FALSE	FALSE	FALSE	46,XY,t(1;3)(p36;q21)[2]/46,sl,-1,+der(1)t(1;3)(p36;q21)[15]/46,sl,add(3)(q12)[2]/46,sl,-1,+t(1;3)(p36;q21),-3[1]	0	Standard Chemotherapy	FALSE	Negative	AML	12.263013698630136	1:DECEASED	MECOM/RPN1:  171/200 cells (85.5%) had a 2 red/ 3 green signal pattern,  reflecting an extra RPN1 (3q21.3) signal, consistent with RPN1 disruption  due to the 1;3 translocation observed in the metaphase karyotype.  There  was no evidence for MECOM/RPN1 fu	No	No		No	No	No	No	No	No	White	6	Refractory	RUNX1 (p.D198N; 44.9%)	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood	CD7, CD13, CD33, CD34, CD117, and HLA-DR positive	248	0.333333333		Standard Chemotherapy	Yes	BCL2 (p.A32G; VAF 48%)|FLT3-ITD (p.N609delinsIIPCPEYDLKWEFPREN; VAF 19%, allelic ratio 0.24)|GATA2 (p.S201fs*1; VAF 13%)|NPM1 (p.H30Q; VAF 3%)|NRAS (p.G12D; VAF 72%)|RUNX1 (p.D198N; VAF 44%)|WT1 (p.R380fs*5; VAF 45%)|WT1 (p.V371fs*14; VAF 22%)|ZRSR2 (p.P3
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2788_BA3357	Acute Myeloid Leukemia	AML with maturation	D600_L601insQQVTGSSDNEYFYVDFREYEYD	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608319	28608320	-	TGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGT	13:g.28608319_28608320insTGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGT	ENST00000241453.7:c.1801_1802insAACAGGTGACCGGCTCCTCAGATAATGAGTACTTCTACGTTGATTTCAGAGAATATGAATATGATC	0.05		11	196			3	14/24					75	75	0.162790698		Dead-Disease	mono	1	Waves3+4	Yes	Gilteritinib (ASP2215)|Venetoclax (ABT-199), Azacitidine|Gilteritinib, Decitabine|PIM kinase inhibitor	4	Salvage|Induction|Re-induction	3	Standard Chemotherapy|Targeted Therapy - Other	2	PIM kinase inhibitor	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M2	Positive	TRUE	FALSE	FALSE	47,XY,+21[2]/46,XY[18]	21	Targeted Therapy - Other	FALSE	Negative	AML	19.16712328767123	1:DECEASED	RUNX1 (21q22): 19/200 cells (9.5%) had three signals for RUNX1, consistent with trisomy 21.	No	No		No	No	No	No	No	No	White	-1	Refractory		1	Male	UNMATCHED	FALSE	AML with maturation	Initial Acute Leukemia Diagnosis	Peripheral Blood	dimCD7, dimCD11b, dimCD13, CD33, varibleCD34, CD38, CD117, partial HLA-DR, and MPO positive	0	0.1		Standard Chemotherapy	Yes	CEBPA (p.R300_D301delinsQY; VAF 85%)|FLT3-ITD (VAF 15%; allelic ratio 0.18)|GATA2 (p.G320S; VAF 30%)|NOTCH1 (p.A929D; VAF 52%)|RAD21 (p.E447fs*19; VAF 3%)|RAD21 (p.N462fs*1; VAF 3%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2791_BA3129	Acute Myeloid Leukemia	AML with mutated NPM1	S574_L610dup	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608336	28608337	-	TAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGTACCATCTGTAGCTGGCT	13:g.28608336_28608337insTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGTACCATCTGTAGCTGGCT	ENST00000241453.7:c.1720_1830dup	0.28		111	290			4	14/24							0.204819277				3	Waves3+4	No		0		0		0	NONE	NONE	Unknown	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	unknown	unknown	unknown			None	FALSE	Positive	AML	0.0			No	No		No	No	No	No	No	No					1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Unknown	Peripheral Blood		0	0.166666667			Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2792_BA3271	Acute Myeloid Leukemia	AML with mutated NPM1	V592_L610dup	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608281	28608282	-	CTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAA	13:g.28608281_28608282insCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAA	ENST00000241453.7:c.1775_1831dup	0.08		10	112			9	14/24					62	62	0.666666667		Dead-Disease		1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	HISPANIC	M5	Positive	TRUE	FALSE	FALSE	46,XX[20]	6	Standard Chemotherapy	FALSE	Positive	AML	0.7561643835616438	1:DECEASED	Normal	No	No		No	No	No	No	No	No	White	6	Unknown		1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim CD4, dim CD7, CD13, CD33, CD38, CD58, CD117, CD123, HLA-DR, and dim partial MPO (Myeloid Blast Population) | CD4, CD11b, CD13, dim CD14, dim CD15, CD16, CD33, CD38, CD58, CD63, CD123, HLA-DR  (Promonocyte/Monocyte Blast Population)	0	0.333333333		Standard Chemotherapy	Yes	FLT3-ITD (ITD; MAF 45%)|IDH2 (p.R140Q; MAF 38%)|NPM1 (p.W288fs*12; MAF 41%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2795_BA3309	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							6	14/24							0.960784314				3	Waves3+4	No		0		0		0	NONE	NONE	Unknown	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	unknown	unknown	unknown			None	FALSE	Positive	AML	0.0			No	No		No	No	No	No	No	No					1		UNMATCHED	FALSE	AML with mutated NPM1	Unknown	Leukapheresis		0	0.266666667			Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2811_BA3306	Acute Myeloid Leukemia	AML with mutated NPM1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							5	14/24					26	26	19		Alive		5	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, Cyclophosphamide, Thiotepa, TBI	3	Consolidation|Induction|Double Umbilical Cord Blood Transplant (DUCBT)	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Cyclophosphamide, Thiotepa, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate			Positive	TRUE	FALSE	FALSE		-1	Bone Marrow Transplant	FALSE	Positive	AML	9.501369863013698	0:LIVING	Normal	No	No		No	No	No	No	No	No	White	-1	Complete Response		1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	Dim Positive (CD13, MPO) | Dim Partial positive (CD34) | Variable partial positive (CD117)	0	0.166666667		Standard Chemotherapy	Yes	FLT3-ITD (ITD, c.l815_1816ins30; p.F605_P606insl0 (MAF 49%))|IDH1 (c.395G>A; p.R132H (MAF 45%))|NPM1 (c.863_864insTCTG; p.W288fs (MAF 43%))
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2194_BA2092	Acute Myeloid Leukemia	AML with mutated NPM1	D600_L601insPLQMVQVTGSSDNEYFYVDFREYEYD	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608330	28608331	-	GGGGTCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGTACCATCTGTAG	13:g.28608330_28608331insGGGGTCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGTACCATCTGTAG	ENST00000241453.7:c.1799_1800insCCCCCTACAGATGGTACAGGTGACCGGCTCCTCAGATAATGAGTACTTCTACGTTGATTTCAGAGAATATGAATATGA	0.14		32	196			17	14/24					46	46		ASXL1 (p.G645Vfs*58; 12.0%)	Dead-Disease		1	Waves1+2	Yes	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Methotrexate	7	Allogeneic - Sibling|Consolidation|Induction|Experimental|CNS|Re-induction	6	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Kinase Inhibitor(s)	4	Dasatinib	Experimental	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC		Positive	FALSE	TRUE	FALSE	46,XX[20]	-1	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Positive	AML	11.835616438356164	1:DECEASED	Normal	No	No		No	No	No	No	No	No	Multiracial	-1	Complete Response i		3	Female	MATCHED	FALSE	AML with mutated NPM1	Relapse	Bone Marrow Aspirate	dim CD7, CD13, CD33, CD71, CD117, CD123,  HLA-DR and MPO	0	0.866666667		Standard Chemotherapy	Yes	DNMT3A (p.R882H; MAF 35% )|FLT3-ITD (MAF 20%)|JAK3 (p.H529R; MAF 49% )|NPM1 (p.W288fs*12; MAF 20%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2194_BA3164	Acute Myeloid Leukemia	AML with mutated NPM1	D600_L601insPLQMVQVTGSSDNEYFYVDFREYEYD	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608330	28608331	-	GGGGTCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGTACCATCTGTAG	13:g.28608330_28608331insGGGGTCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGTACCATCTGTAG	ENST00000241453.7:c.1799_1800insCCCCCTACAGATGGTACAGGTGACCGGCTCCTCAGATAATGAGTACTTCTACGTTGATTTCAGAGAATATGAATATGA	0.47		245	277			7	14/24					46	47	11.5		Dead-Disease		1	Waves3+4	Yes	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Methotrexate	7	Allogeneic - Sibling|Consolidation|Induction|Experimental|CNS|Re-induction	6	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Kinase Inhibitor(s)	4	Dasatinib	Experimental	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC		Positive	FALSE	TRUE	FALSE	46,XX,t(10;16)(q22;q24)[10]/46,X,t(X;1)(q23;q44),t(10;16)(q22;q24)[3]/46,X,t(X;13)(p21;q14),t(3;22)(q13.2;p11.1),t(5;6)(q31;q24),add(9)(q13),t(10;16)(q22;q24)[2]/46,sl,der(1)t(1;2)(p32;q32)t(1;15)(q23;q24),der(2)t(1;2)(p32;q32),der(15)t(1;15)(q23;q24)[2]/	-1	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Positive	AML	11.835616438356164	1:DECEASED	Normal	No	No		No	No	No	No	No	No	Multiracial	-1	Complete Response i		3	Female	UNMATCHED	FALSE	AML with mutated NPM1	Relapse|Post-Chemotherapy|Post-Transplant	Peripheral Blood	partial CD7, CD13, CD33, partial CD34, CD38,  CD58, CD71, partial CD117, CD123, and HLA-DR +	124	0.3		Standard Chemotherapy	No	DNMT3A (p.R882H; MAF 43%)|FLT3-ITD (Internal tandem duplication (~75 bp; in-frame); MAF 79%)|JAK3 (p.H529R; MAF 50%)|NPM1 (p.W288fs*12; MAF 36%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2194_BA3235	Acute Myeloid Leukemia	AML with mutated NPM1	D600_L601insPLQMVQVTGSSDNEYFYVDFREYEYD	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608330	28608331	-	GGGGTCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGTACCATCTGTAG	13:g.28608330_28608331insGGGGTCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGTACCATCTGTAG	ENST00000241453.7:c.1799_1800insCCCCCTACAGATGGTACAGGTGACCGGCTCCTCAGATAATGAGTACTTCTACGTTGATTTCAGAGAATATGAATATGA	0.40		85	125			8	14/24					46	47	15.66666667		Dead-Disease		1	Waves3+4	Yes	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Methotrexate	7	Allogeneic - Sibling|Consolidation|Induction|Experimental|CNS|Re-induction	6	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Kinase Inhibitor(s)	4	Dasatinib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC		Positive	FALSE	FALSE	FALSE	46,XX,t(10;16)(q22;q24)[cp12]/46,sl,t(1;4)(q41;q33),t(7;9)(p15;q32)[5]/46,sl,t(X;1)(q23;q44)[2]/46,sl,der(1)t(1;2)(p32;q32)t(1;15)(q23;q24),der(2)t(1;2)(p32;q32),der(15)t(1;15)(q23;q24)[1]	-1	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Positive	AML	11.835616438356164	1:DECEASED		No	No		No	No	No	No	No	No	Multiracial	-1	Complete Response i		3	Female	UNMATCHED	FALSE	AML with mutated NPM1	Residual Disease|Post-Chemotherapy|Post-Transplant	Peripheral Blood		168	0.333333333		Standard Chemotherapy	No	FLT3-ITD (ITD; MAF 60%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2332_BA2989	Acute Myeloid Leukemia	AML with myelodysplasia-related changes	E596_Y597insSQSQLQMVQVTGSSDNEYFYVDFRE	OncoKB: Likely Oncogenic, level_1, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608338	28608339	-	GGGATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGTACCATCTGTAGCTGGCTTT	13:g.28608338_28608339insGGGATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGTACCATCTGTAGCTGGCTTT	ENST00000241453.7:c.1789_1790insCCCAAAGCCAGCTACAGATGGTACAGGTGACCGGCTCCTCAGATAATGAGTACTTCTACGTTGATTTCAGAGAAT	0.15		35	196			8	14/24					70	71	0.086956522		Alive		2	Waves1+2	Yes	Azacitidine|Decitabine	2	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	FALSE	FALSE	FALSE	47,XY,+21[19]/46,XY[1]	98	Standard Chemotherapy	FALSE	Negative	AML	10.027397260273972	0:LIVING	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],	No	No		No	No	No	No	No	No	White			RUNX1 (p.I366Vfs*231; 65.5%)	1	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	CD2(-), CD4(dim +), CD7(-), CD10(-), CD11b(-), CD13(bright +), CD14(-), CD15(partial +), CD16(-), CD22(-), CD19(partial +), CD33(partial +), CD34(+), CD36(-), CD38(bright and variably +), CD45(+), CD56(-), CD64(-), CD79a(-), CD117(+), HLA-DR(predominantly	0	0.4			Yes	BCOR (Foundation; R1480*; MAFs: 88%)|BCORL1 (Foundation; P304fs*117; MAFs: 72%)|FLT3-ITD|NF1 (Foundation; I679fs*21; MAFs: 5%)|NF1 (Foundation; V2649fs*31 (subclonal); MAFs: 12%)|PHF6 (Foundation; R225*; MAFs: 87%)|PTPN11 (Foundation; A72T; MAFs: 8%)|RUNX
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2000_BA2123	Acute Myeloid Leukemia	AML with mutated NPM1	D835Y	OncoKB: Oncogenic, level_1, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 10, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 1, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9341	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	A	13:g.28592642C>A	ENST00000241453.7:c.2503G>T	0.17		21	105			14	20/24		Pathogenic			65	65	0		Dead-Treatment		2	Waves1+2	Yes	Decitabine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Decitabine	Hypomethylating/Low Dose Cytarabine	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable			Negative	TRUE	FALSE	FALSE	46,XY[20]	214	Standard Chemotherapy	FALSE	Positive	AML	8.843835616438355	1:DECEASED	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199](RUNX1T1, RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No		No	No	No	No	No	No					1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33 (bright +), CD34(partial +), CD36(-), CD38(variably +), CD45(+), CD56(-), CD64(-), CD117(+), HLA-DR (+), GLy-A(-), MPO(partial +), TdT(-).	0	0.9			Yes	DNMT3A (W297*; MAF 44%)|FLT3-D835 (D835Y; MAF 6%)|GATA2 (P161A; MAF 51%)|NPM1 (W288fs*10+; MAF 26%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2003_BA2499	Acute Myeloid Leukemia	AML with myelodysplasia-related changes	D835Y	OncoKB: Oncogenic, level_1, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 10, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 1, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9341	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	A	13:g.28592642C>A	ENST00000241453.7:c.2503G>T	0.43		58	77			19	20/24		Pathogenic			71	71	0		Dead-Disease		2	Waves1+2	Yes	Azacitidine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Azacitidine	Hypomethylating/Low Dose Cytarabine	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse			Negative	FALSE	FALSE	TRUE		107	Standard Chemotherapy	FALSE	Negative	AML	1.7424657534246575	1:DECEASED		No	No		Yes	Yes	No	No	No	No				RUNX1 (p.R320*; 46.2%)	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Initial Acute Leukemia Diagnosis	Peripheral Blood		0	0.966666667			Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2014_BA2226	Acute Myeloid Leukemia	AML with mutated NPM1	D835Y	OncoKB: Oncogenic, level_1, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 10, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 1, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9341	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	A	13:g.28592642C>A	ENST00000241453.7:c.2503G>T	0.54		28	24			10	20/24		Pathogenic			53	53	0		Alive		1	Waves1+2	Yes	SWOG S1203 (7+3 +/- Vorinostat)	1	Induction	1	Standard Chemotherapy	1	SWOG S1203 (7+3 +/- Vorinostat)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M5	Negative	TRUE	FALSE	FALSE	46,XX[20]	153	Standard Chemotherapy	FALSE	Positive	AML	60.26301369863013	0:LIVING	Normal	No	No		No	No	No	No	No	No	White	153	Complete Response		1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Blast immunophenotype: partial CD11b, CD13, CD33, CD38, CD58, partial CD64, partial CD117 and a subset with MPO - Blast/promonocyte immunophenotype: CD11b, CD13, partial CD14, CD15, CD33, CD38, CD58 and CD64	0	0.4		Standard Chemotherapy	Yes	FLT3-D835 (p.D835Y; MAF: 40%)|NPM1 (p.W288fs*12; MAF 40%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2022_BA2032	Acute Myeloid Leukemia	AML with mutated NPM1	D835Y	OncoKB: Oncogenic, level_1, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 10, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 1, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9341	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	A	13:g.28592642C>A	ENST00000241453.7:c.2503G>T	0.38		42	70			4	20/24		Pathogenic			64	65	15.66666667		Dead-Disease		2	Waves1+2	Yes	Crenolanib|MEC, plexifor, GCSF|Sorafenib|7+3 (Cytarabine, Idarubicin) plus LBH|Clofarabine, Cytarabine	5	Salvage|Induction|Experimental|Re-induction	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Crenolanib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	FALSE	FALSE	FALSE	46,XX,t(3;11)(q21;p11.2),t(15;15)(q15;q22)[19]/46,XX,t(2;14)(q21;q11.2)[2]	124	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Positive	AML	14.958904109589042	1:DECEASED	nuc ish(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2 (5'MLL con 3'MLLx2)[198],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No		No	No	No	No	No	No		21	Refractory		1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood	CD7(partial +), CD15(partial +), CD33(bright +), CD34(partial +), CD45(+), and CD117(variably +). (80% population of variably-sized cells)	0	0.133333333		Standard Chemotherapy	Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2055_BA2106	Acute Myeloid Leukemia	AML with mutated NPM1	D835Y	OncoKB: Oncogenic, level_1, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 10, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 1, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9341	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	A	13:g.28592642C>A	ENST00000241453.7:c.2503G>T	0.50		66	66			11	20/24		Pathogenic			35	37	0		Dead-Disease		4	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cyclophosphamide, Etoposide, TBI	5	Allogeneic - Sibling|Consolidation|Salvage|Induction|Re-induction	5	Standard Chemotherapy|Bone Marrow Transplant	2	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial		M5	Negative	FALSE	TRUE	FALSE	46,XX[5]	53	Standard Chemotherapy	FALSE	Positive	AML	25.01917808219178	1:DECEASED		No	No		No	No	No	No	No	No		6	Complete Response		2	Female	MATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Relapse	Bone Marrow Aspirate	CD45, DIM CD64, DIM CD13, DIM CD33, CD15, CD38, MPO, CD11C, DIM CD4, DIM PARTIAL CD19, CD117, AND HLA-DR	1	0.666666667		Standard Chemotherapy	Yes	FLT3-D835|IDH1|NPM1
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2058_BA2054	Acute Myeloid Leukemia	AML with mutated NPM1	D835E	OncoKB: Oncogenic, level_1, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 1, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 0, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.969;AlphaMissense: pathogenicity: pathogenic, score: 0.9558	Missense_Mutation	SNP		NA	NA	NA	13	28592640	28592640	A	C	13:g.28592640A>C	ENST00000241453.7:c.2505T>G	0.35		48	90			14	20/24					49	49	0		Alive		3	Waves1+2	Yes	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable		M5	Negative	TRUE	FALSE	FALSE	46,XX,del(17)(p11.2)[15]/46,XX[5]	-1	Bone Marrow Transplant	FALSE	Positive	AML	38.400000000000006	0:LIVING	consistent with karyotype (68% del 17p13)	No	No		No	No	No	No	No	No		-1	Complete Response		1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Most of the atypical cells (data not shown) are myeloid blasts that express CD117, partial CD7 (about 30% positive), CD13, CD33, HLA-DR, weak CD4, and partial CD15 (about 50% positive), but do not express CD34, CD14(MO2), or CD64. (The monocytic cells (pe	0	0.733333333		Standard Chemotherapy	Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2070_BA2592	Acute Myeloid Leukemia	AML with myelodysplasia-related changes	D835E	OncoKB: Oncogenic, level_1, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 1, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 0, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.969;AlphaMissense: pathogenicity: pathogenic, score: 0.9558	Missense_Mutation	SNP		NA	NA	NA	13	28592640	28592640	A	T	13:g.28592640A>T	ENST00000241453.7:c.2505T>A	0.24		23	72			5	20/24		Pathogenic			31	38	0		Dead-Unknown		2	Waves1+2	Yes	Fludarabine, Melphalan|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Rituximab|Busulfan, Cyclophosphamide	9	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Experimental|Re-induction	7	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s)	4	Dasatinib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Negative	FALSE	FALSE	TRUE	46,XX[20]	24	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Negative	AML	87.4849315068493	1:DECEASED	nuc ish(DXZ1x2)[200]	No	No		Yes	Yes	No	No	No	No		-1	Complete Response		2	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Post-Transplant|Residual Disease	Bone Marrow Aspirate		1496	0.3		Standard Chemotherapy	No	BCOR (S259fs*10; MAF 15%)|CCND2 (P281R; MAF 19%)|FLT3-D835 (D835E; MAF 13%)|GATA2 (N297S; MAF 18%)|IKZF1 (Q44*; MAF 14%)|MLL2 (Y2907*; MAF 7%)|PTPN11 (E76V; MAF 17%)|PTPN11 (V45L; MAF 13%)|SETBP1 (H1100R; MAF 51%)|SF3B1 (K700E; MAF 18%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2238_BA2249	Acute Myeloid Leukemia	AML with mutated NPM1	D835H	OncoKB: Oncogenic, level_1, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 4, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 0, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9725	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	G	13:g.28592642C>G	ENST00000241453.7:c.2503G>C	0.16		15	80			20	20/24		Pathogenic			53	54	9		Dead-Disease		1	Waves1+2	Yes	HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea	4	Induction|Experimental|Re-induction|Maintenance	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Sorafenib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC		Positive	FALSE	FALSE	FALSE	46,XY,t(7;17)(q22;q21)[3]/46,XY,t(2;4)(q33;q25),del(9)(q2?1;q3?2),add(17)(q21)[cp3]/46,XY,t(1;2)(q31;p25),inv(9)(q3?1q34)[2]/46,XY,t(13;14)(q14;q32)[cp2]/46,XY,add(3)(p24)[1]/46,XY[3]	49	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Positive	AML	5.523287671232877	1:DECEASED	normal	No	No		No	No	No	No	No	No	White	6	Refractory		4	Male	MATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood	dimCD7, CD13, dimCD11b, CD33, variable CD34, CD58,  CD117, CD123, and HLA-DR positive	63	1.1		Standard Chemotherapy	No	DNMT3A (p.R882C; MAF 45%)|FLT3-D835 (p.D835H; MAF 15%)|FLT3-ITD (MAF 78%)|NPM1 (p.W288fs*12; MAF 40%)|TET2 (p.Q548*; MAF 45%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2238_BA2979	Acute Myeloid Leukemia	AML with mutated NPM1	D835H	OncoKB: Oncogenic, level_1, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 4, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 0, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9725	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	G	13:g.28592642C>G	ENST00000241453.7:c.2503G>C	0.14		20	125			17	20/24		Pathogenic			53	54	19		Dead-Disease		1	Waves1+2	Yes	HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea	4	Induction|Experimental|Re-induction|Maintenance	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Sorafenib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC		Positive	FALSE	FALSE	FALSE	46,XY,t(7;17)(q22;q21)[3]/46,XY,t(2;4)(q33;q25),del(9)(q2?1;q3?2),add(17)(q21)[cp3]/46,XY,t(1;2)(q31;p25),inv(9)(q3?1q34)[2]/46,XY,t(13;14)(q14;q32)[cp2]/46,XY,add(3)(p24)[1]/46,XY[3]	49	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Positive	AML	5.523287671232877	1:DECEASED	normal	No	No		No	No	No	No	No	No	White	6	Refractory		4	Male	MATCHED	FALSE	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Peripheral Blood		75	0.9		Standard Chemotherapy	No	DNMT3A (p.R882C; MAF 45%)|FLT3-D835 (p.D835H; MAF 15%)|FLT3-ITD (MAF 78%)|NPM1 (p.W288fs*12; MAF 40%)|TET2 (p.Q548*; MAF 45%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2257_BA2512	Acute Myeloid Leukemia	AML with mutated NPM1	D835Y	OncoKB: Oncogenic, level_1, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 10, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 1, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9341	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	A	13:g.28592642C>A	ENST00000241453.7:c.2503G>T	0.15		24	136			5	20/24		Pathogenic			72	72	0		Dead-Disease		3	Waves1+2	No	SGN-CD33A	1	Experimental	1	Targeted Therapy - Other	1	SGN-CD33A	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable		M5	Negative	TRUE	FALSE	FALSE		-1	Targeted Therapy - Other	FALSE	Positive	AML	5.884931506849314	1:DECEASED	Normal	No	No		No	No	No	No	No	No					1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	partial CD56, bright CD33,  CD13, bright CD64, HLA-DR (Monocytic cells)	0	0.266666667			Yes	DNMT3A (c.2645G>A; MAF 45.4%)|FLT3-D835 (c.2503G>T (D835Y); MAF 15.5%)|NPM1 (c.860_863dup; MAF 11%)|PTPN11 (c.178G>C; MAF 8.4%)|PTPN11 (c.211T>C; MAF 10%)|TET2 (c.3955-2A>G; MAF 45.4%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2284_BA2450	Acute Myeloid Leukemia	AML with mutated NPM1	D835H	OncoKB: Oncogenic, level_1, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 4, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 0, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9725	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	G	13:g.28592642C>G	ENST00000241453.7:c.2503G>C	0.30		32	76			13	20/24		Pathogenic			46	46	0.25		Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea	5	Consolidation|Salvage|Induction|Supportive/Palliative Care	4	Standard Chemotherapy|Supportive/Palliative Care	2	Sunitinib	Consolidation	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC		Positive	FALSE	FALSE	FALSE		2	Standard Chemotherapy	FALSE	Positive	AML	8.843835616438355	1:DECEASED	metaphases positive for 45XX monosomy chromosome 17,20/22 metaphases positive for 46XX diploid	No	No		No	No	No	No	No	No	White	32	Complete Response		3	Female	MATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood		0	0.533333333		Standard Chemotherapy	Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2284_BA2824	Acute Myeloid Leukemia	AML with mutated NPM1	D835H	OncoKB: Oncogenic, level_1, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 4, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 0, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9725	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	G	13:g.28592642C>G	ENST00000241453.7:c.2503G>C	0.29		18	44			14	20/24		Pathogenic			46	47	0.515151515		Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea	5	Consolidation|Salvage|Induction|Supportive/Palliative Care	4	Standard Chemotherapy|Supportive/Palliative Care	2	Sunitinib	Consolidation	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC		Positive	FALSE	FALSE	FALSE		2	Standard Chemotherapy	FALSE	Positive	AML	8.843835616438355	1:DECEASED	Positive	No	No		No	No	No	No	No	No	White	32	Complete Response		3	Female	MATCHED	FALSE	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Peripheral Blood	variable CD7, CD13, dim CD33, partial CD34, CD38,dim CD58, partial and variable CD117 and CD123 positive	23	0.633333333		Standard Chemotherapy	No	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2284_BA2994	Acute Myeloid Leukemia	AML with mutated NPM1	D835H	OncoKB: Oncogenic, level_1, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 4, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 0, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9725	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	G	13:g.28592642C>G	ENST00000241453.7:c.2503G>C	0.33		29	59			13	20/24		Pathogenic			46	47	0		Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea	5	Consolidation|Salvage|Induction|Supportive/Palliative Care	4	Standard Chemotherapy|Supportive/Palliative Care	2	Sunitinib	Consolidation	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC		Negative	FALSE	FALSE	FALSE		2	Standard Chemotherapy	FALSE	Positive	AML	8.843835616438355	1:DECEASED	metaphases positive for 45XX monosomy chromosome 17,20/22 metaphases positive for 46XX diploid	No	No		No	No	No	No	No	No	White	32	Complete Response		3	Female	MATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood		14	0.6		Standard Chemotherapy	No	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2287_BA2661	Acute Myeloid Leukemia	AML with mutated NPM1	D835V	OncoKB: Oncogenic, level_1, resistance NA;CIViC: diagnosticCount: 3, predictiveCount: 10, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 0, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9745	Missense_Mutation	SNP		NA	NA	NA	13	28592641	28592641	T	A	13:g.28592641T>A	ENST00000241453.7:c.2504A>T	0.28		36	94			20	20/24		Pathogenic			56	56	0		Alive		3	Waves1+2	Yes	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG (Cladribine, Cytarabine, Filgrastim)	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable			Negative	FALSE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	FALSE	Positive	AML	20.843835616438355	0:LIVING	Normal	Yes	No	Prostate Cancer	No	No	No	No	No	No	White	12	Complete Response i		1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	84% are monocytes, and 9% are myeloid  cells. The monocytic cells (percentages shown) appear  atypical with expression of CD13, bright CD33, and bright  CD64, but weaker than normal HLA-DR and include 48% that  are phenotypically consistent with promonocy	0	1.266666667		Standard Chemotherapy	Yes	DNMT3A (p.Val716Asp; MAF 45%)|FLT3-D835 (p.Asp835Val; MAF 30.5%)|NPM1 (p.Trp288fs; MAF 16.1%)|RAD21 (p.Glu178*; MAF 12%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2302_BA2881	Acute Myeloid Leukemia	AML with mutated NPM1	D835Y	OncoKB: Oncogenic, level_1, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 10, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 1, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9341	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	A	13:g.28592642C>A	ENST00000241453.7:c.2503G>T	0.40		66	100			4	20/24		Pathogenic			66	67	0		Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Quizartinib	4	Consolidation|Induction|Experimental|Re-induction	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Quizartinib	Experimental	Residual	Myeloproliferative Neoplasms	NonInitial	NON-HISPANIC		Negative	FALSE	FALSE	TRUE	46,XY[20]	57	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Positive	AML	12.0	1:DECEASED	normal	No	No		No	No	No	No	Yes	Yes	White	7	Complete Response		1	Male	UNMATCHED	FALSE	Mastocytosis	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	CD13, CD33, partial CD34, CD38, CD117 and CD123	386	0.2		Standard Chemotherapy	Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2328_BA2502	Acute Myeloid Leukemia	AML with minimal differentiation	D835Y	OncoKB: Oncogenic, level_1, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 10, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 1, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9341	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	A	13:g.28592642C>A	ENST00000241453.7:c.2503G>T	0.63		183	106			5	20/24		Pathogenic			50	50	0		Dead-Disease		1	Waves1+2	Yes	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Hydroxyurea	6	Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction|Re-induction	5	Standard Chemotherapy|Other	2	Hydroxyurea	Hypomethylating/Low Dose Cytarabine	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M0	Negative	FALSE	FALSE	FALSE	48,XX,+11,+13[19]	365	Other	FALSE	Negative	AML	9.928767123287672	1:DECEASED		No	No		No	No	No	No	No	No	White	6	Refractory		1	Female	UNMATCHED	FALSE	AML with minimal differentiation	Residual Disease	Peripheral Blood		0	0.266666667		Standard Chemotherapy	Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2373_BA2455	Acute Myeloid Leukemia	AML with mutated NPM1	D835E	OncoKB: Oncogenic, level_1, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 1, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 0, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.969;AlphaMissense: pathogenicity: pathogenic, score: 0.9558	Missense_Mutation	SNP		NA	NA	NA	13	28592640	28592640	A	C	13:g.28592640A>C	ENST00000241453.7:c.2505T>G	0.21		20	75			11	20/24					72	72	0		Dead-Disease		4	Waves1+2	No	Hydroxyurea	1	Supportive/Palliative Care	1	Supportive/Palliative Care	1	Hydroxyurea	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable		M5	Negative	TRUE	FALSE	FALSE	48,XYY,+8[21]	-1	Supportive/Palliative Care	FALSE	Positive	AML	1.084931506849315	1:DECEASED		No	No		No	No	No	No	No	No					1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD38, CD56, CD13(dim), CD64, CD11c, CD4, CD56, HLA-DR, and CD15	0	0.666666667			Yes	FLT3-D835|NPM1
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2378_BA2104	Acute Myeloid Leukemia	Therapy-related myeloid neoplasms	D835V	OncoKB: Oncogenic, level_1, resistance NA;CIViC: diagnosticCount: 3, predictiveCount: 10, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 0, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9745	Missense_Mutation	SNP		NA	NA	NA	13	28592641	28592641	T	A	13:g.28592641T>A	ENST00000241453.7:c.2504A>T	0.50		74	75			5	20/24		Pathogenic			83	83	0		Dead-Disease		1	Both	Yes		0		0		0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M5	Negative	FALSE	FALSE	FALSE	47,XY,+8[6]/46,XY[13] (Specimen Source: Blood)		None	FALSE	Positive	AML	0.2958904109589041	1:DECEASED	trisomy 8 (Specimen Source: Blood)	Yes	No	Colon Cancer	No	No	No	No	No	No	White				1	Male	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Peripheral Blood	CD11b, CD13, dimCD14, CD15, dim CD16, CD33,     CD56,     CD58, CD64, CD123, and HLA-DR positive	0	0.266666667			No	FLT3-D835 (bone marrow)|NPM1 (An insertion mutation is present in exon 12 (near the C-terminus) of NPM.)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2417_BA2598	Acute Myeloid Leukemia	AML with myelodysplasia-related changes	D835H	OncoKB: Oncogenic, level_1, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 4, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 0, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9725	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	G	13:g.28592642C>G	ENST00000241453.7:c.2503G>C	0.17		26	126			13	20/24		Pathogenic			72	72	0	ASXL1 (p.A619Pfs*15; 38.1%)	Dead-Unknown		1	Waves1+2	Yes	3+7 (Cytarabine, Daunorubicin)	1	Induction	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M4	Negative	FALSE	FALSE	TRUE	46,XY,del(12)(p11.2p13)[15]/46,XY[5]	6	Standard Chemotherapy	FALSE	Negative	AML	5.786301369863014	1:DECEASED	84% 12p deletion	No	No		No	No	Yes	Yes	No	No	White	6	Complete Response		2	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Myeloid blast immunophenotype: CD13, dim CD33, CD34, CD38, CD58, CD117, HLA-DR and MPO positive | Promonocyte immunophenotype: CD11b, CD13, CD14, CD33, CD38, CD56, CD58, CD64 and HLA-DR positive	0	0.733333333		Standard Chemotherapy	Yes	ASXL1 (p.A619fs*14; MAF 50%)|EZH2 (p.R583*; MAF 95%)|FLT3-D835|FLT3-D835 (MAF unavailable)|PTPN11 (p.D61H; MAF 15%)|RUNX1 ( p.P345?S356del; MAF 25%)|RUNX1 (p.P345?S356del; MAF 25%)|RUNX1 (p.V51; MAF 50%)|RUNX1 (p.V5I; MAF 50%)|TET2 (p.Y867H; MAF 50%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2429_BA2025	Acute Myeloid Leukemia	Therapy-related myeloid neoplasms	D835H	OncoKB: Oncogenic, level_1, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 4, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 0, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9725	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	G	13:g.28592642C>G	ENST00000241453.7:c.2503G>C	0.77		88	27			16	20/24		Pathogenic			30	31	0		Dead-Disease		1	Waves1+2	Yes	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine	4	Consolidation|Salvage|Induction|Supportive/Palliative Care	4	Standard Chemotherapy|Supportive/Palliative Care	2	Decitabine	Supportive/Palliative Care	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M1	Negative	FALSE	TRUE	FALSE	46,XX,t(9;11)(p22;q23)[20]/46,XX[1]	31	Supportive/Palliative Care	FALSE	Negative	AML	8.876712328767123	1:DECEASED	MLL disruption and t(9;11) (70%)	Yes	No	Acute Promyelocytic Leukemia	No	No	No	No	No	No	Pacific Islander	6	Complete Response		2	Female	MATCHED	FALSE	Therapy-related myeloid neoplasms	Relapse|Post-Chemotherapy	Bone Marrow Aspirate	dim/partial CD13, CD33, CD38, CD56, CD58, CD64, partialCD117, CD123 and HLA-DR positive	147	0.766666667		Standard Chemotherapy	No	FLT3-D835 (MAF 70%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2429_BA2446	Acute Myeloid Leukemia	Therapy-related myeloid neoplasms	D835H	OncoKB: Oncogenic, level_1, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 4, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 0, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9725	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	G	13:g.28592642C>G	ENST00000241453.7:c.2503G>C	0.32		40	86			14	20/24		Pathogenic			30	30	0		Dead-Disease		1	Waves1+2	Yes	GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine	4	Consolidation|Salvage|Induction|Supportive/Palliative Care	4	Standard Chemotherapy|Supportive/Palliative Care	2	Decitabine	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M1	Negative	FALSE	FALSE	FALSE	46,XX,t(9;11)(p11;q34)[19]/46,XX[1]	31	Supportive/Palliative Care	FALSE	Negative	AML	8.876712328767123	1:DECEASED	Disruption of MLL signal and t(9;11) (65%)	Yes	No	Acute Promyelocytic Leukemia	No	No	No	No	No	No	Pacific Islander	6	Complete Response		2	Female	MATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Bone Marrow Aspirate	CD11b, CD13, CD14,  CD33, CD64, CD56, CD123 and HLA-DR positive	0	0.633333333		Standard Chemotherapy	Yes	CREBBP (p.A254T; MAF 50%)|CREBBP (p.T910S; MAF 40%)|FLT3-D835 (p.D835; MAF 35%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2446_BA2236	Acute Myeloid Leukemia	AML with mutated NPM1	D835Y	OncoKB: Oncogenic, level_1, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 10, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 1, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9341	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	A	13:g.28592642C>A	ENST00000241453.7:c.2503G>T	0.44		54	68			4	20/24		Pathogenic			54	57	0		Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	7	Consolidation|Salvage|Induction|Re-induction|Maintenance	5	Standard Chemotherapy	1	Decitabine	Re-induction	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M4	Negative	FALSE	TRUE	FALSE	47,XY,+21[17]/47,idem,t(10;22)(q22;q13)[cp3]/46,XY[1]	160	Standard Chemotherapy	FALSE	Positive	AML	45.30410958904109	1:DECEASED	80% Trisomy 21	No	No		No	No	No	No	No	No	White	7	Complete Response		1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Relapse|Post-Chemotherapy	Bone Marrow Aspirate	CD13, CD33, CD38, CD58, dim CD64, CD117, and CD123	349	0.233333333		Standard Chemotherapy	Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2456_BA2670	Acute Myeloid Leukemia	AML with myelodysplasia-related changes	D835Y	OncoKB: Oncogenic, level_1, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 10, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 1, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9341	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	A	13:g.28592642C>A	ENST00000241453.7:c.2503G>T	0.31		46	101			7	20/24		Pathogenic			72	73	0		Dead-Disease		2	Waves1+2	Yes	Lenalidomide|Azacitidine|Decitabine|Clofarabine, Cytarabine	4	Hypomethylating/Low Dose Cytarabine|Maintenance	2	Standard Chemotherapy|Other	2	Clofarabine, Cytarabine	Hypomethylating/Low Dose Cytarabine	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Negative	FALSE	FALSE	TRUE	46,XX,+1,der(1;21)(q10;q10)[6]/46,XX[14]	-1	Other	FALSE	Negative	AML	15.287671232876711	1:DECEASED	nuc ish(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200]	No	No		Yes	Yes	No	No	No	No	White				1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Residual Disease|Post-Chemotherapy	Peripheral Blood		0	0.3			Yes	RUNX1 (PB)|SF3B1 (PB)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2522_BA2746	Acute Myeloid Leukemia	AML with mutated NPM1	D835Y	OncoKB: Oncogenic, level_1, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 10, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 1, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9341	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	A	13:g.28592642C>A	ENST00000241453.7:c.2503G>T	0.29		30	75			6	20/24		Pathogenic			56	56	0.111111111		Dead-Disease		5	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI	4	Consolidation|Salvage|Induction|Double Umbilical Cord Blood Transplant (DUCBT)	4	Standard Chemotherapy|Bone Marrow Transplant	2	GCLAC (GCSF, Clofarabine & Cytarabine)	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	HISPANIC		Positive	TRUE	FALSE	FALSE	46,XX[19]	-1	Standard Chemotherapy	FALSE	Positive	AML	10.61917808219178	1:DECEASED	Normal	No	No		No	No	No	No	No	No		27	Complete Response		2	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Positive (Approximately 55% of assayed cells are an abnormal population of immature monocytic cells (consistent with monoblasts and promonocytes). Approximately 30% of assayed cells are mature monocytes. Both the immature and mature monocytic cells show u	0	0.166666667		Standard Chemotherapy	Yes	ASXL1 (c.1954G>A; p.G652S)|DNMT3A (c.2644C>T; p.R882C)|FLT3 (c.2503G>T; p.D835Y)|FLT3-ITD (FLT3-ITD 21 bp insertion)|NPM1 (c.859_860insTCTG; p.W288fs)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2536_BA2784	Acute Myeloid Leukemia	AML with mutated NPM1	D835H	OncoKB: Oncogenic, level_1, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 4, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 0, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9725	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	G	13:g.28592642C>G	ENST00000241453.7:c.2503G>C	0.18		19	87			4	20/24		Pathogenic			83	85	0		Dead-Disease		1	Waves1+2	Yes	Decitabine	1	Hypomethylating/Low Dose Cytarabine	1	Standard Chemotherapy	1	Decitabine	Hypomethylating/Low Dose Cytarabine	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC		Negative	FALSE	FALSE	FALSE		-1	Standard Chemotherapy	FALSE	Positive	AML	19.857534246575344	1:DECEASED		No	No		No	No	No	No	No	No	White				1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood		0	0.233333333			Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2561_BA2906	Acute Myeloid Leukemia	Therapy-related myeloid neoplasms	D835Y	OncoKB: Oncogenic, level_1, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 10, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 1, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9341	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	A	13:g.28592642C>A	ENST00000241453.7:c.2503G>T	0.15		20	113			1	20/24		Pathogenic			5	5	0		Dead-Other		1	Waves1+2	Yes	ADE (Cytarabine, Daunorubicin & Etoposide)|Cyclophosphamide, TBI|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	3	Allogeneic - Sibling|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M5	Negative	FALSE	FALSE	FALSE	46,XY[25]	-1	Bone Marrow Transplant	FALSE	Negative	AML	73.67671232876712	1:DECEASED	MLL rearrangement (76%)	Yes	No	B lymphoblastic leukaemia/lymphoma with t(v;11q23); MLL rearranged	No	No	No	No	No	No	White	9	Complete Response		1	Male	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis|Post-Transplant|Post-Chemotherapy	Peripheral Blood	CD4, CD11b, CD15, CD33, bright CD34, CD38, CD58, CD64,CD71, CD117, CD123, HLA-DR and dim/partial MPO positive	0	0.066666667		Standard Chemotherapy	Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2579_BA3045	Acute Myeloid Leukemia	AML with myelodysplasia-related changes	D835E	OncoKB: Oncogenic, level_1, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 1, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 0, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.969;AlphaMissense: pathogenicity: pathogenic, score: 0.9558	Missense_Mutation	SNP		NA	NA	NA	13	28592640	28592640	A	C	13:g.28592640A>C	ENST00000241453.7:c.2505T>G	0.26		39	111			5	20/24					46	47	0.538461538		Dead-Disease		2	Waves1+2	Yes	Azacitidine, Sorafenib|7+3 (Cytarabine, Idarubicin)|HiDAC|Crenolanib|PLX3397|Fludarabine, Cyclophosphamide, Thiotepa, TBI|AC220 (Ambit)	7	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT)	6	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Crenolanib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	FALSE	FALSE	FALSE	46,X,t(X;11)(p22.1;q13),add(7)(p22),add(17)(q21)[cp3]/45,X,-X,add(1)(q21),add(2)(q37),add(5)(q35),add(7)[cp3]/46,XX[4]	-1	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Negative	AML	15.747945205479454	1:DECEASED	Normal	No	No		No	No	No	No	No	No		9	Complete Response i		1	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Post-Transplant|Residual Disease	Peripheral Blood	CD2(dim +), CD7(-), CD13(partial dim +), CD14(-), CD15(partial +), CD33(+), CD34(+), CD38(partial +), CD45(moderately +), CD117(partial +), HLA-DR(variably +)	0	0.2		Standard Chemotherapy	Yes	FLT3-D835 (NOT FOUNDATION NO MAF AVAILABLE)|FLT3-ITD (NOT FOUNDATION NO MAF AVAILABLE)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2605_BA3423	Acute Myeloid Leukemia	AML with mutated NPM1	D835Y	OncoKB: Oncogenic, level_1, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 10, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 1, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9341	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	A	13:g.28592642C>A	ENST00000241453.7:c.2503G>T	0.51		58	55			5	20/24		Pathogenic			49	50	0		Alive		6	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC		Negative	FALSE	FALSE	FALSE		114	Standard Chemotherapy	FALSE	Positive	AML	11.342465753424658	0:LIVING		No	No		No	No	No	No	No	No		28	Unknown		1	Female	UNMATCHED	FALSE	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	Positive for CD34, CD117, HLADR, CD33 and CD13.  (Bone Marrow Immunophentyping)	0	0.233333333		Standard Chemotherapy	Yes	FLT3-TKD
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2655_BA3362	Acute Myeloid Leukemia	AML with myelodysplasia-related changes	D835E	OncoKB: Oncogenic, level_1, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 1, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 0, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.969;AlphaMissense: pathogenicity: pathogenic, score: 0.9558	Missense_Mutation	SNP		NA	NA	NA	13	28592640	28592640	A	C	13:g.28592640A>C	ENST00000241453.7:c.2505T>G	0.38		40	64			5	20/24					72	72	0		Dead-Disease		1	Waves3+4	Yes	3+7 (Cytarabine, Daunorubicin)	1	Induction	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M5	Negative	TRUE	FALSE	FALSE	46,XX,der(1)t(1;1)(p36.3;q21),t(8;16)(p11.2;p13.3),add(15)(q24)[20]	-1	Standard Chemotherapy	FALSE	Negative	AML	0.7890410958904108	1:DECEASED	In 95/100 cells (95%), three  signals for chromosome 1q25 were observed, and only two signals for 1p36  were observed, consistent with gain of 1q by der(1)t(1;1)	No	No		No	No	No	No	No	No	White	-1	Unknown		1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD4, CD11b, partial CD13, CD33, CD56, bright CD64, partial CD117, CD123, HLA-DR and partial MPO-positive	0	0.166666667	TP53 (p.R175H; 55.0%)	Standard Chemotherapy	Yes	FLT3 (p.D835E; MAF 42%)|TP53 (p.R175H; MAF 43%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2662_BA3169	Acute Myeloid Leukemia	Therapy-related myeloid neoplasms	D835H	OncoKB: Oncogenic, level_1, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 4, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 0, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9725	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	G	13:g.28592642C>G	ENST00000241453.7:c.2503G>C	0.17		17	82			6	20/24		Pathogenic			88	88	0		Dead-Disease		5	Waves3+4	No		0		0		0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse			Negative	FALSE	FALSE	FALSE	47,XX,+8[4]/47,sl,add(10)(q22)[10]/89~94,sdlx2[cp3]/55,sl,+X,+6,+8,+ 8,+9,+13,+21,+22[2]/46,XX[1]		None	FALSE	Positive	AML	0.1643835616438356	1:DECEASED	MLL (KMT2A) rearrangement in 94% of 200 cells | gain of 8q22 sequence in 94% of 200 cells	Yes	No	Uterine Sarcoma	No	No	No	No	No	No	White				1	Female	UNMATCHED	FALSE	Therapy-related myeloid neoplasms	Initial Acute Leukemia Diagnosis	Peripheral Blood	positive for CD11b, dim CD7, CD13, CD14, CD33, CD38, CD15, CD45, CD56, CD64 and HLA-DR	0	0.3			Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2754_BA3381	Acute Myeloid Leukemia	AML with myelodysplasia-related changes	D835V	OncoKB: Oncogenic, level_1, resistance NA;CIViC: diagnosticCount: 3, predictiveCount: 10, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 0, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9745	Missense_Mutation	SNP		NA	NA	NA	13	28592641	28592641	T	A	13:g.28592641T>A	ENST00000241453.7:c.2504A>T	0.44		78	99			5	20/24		Pathogenic			51	51	0	ASXL1 (p.G646Wfs*12; 32.0%)	Dead-Treatment		1	Waves3+4	Yes	HiDAC + Midostaurin|Fludarabine, TBI|Azacitidine|7+3 (Cytarabine, Idarubicin) plus Midostaurin|Decitabine, Venetoclax	5	Consolidation|Induction|Allogeneic - Child|Maintenance|Re-induction	5	Standard Chemotherapy|Bone Marrow Transplant	2	Decitabine, Venetoclax	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M4	Negative	TRUE	FALSE	FALSE	46,XY[20]	-1	Standard Chemotherapy	FALSE	Negative	AML	15.978082191780823	1:DECEASED	Normal	No	No		No	No	No	No	No	No	Black	6	Complete Response	RUNX1 (p.F259Sfs*338; 18.3%)	1	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD34, CD38, CD58, dim CD71, CD117, dim CD123  and HLA-DR+	0	0.266666667		Standard Chemotherapy	Yes	ASXL1 (p.S1236A; MAF 51% )|CBL (p.R420Q, MAF 3%)|CBL (p.Y368_C372delinsP; MAF 9%)|DNMT3A (p.E616*; MAF 50%)|FLT3 (p.D835V; MAF 37%)|FLT3-ITD (Allelic Ratio = .03)|SF3B1 (p.K666N; MAF 47%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2800_BA3284	Acute Myeloid Leukemia	AML with mutated NPM1	D835Y	OncoKB: Oncogenic, level_1, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 10, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 1, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9341	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	A	13:g.28592642C>A	ENST00000241453.7:c.2503G>T	0.09		24	229			7	20/24		Pathogenic			56	56	0				1	Waves3+4	No		0		0		0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	46,XY[20]		None	FALSE	Positive	AML	0.0			No	No		No	No	No	No	No	No	White				1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD7, CD13, bright CD33, partial CD34, CD38, CD117, dim HLA-DR+, dim MPO	0	0.3			Yes	BLM (p.D1010fs*24; VAF 51%)|FLT3 (p.N676T; VAF 7%)|FLT3 (p.N841I; VAF 5%)|FLT3-D835 (p.D835H; VAF 7%)|FLT3-D835 (p.D835Y; VAF 6%)|NBN (p.L421S; VAF 48%)|NPM1 (p.W288fs*12; VAF 47%)|PTPN11 (p.E76Q; VAF 5%)|STAG2 (p.I1063fs*10; VAF 64%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2835_BA3452	Acute Myeloid Leukemia	AML with mutated NPM1	D835H	OncoKB: Oncogenic, level_1, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 4, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 0, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9725	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	G	13:g.28592642C>G	ENST00000241453.7:c.2503G>C	0.43		95	128			4	20/24		Pathogenic			56	64	0		Alive		2	Waves3+4	Yes	Azacitidine, Sorafenib|7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine, Trametinib	4	Consolidation|Salvage|Induction	3	Standard Chemotherapy	1	Azacitidine, Trametinib	Salvage	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Negative	FALSE	TRUE	FALSE	46,XXder(22)t(1;22)(q12;p11.2)[1]/46,XX[19]	-1	Standard Chemotherapy	FALSE	Negative	AML	96.2958904109589	0:LIVING		No	No		No	No	No	No	No	No	White	-1	Complete Response	RUNX1 (p.S100Lfs*38; 47.8%)	3	Female	UNMATCHED	FALSE	AML with mutated NPM1	Relapse	Peripheral Blood		455	0.2		Standard Chemotherapy	No	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2169_BA2086	Acute Myeloid Leukemia	AML with mutated NPM1	N676K	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 1, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 1, functionalCount: 1;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: medium, score: 5.851706792215288;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9527	Missense_Mutation	SNP		NA	NA	NA	13	28602340	28602340	G	T	13:g.28602340G>T	ENST00000241453.7:c.2028C>A	0.10		8	74			17	16/24					69	69	0		Dead-Disease		4	Waves1+2	Yes	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine, Midostaurin|FLAG-IDA, Gemtuzumab|MEC, Lenalidomide	4	Salvage|Induction|Re-induction	3	Standard Chemotherapy	1	MEC, Lenalidomide	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Negative	FALSE	FALSE	FALSE	46,XY[22]	5	Standard Chemotherapy	FALSE	Positive	AML	9.994520547945205	1:DECEASED		No	No		No	No	No	No	No	No		79	Refractory		2	Male	MATCHED	FALSE	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Peripheral Blood		0	0.833333333		Standard Chemotherapy	No	FLT3-ITD|IDH1
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2292_BA2879	Acute Myeloid Leukemia	AML with mutated NPM1	Y842C	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 7, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 0, functionalCount: 1;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: medium, score: 5.822090885774011;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 1;AlphaMissense: pathogenicity: pathogenic, score: 0.9363	Missense_Mutation	SNP		NA	NA	NA	13	28592620	28592620	T	C	13:g.28592620T>C	ENST00000241453.7:c.2525A>G	0.10		9	79			3	20/24				0.000058	52	53	0		Dead-Disease		2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation|Salvage|Induction	3	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial		M1	Negative	FALSE	TRUE	FALSE	46,XX[20]	-1	Standard Chemotherapy	FALSE	Negative	AML	20.81095890410959	1:DECEASED	nuc ish(D4Z1,D10Z1)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No		No	No	No	No	No	No	Unknown	7	Complete Response		3	Female	UNMATCHED	FALSE	AML with mutated NPM1	Relapse	Bone Marrow Aspirate		462	0.166666667		Standard Chemotherapy	No	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2292_BA3400	Acute Myeloid Leukemia	AML with mutated NPM1	Y842C	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 7, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 0, functionalCount: 1;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: medium, score: 5.822090885774011;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 1;AlphaMissense: pathogenicity: pathogenic, score: 0.9363	Missense_Mutation	SNP		NA	NA	NA	13	28592620	28592620	T	C	13:g.28592620T>C	ENST00000241453.7:c.2525A>G	0.77		48	14			5	20/24				0.000058	52	54	0		Dead-Disease		2	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation|Salvage|Induction	3	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial		M1	Negative	FALSE	TRUE	FALSE	46,XX[20]	-1	Standard Chemotherapy	FALSE	Positive	AML	20.81095890410959	1:DECEASED	nuc ish(D4Z1,D10Z1)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No		No	No	No	No	No	No	Unknown	7	Complete Response		3	Female	UNMATCHED	FALSE	AML with mutated NPM1	Relapse	Peripheral Blood		616	0.233333333		Standard Chemotherapy	No	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2316_BA2233	Acute Myeloid Leukemia	AML with mutated NPM1	D839G	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 0, prognosticCount: 1, predisposingCount: 0, oncogenicCount: 1, functionalCount: 1;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: medium, score: 5.819594001683767;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: possibly_damaging, score: 0.89;AlphaMissense: pathogenicity: pathogenic, score: 0.8678	Missense_Mutation	SNP		NA	NA	NA	13	28592629	28592629	T	C	13:g.28592629T>C	ENST00000241453.7:c.2516A>G	0.39		45	69			11	20/24					72	72	0		Alive		4	Waves1+2	Yes	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Hydroxyurea	2	Induction	1	Standard Chemotherapy	1	CPX-351 (Liposomal Cytarabine + Daunorubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable		M1	Negative	TRUE	FALSE	FALSE	46,XY[5]	-1	Standard Chemotherapy	FALSE	Positive	AML	3.1232876712328768	0:LIVING	D5S721, EGR1  del(5q)/monosomy 5, D7Z1, D7S522  del(7q)/monosomy 7, D8Z2 trisomy #8, D20S108, 20qter del(20q)	No	No		No	No	No	No	No	No	White	-1	Complete Response		1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD117, MPO,CD38(PARTIAL), CD33(DIM) AND NOT EXPRESSING CD34 AND HLA-DR	0	0.5		Standard Chemotherapy	Yes	FLT3 (p.D839G; MAF~45%)|IDH2 (p.R140L; MAF ~50%)|MLL2 (p.V2338I; MAF ~50%)|NPM1 (p.W288fs*12;MAF ~35%)|SRSF2 (p.P95H, MAF~55%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2369_BA2631	Acute Myeloid Leukemia	AML with mutated NPM1	N841I	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 4, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 5, functionalCount: 0;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: medium, score: 5.788616354682698;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: possibly_damaging, score: 0.489;AlphaMissense: pathogenicity: ambiguous, score: 0.5414	Missense_Mutation	SNP		NA	NA	NA	13	28592623	28592623	T	A	13:g.28592623T>A	ENST00000241453.7:c.2522A>T	0.14		14	84			5	20/24					60	60	0		Alive		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	MiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	46,XY[21]	114	Standard Chemotherapy	FALSE	Positive	AML	91.03561643835616	0:LIVING	Normal	No	No		No	No	No	No	No	No	White	6	Complete Response		1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD7, CD13, CD33, partial CD34, CD38, CD58, CD117, CD123,HLA-DR, and MPO positive	0	0.166666667		Standard Chemotherapy	Yes	CEBPA (p. Q83fs*27 (c.245?246insTGTTCCA); MAF 50%)|FLT3 ( p.N841I; MAF 12%)|FLT3 (p.I836delI; MAF 25%)|NPM1 (p.W288fs*>9; MAF 40%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2514_BA2103	Acute Myeloid Leukemia	AML with mutated NPM1	N841I	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 4, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 5, functionalCount: 0;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: medium, score: 5.788616354682698;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: possibly_damaging, score: 0.489;AlphaMissense: pathogenicity: ambiguous, score: 0.5414	Missense_Mutation	SNP		NA	NA	NA	13	28592623	28592623	T	A	13:g.28592623T>A	ENST00000241453.7:c.2522A>T	0.12		12	90			16	20/24					54	54	0		Alive		2	Waves1+2	Yes	HiDAC|7+3 (Cytarabine, Idarubicin) plus Crenolanib	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable			Negative	TRUE	FALSE	FALSE		88	Standard Chemotherapy	FALSE	Positive	AML	22.06027397260274	0:LIVING	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[196],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[198] (MDS Fish Panel) | nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con	No	No		No	No	No	No	No	No	White	-1	Complete Response		1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD2(-), CD4(dim +), CD7(-), CD11b(-), CD13(-), CD14(-), CD15(-), CD16(-), CD33(variably +), CD34(-), CD36(-), CD38(variably +), CD45(+), CD56(partial +), CD64 (partial +), CD117(variably +), HLA-DR(-).	0	0.8		Standard Chemotherapy	Yes	FLT3 (I836DEL; MAF 18.0%)|FLT3 (N841I; MAF 8.0%)|FLT3 (V491L; MAF 3.0%)|FLT3 (V592A; MAF 1.0%)|IDH2 (R140Q; MAF 47.0%)|NPM1 (W288FS*10+; MAF 35.0%)|SRSF2 (P95L; MAF 41.0%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2622_BA3269	Acute Myeloid Leukemia	AML with mutated NPM1	N676K	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 1, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 1, functionalCount: 1;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: medium, score: 5.851706792215288;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9527	Missense_Mutation	SNP		NA	NA	NA	13	28602340	28602340	G	T	13:g.28602340G>T	ENST00000241453.7:c.2028C>A	0.32		25	54			5	16/24					66	66	0		Dead-Disease		5	Waves3+4	Yes	AG-221|Azacitidine	2	Supportive/Palliative Care	1	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Azacitidine	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable		M0	Negative	TRUE	FALSE	FALSE	46,XX[19]	6	Standard Chemotherapy	FALSE	Positive	AML	2.0054794520547947	1:DECEASED	Normal	No	No		No	No	No	No	No	No	White				1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	negative (CD19, CD22, Cyt CD79a, Cyt CD3, CD7, CD56, CD14, CD15, CD34, CD64 TdT) | positive (CD38, CD13, CD33, CD117, MPO, HLA-DR) | dim (CD11b, CD45)	0	0.2			Yes	DNMT3A (c.1903C>G; p.R635G (COSM144550) MAF 44%)|IDH2 (c.419G>A; p.R140Q (COSM41590) MAF 44%)|NPM1 (c.863_864insTCTG; p.W288fs (COSM158604) MAF 37%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2800_BA3284	Acute Myeloid Leukemia	AML with mutated NPM1	N841I	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 4, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 5, functionalCount: 0;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: medium, score: 5.788616354682698;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: possibly_damaging, score: 0.489;AlphaMissense: pathogenicity: ambiguous, score: 0.5414	Missense_Mutation	SNP		NA	NA	NA	13	28592623	28592623	T	A	13:g.28592623T>A	ENST00000241453.7:c.2522A>T	0.10		25	216			7	20/24					56	56	0				1	Waves3+4	No		0		0		0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	46,XY[20]		None	FALSE	Positive	AML	0.0			No	No		No	No	No	No	No	No	White				1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD7, CD13, bright CD33, partial CD34, CD38, CD117, dim HLA-DR+, dim MPO	0	0.3			Yes	BLM (p.D1010fs*24; VAF 51%)|FLT3 (p.N676T; VAF 7%)|FLT3 (p.N841I; VAF 5%)|FLT3-D835 (p.D835H; VAF 7%)|FLT3-D835 (p.D835Y; VAF 6%)|NBN (p.L421S; VAF 48%)|NPM1 (p.W288fs*12; VAF 47%)|PTPN11 (p.E76Q; VAF 5%)|STAG2 (p.I1063fs*10; VAF 64%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2105_BA2248	Acute Myeloid Leukemia	Acute myeloid leukaemia, NOS	D835H	OncoKB: Oncogenic, level NA, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 4, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 0, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9725	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	G	13:g.28592642C>G	ENST00000241453.7:c.2503G>C	0.43		46	62			12	20/24		Pathogenic			21	22	0		Dead-Disease		2	Waves1+2	Yes	HiDAC|Crenolanib|Etoposide|Topotecan|Decitabine|Clofarabine|Thioguanine|7+3 (Cytarabine, Idarubicin)|Cyclophosphamide|Thiotepa|Sorafenib|Mitoxantrone|Vinorelbine	13	Induction|Experimental|Re-induction|Supportive/Palliative Care	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Crenolanib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Negative	FALSE	FALSE	FALSE		15	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Negative	AML	18.115068493150684	1:DECEASED		No	No		No	No	No	No	No	No		5	Refractory		1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Peripheral Blood		0	0.6		Standard Chemotherapy	Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2270_BA2334	Acute Myeloid Leukemia	AML with t(6;9)(p23;q34); DEK-NUP214	D835V	OncoKB: Oncogenic, level NA, resistance NA;CIViC: diagnosticCount: 3, predictiveCount: 10, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 0, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9745	Missense_Mutation	SNP		NA	NA	NA	13	28592641	28592641	T	A	13:g.28592641T>A	ENST00000241453.7:c.2504A>T	0.13		18	118			14	20/24		Pathogenic			30	31	2.125		Dead-Disease		2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Crenolanib|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine, Sorafenib |Quizartinib	6	Salvage|Induction|Experimental	3	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Crenolanib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	FALSE	FALSE	FALSE	47~49,XX,t(6;9)(p23;q24),+8,+13,+15[cp8]/47~49,idem,+del(13)(q12q22)[cp12]	52	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Negative	AML	18.673972602739727	1:DECEASED		No	No		No	No	No	No	No	No		-1	Refractory		2	Female	MATCHED	FALSE	AML with t(6;9)(p23;q34); DEK-NUP214	Post-Chemotherapy|Residual Disease	Peripheral Blood	CD34(partial +), CD13(+), CD14(-), CD15(few +), CD30(-), CD33(+), CD38(variably +), CD45 (moderately +), CD64(variably +), CD4(partial +), CD117(+), CD123(variably +), HLA-DR(+), CD79a(-), CD22(-), intracellular CD3(-), TdT(-), MPO(partial +), other myelo	0	0.666666667		Standard Chemotherapy	Yes	FLT3-D835|FLT3-ITD
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2387_BA2031	Acute Myeloid Leukemia	Acute monoblastic and monocytic leukaemia	D835Y	OncoKB: Oncogenic, level NA, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 10, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 1, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9341	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	A	13:g.28592642C>A	ENST00000241453.7:c.2503G>T	0.10		10	89			2	20/24		Pathogenic			2	2	0		Alive		1	Waves1+2	Yes	COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Cytarabine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide	4	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	3	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M5	Negative	TRUE	FALSE	FALSE	46,XX,t(6;11)(q27;q23)[19]/46,XX[1]	-1	Bone Marrow Transplant	FALSE	Negative	AML	63.68219178082191	0:LIVING		No	No		No	No	No	No	No	No	White	136	Complete Response		2	Female	UNMATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD4, CD11b, variable CD13, CD15, CD33, variable CD56, CD58, CD64, lysozyme, and dim HLA-DR positive	0	0.133333333		Standard Chemotherapy	Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2489_BA2488	Acute Myeloid Leukemia	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	D835H	OncoKB: Oncogenic, level NA, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 4, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 0, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9725	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	G	13:g.28592642C>G	ENST00000241453.7:c.2503G>C	0.16		22	116			15	20/24		Pathogenic			83	83	0		Alive		1	Waves1+2	Yes	Ruxolitinib|ATRA, Arsenic Trioxide|Idarubicin	3	Induction|Maintenance|Symptom Control	3	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Idarubicin	Symptom Control	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M3	Negative	FALSE	FALSE	TRUE	46,XX,t(15;17)(q24;q21)[12]/46,XX,idem,del(16)(q12.1q24)[3]/46,XX[5]	0	Standard Chemotherapy	FALSE	Negative	AML	92.25205479452055	0:LIVING	7% 16q deletion	No	No		No	No	No	No	Yes	Yes	White	253	Complete Response		1	Female	MATCHED	FALSE	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, partial CD34, CD64, CD117, CD123, and MPO-positive	0	0.933333333		Standard Chemotherapy	Yes	FLT3-D835 (D835H; MAF Unlisted)|JAK2 (p.V617F; MAF 90%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2490_BA2928	Acute Myeloid Leukemia	AML with t(9;11)(p22;q23); MLLT3-MLL	D835V	OncoKB: Oncogenic, level NA, resistance NA;CIViC: diagnosticCount: 3, predictiveCount: 10, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 0, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9745	Missense_Mutation	SNP		NA	NA	NA	13	28592641	28592641	T	A	13:g.28592641T>A	ENST00000241453.7:c.2504A>T	0.08		10	111			3	20/24		Pathogenic			48	48	0		Dead-Treatment		1	Both	Yes	Fludarabine, Melphalan|Idarubicin and Cytarabine	2	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M5	Negative	TRUE	FALSE	FALSE	47,XX,+8,t(9;11)(p22;q23)[20]	-1	Bone Marrow Transplant	FALSE	Negative	AML	56.054794520547944	1:DECEASED	MLL rearrangement (80%) | Trisomy 8 (78%)	No	No		No	No	No	No	No	No	White	5	Complete Response		1	Female	UNMATCHED	FALSE	AML with t(9;11)(p22;q23); MLLT3-MLL	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD4, partial CD11b, CD15, CD33, CD56, CD58, CD64, CD117, CD123, HLA-DR, and butyrate esterase positive	0	0.133333333		Standard Chemotherapy	No	FLT3-D835 (MAF 10%)|JAK1 (p.I878V; MAF 50%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2539_BA2255	Acute Myeloid Leukemia	AML with t(9;11)(p22;q23); MLLT3-MLL	D835H	OncoKB: Oncogenic, level NA, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 4, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 0, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9725	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	G	13:g.28592642C>G	ENST00000241453.7:c.2503G>C	0.08		10	115			14	20/24		Pathogenic			62	62	0		Dead-Disease		3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Fludarabine, TBI|MiDAC|FATE Trial RIC (Fludarabine, Melphalan, Rabbit ATG) |ODSH (2 O, 3-O Desulfated Heparin)	5	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, TBI	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate		M5a	Negative	FALSE	FALSE	FALSE	47,XY,+8,t(9;11)(p21;q23)[9]/46,XY[11]	-1	Bone Marrow Transplant	FALSE	Negative	AML	32.18630136986302	1:DECEASED	8q22 (RUNX1T1): gain present  11q23 (MLL): rearrangement present (83.5% 11q23, 84.5% 8q22)	Yes	No	Prostate Cancer	No	No	No	No	No	No		-1	Complete Response		2	Male	MATCHED	FALSE	AML with t(9;11)(p22;q23); MLLT3-MLL	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Large population of promonocytes/monoblasts that represent approximately 88% of the leukocytes, consider acute monoblastic leukemia.	0	0.833333333		Standard Chemotherapy	No	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2589_BA3064	Acute Myeloid Leukemia	Acute myeloid leukaemia, NOS	D835H	OncoKB: Oncogenic, level NA, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 4, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 0, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9725	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	G	13:g.28592642C>G	ENST00000241453.7:c.2503G>C	0.36		86	155			2	20/24		Pathogenic			38	40	4		Dead-Disease		3	Waves1+2	Yes	Azacitidine, Sorafenib|Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|Gilteritinib (ASP2215)|Sorafenib|Cladribine, Cytarabine, Idarubicin	6	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Experimental|Intensification|Re-induction	7	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Sorafenib	Experimental	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	FALSE	TRUE	FALSE		38	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Negative	AML	23.57260273972603	1:DECEASED	Normal	No	No		No	No	No	No	No	No		-1	Refractory		1	Male	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Relapse|Post-Chemotherapy|Post-Transplant	Peripheral Blood	CD4,  CD11b, dim CD13, variable CD15, CD33, partial CD34  (approximately 25%), variable CD64 (dim to bright), CD117,  HLA-DR, and myeloperoxidase	0	0.066666667		Standard Chemotherapy	Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2616_BA3355	Acute Myeloid Leukemia	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	D835Y	OncoKB: Oncogenic, level NA, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 10, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 1, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9341	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	A	13:g.28592642C>A	ENST00000241453.7:c.2503G>T	0.19		30	125			7	20/24		Pathogenic			70	70	0	ASXL1 (p.G646Wfs*12; 24.8%)	Dead-Disease		1	Waves3+4	No	Azacitidine, Itacitinib|Azacitidine, BI 836858 (anti-CD33)	2	Induction	1	Targeted Therapy - Kinase Inhibitor(s)	1	Azacitidine, Itacitinib	Induction	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC		Negative	FALSE	FALSE	FALSE	45,XX,inv(3)(q21q26),-7[20]	8	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Positive	AML	6.2465753424657535	1:DECEASED	Abnormal (MECOM/RPN1 Fusion: 99% of  cells had a 1r/1g/2f dual-fusion signal pattern, reflecting MECOM/RPN1  fusion)	No	No		No	No	No	No	No	No	White	39	Refractory		1	Female	UNMATCHED	FALSE	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Post-Chemotherapy|Residual Disease	Peripheral Blood		0	0.3		Targeted Therapy - Kinase Inhibitor(s)	Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2621_BA3369	Acute Myeloid Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	D835V	OncoKB: Oncogenic, level NA, resistance NA;CIViC: diagnosticCount: 3, predictiveCount: 10, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 0, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9745	Missense_Mutation	SNP		NA	NA	NA	13	28592641	28592641	T	A	13:g.28592641T>A	ENST00000241453.7:c.2504A>T	0.28		57	144			4	20/24		Pathogenic			73	73	0		Dead-Unknown		1	Waves3+4	No		0		0		0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M4	Negative	FALSE	FALSE	FALSE	46,XY,inv(16)(p13.1q22)[cp20]		None	FALSE	Negative	AML	0.3287671232876712	1:DECEASED	CBFB/MYH11: 93/100 cells (93%) had the abnormal 1 red/ 1 green/ 2 yellow signal pattern, reflecting CBFB/MYH11 fusion, consistent with the metaphase karyotype and the diagnosis of AML.	Yes	No	Melanoma	No	No	No	No	No	No	White				1	Male	UNMATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	Myeloid blasts: CD13, CD33, CD34, dimCD38, CD117, dim HLA-DR, and MPO. | Promonocytes/monocytes: dimCD4, CD11b, bright CD13, variable CD14, bright CD33, CD64, variable HLA-DR positive	0	0.2			Yes	EP300 (p.S1033L; VAF 50%)|FLT3-TKD (p.D835V; VAF 26%)|KRAS (p.G12V; VAF 19%)|WT1 (p.T225M; VAF 50%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2686_BA3126	Acute Myeloid Leukemia	Acute monoblastic and monocytic leukaemia	D835Y	OncoKB: Oncogenic, level NA, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 10, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 1, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9341	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	A	13:g.28592642C>A	ENST00000241453.7:c.2503G>T	0.39		50	78			4	20/24		Pathogenic			66	66	0		Alive		1	Waves3+4	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M5	Negative	TRUE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	FALSE	Negative	AML	51.945205479452056	0:LIVING	MLL: 86% of cells had a split signal pattern consistent with MLL rearrangement.	No	No		No	No	No	No	No	No	White	5	Complete Response		1	Male	UNMATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD11b, CD13, CD14, CD33, bright CD64, HLA-DR and partial MPO-positive	2	0.2		Standard Chemotherapy	Yes	FLT3 (p.D835Y; MAF 35%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2694_BA3084	Acute Myeloid Leukemia	Acute myelomonocytic leukaemia	D835Y	OncoKB: Oncogenic, level NA, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 10, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 1, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9341	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	A	13:g.28592642C>A	ENST00000241453.7:c.2503G>T	0.28		46	117			5	20/24		Pathogenic			22	22	0		Dead-Disease		1	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone) + Midostaurin|Busulfan, Cyclophosphamide	3	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M4	Negative	TRUE	FALSE	FALSE	46,XY,t(10;11)(p13;q23)[20]	-1	Bone Marrow Transplant	FALSE	Negative	AML	10.783561643835617	1:DECEASED	MLL: 88% of cells had a 1g/0r/2f signal pattern, where the lone green signal was small and the green component suggesting a disruption of MLL (11q23) within the green portion of  the probe.  This result is consistent with MLL rearrangement and with the t(	No	No		No	No	No	No	No	No	White	-1	Refractory		1	Male	MATCHED	FALSE	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Immunophenotype 1(15% WBCs): dim CD4, variable CD13, CD33, bright  CD34, CD58, CD64, CD117, CD123, variable MPO  | Immunophenotype 2 (79% WBCs): dim CD4, CD11b, variable CD13, CD33, CD38, CD58, CD64, CD117, CD123	0	0.266666667		Standard Chemotherapy	Yes	FLT3-D835 (MAF: 31%)|KRAS (p.G12D; MAF 4%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2762_BA3409	Acute Myeloid Leukemia	Acute myeloid leukaemia, NOS	D835N	OncoKB: Oncogenic, level NA, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 0, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 1, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.474894242453915;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.934;AlphaMissense: pathogenicity: pathogenic, score: 0.7605	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	T	13:g.28592642C>T	ENST00000241453.7:c.2503G>A	0.38		31	51			7	20/24		Pathogenic			64	65	1		Dead-Disease		2	Waves3+4	Yes	J1219, quizartinib|7+3 (Cytarabine, Idarubicin)|Crenolanib|Azacitidine|Sorafenib|Valproic Acid|E1906, topotecan, carboplatin	7	Induction|Experimental|Re-induction|Maintenance	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Crenolanib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M4	Positive	FALSE	FALSE	FALSE	46,XX[20]	21	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Negative	AML	8.810958904109588	1:DECEASED		No	No		No	No	No	No	No	No	White	-1	Refractory		1	Female	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Peripheral Blood		0	0.333333333		Standard Chemotherapy	Yes	FLT3-ITD
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2762_BA3409	Acute Myeloid Leukemia	Acute myeloid leukaemia, NOS	D835V	OncoKB: Oncogenic, level NA, resistance NA;CIViC: diagnosticCount: 3, predictiveCount: 10, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 0, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9745	Missense_Mutation	SNP		NA	NA	NA	13	28592641	28592641	T	A	13:g.28592641T>A	ENST00000241453.7:c.2504A>T	0.37		30	52			7	20/24		Pathogenic			64	65	1		Dead-Disease		2	Waves3+4	Yes	J1219, quizartinib|7+3 (Cytarabine, Idarubicin)|Crenolanib|Azacitidine|Sorafenib|Valproic Acid|E1906, topotecan, carboplatin	7	Induction|Experimental|Re-induction|Maintenance	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Crenolanib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M4	Positive	FALSE	FALSE	FALSE	46,XX[20]	21	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Negative	AML	8.810958904109588	1:DECEASED		No	No		No	No	No	No	No	No	White	-1	Refractory		1	Female	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Peripheral Blood		0	0.333333333		Standard Chemotherapy	Yes	FLT3-ITD
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2831_BA3141	Acute Myeloid Leukemia	Acute myeloid leukaemia, NOS	D835Y	OncoKB: Oncogenic, level NA, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 10, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 1, functionalCount: 0;CancerHotspot: yes;3DHotspot: no			MutationAssessor: impact: medium, score: 5.821467832733887;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.999;AlphaMissense: pathogenicity: pathogenic, score: 0.9341	Missense_Mutation	SNP		NA	NA	NA	13	28592642	28592642	C	A	13:g.28592642C>A	ENST00000241453.7:c.2503G>T	0.50		84	85			4	20/24		Pathogenic					0				3	Waves3+4	No		0		0		0	NONE	NONE	Unknown	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Negative	unknown	unknown	unknown			None	FALSE	Negative	AML	0.0			No	No		No	No	No	No	No	No					1	Female	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Unknown	Bone Marrow Aspirate		0	0.166666667			Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2123_BA2956	Acute Myeloid Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	D839G	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 0, prognosticCount: 1, predisposingCount: 0, oncogenicCount: 1, functionalCount: 1;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: medium, score: 5.819594001683767;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: possibly_damaging, score: 0.89;AlphaMissense: pathogenicity: pathogenic, score: 0.8678	Missense_Mutation	SNP		NA	NA	NA	13	28592629	28592629	T	C	13:g.28592629T>C	ENST00000241453.7:c.2516A>G	0.11		9	70			3	20/24					56	57	0		Dead-Disease		2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable			Negative	TRUE	FALSE	FALSE	46,XY,del(5)(q15q35),inv(16)(p13.1q22)[20]	3	Standard Chemotherapy	FALSE	Negative	AML	13.841095890410958	1:DECEASED	nuc ish(D5S721x2,D5S23x2,EGR1x1)[182/200],(D7Z1,D7S522)x2[199], (RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[192],(PML,RARA)x2[198],(5'CBFB,3'CBFB)x2(5'CBFB sep 3'CBFBx1)[176/200]	No	No		No	No	No	No	No	No		3	Unknown		1	Male	UNMATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD2(-), CD4(partial dim +), CD7(partial dim +), CD11b(-), CD13(+), CD14(-), CD15(+), CD16(-), CD19(-), CD20(-), CD22(few dim +), CD25(-), CD33(+), CD34(+), CD36 (-), CD38(variably +), CD45(moderately +), CD56(-), CD64(few dim +), CD79a(-), CD117(+), CD123	0	0.166666667		Standard Chemotherapy	Yes	NRAS (G12D; MAF 16%)|NRAS (G13D; MAF 13%)|NRAS (Q61H; MAF 5%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2287_BA2661	Acute Myeloid Leukemia	AML with mutated NPM1	N841K	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 0, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 2, functionalCount: 0;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: medium, score: 5.788616354682698;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: possibly_damaging, score: 0.506;AlphaMissense: pathogenicity: pathogenic, score: 0.7521	Missense_Mutation	SNP		NA	NA	NA	13	28592622	28592622	G	T	13:g.28592622G>T	ENST00000241453.7:c.2523C>A	0.15		15	85			20	20/24					56	56	0		Alive		3	Waves1+2	Yes	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG (Cladribine, Cytarabine, Filgrastim)	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable			Negative	FALSE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	FALSE	Positive	AML	20.843835616438355	0:LIVING	Normal	Yes	No	Prostate Cancer	No	No	No	No	No	No	White	12	Complete Response i		1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	84% are monocytes, and 9% are myeloid  cells. The monocytic cells (percentages shown) appear  atypical with expression of CD13, bright CD33, and bright  CD64, but weaker than normal HLA-DR and include 48% that  are phenotypically consistent with promonocy	0	1.266666667		Standard Chemotherapy	Yes	DNMT3A (p.Val716Asp; MAF 45%)|FLT3-D835 (p.Asp835Val; MAF 30.5%)|NPM1 (p.Trp288fs; MAF 16.1%)|RAD21 (p.Glu178*; MAF 12%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2344_BA3001	Acute Myeloid Leukemia	AML with mutated NPM1	N841K	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 0, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 2, functionalCount: 0;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: medium, score: 5.788616354682698;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: possibly_damaging, score: 0.506;AlphaMissense: pathogenicity: pathogenic, score: 0.7521	Missense_Mutation	SNP		NA	NA	NA	13	28592622	28592622	G	T	13:g.28592622G>T	ENST00000241453.7:c.2523C>A	0.22		24	84			22	20/24					51	51	0		Alive		1	Waves1+2	Yes	HiDAC|Hydroxyurea|7+3 (Cytarabine, Idarubicin) plus Sorafenib	3	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M1	Negative	TRUE	FALSE	FALSE	46,XX[20]	-1	Standard Chemotherapy	FALSE	Positive	AML	62.7945205479452	0:LIVING	Normal	No	No		No	No	No	No	No	No	White	2	Complete Response		1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Immunophenotype: CD7, CD13, CD33, CD38, CD117, CD123 and MPO positive	0	1.166666667		Standard Chemotherapy	Yes	CBL (p.R420Q; MAF ~20%)|FLT3 (p.N841K; MAF ~30%)|IDH2 (p.R140Q; MAF ~30%)|NPM1 (p.W288fs*12; MAF ~25%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2366_BA3317	Acute Myeloid Leukemia	AML with mutated NPM1	N841T	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 0, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 1, functionalCount: 0;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: medium, score: 5.788616354682698;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: benign, score: 0.141;AlphaMissense: pathogenicity: benign, score: 0.141	Missense_Mutation	SNP		NA	NA	NA	13	28592623	28592623	T	G	13:g.28592623T>G	ENST00000241453.7:c.2522A>C	0.45		68	83			13	20/24					60	62	0		Dead-Disease		1	Waves3+4	Yes	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)	3	Salvage|Induction|Re-induction	3	Standard Chemotherapy	1	Azacitidine	Salvage	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M4	Negative	FALSE	TRUE	FALSE	46,XY,t(3;4)(p21;q21)[20]	6	Standard Chemotherapy	FALSE	Positive	AML	28.6027397260274	1:DECEASED	Normal	No	No		No	No	No	No	No	No	White	167	Complete Response		2	Male	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Relapse	Bone Marrow Aspirate	CD13, CD34, dim CD33, CD38, CD58, CD71, CD117, CD123, partial TdT, and partial MPO+	769	0.733333333		Standard Chemotherapy	No	FLT3 (p.N841T; MAF 43%)|NPM1 (p.W288fs*12; MAF 41%)|SF3B1 (p.K666Q; MAF 48%)|WT1 (p.Y395fs*51; MAF 44%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2640_BA3334	Acute Myeloid Leukemia	Acute myeloid leukaemia, NOS	N841K	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 0, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 2, functionalCount: 0;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: medium, score: 5.788616354682698;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: possibly_damaging, score: 0.506;AlphaMissense: pathogenicity: pathogenic, score: 0.7521	Missense_Mutation	SNP		NA	NA	NA	13	28592622	28592622	G	T	13:g.28592622G>T	ENST00000241453.7:c.2523C>A	0.55		51	41			5	20/24					76	76	0	ASXL1 (p.C687Yfs*30; 45.2%)	Alive		2	Waves3+4	No	Entospletinib	1	Experimental	1	Targeted Therapy - Other	1	Entospletinib	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse			Negative	TRUE	FALSE	FALSE		-1	Targeted Therapy - Other	FALSE	Negative	AML	1.5452054794520547	0:LIVING	Normal	No	No		No	No	No	No	No	No	White				1	Female	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate		0	0.266666667			Yes	ASXL1|FLT3 (N841K)|SRSF2|STAG2
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2835_BA3343	Acute Myeloid Leukemia	AML with mutated NPM1	N841T	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: diagnosticCount: 0, predictiveCount: 0, prognosticCount: 0, predisposingCount: 0, oncogenicCount: 1, functionalCount: 0;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: medium, score: 5.788616354682698;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: benign, score: 0.141;AlphaMissense: pathogenicity: benign, score: 0.141	Missense_Mutation	SNP		NA	NA	NA	13	28592623	28592623	T	G	13:g.28592623T>G	ENST00000241453.7:c.2522A>C	0.30		54	125			7	20/24					56	66	0		Alive		2	Waves3+4	Yes	Azacitidine, Sorafenib|7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine, Trametinib	4	Consolidation|Salvage|Induction	3	Standard Chemotherapy	1	Azacitidine, Trametinib	Salvage	Unknown	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Negative	unknown	unknown	unknown	46,XXder(22)t(1;22)(q12;p11.2)[1]/46,XX[19]	-1	Standard Chemotherapy	FALSE	Negative	AML	96.2958904109589	0:LIVING		No	No		No	No	No	No	No	No	White	-1	Complete Response	RUNX1 (p.S100Lfs*38; 36.8%)	3	Female	UNMATCHED	FALSE	AML with mutated NPM1	Unknown	Peripheral Blood		893	0.366666667		Standard Chemotherapy	No	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2031_BA2501	Acute Myeloid Leukemia	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							1	14/24					36	36	0.25		Alive		3	Waves1+2	Yes	Methotrexate, Mercaptopurine, Tretinoin|ATRA, Idarubicin|ATRA, Cytarabine, Idarubicin	3	Consolidation|Induction|Maintenance	3	Standard Chemotherapy	1	Methotrexate, Mercaptopurine, Tretinoin	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable		M3	Positive	TRUE	FALSE	FALSE	46,XY,t(15;17)(q24;q21)[18]/46,XY[2]	-1	Standard Chemotherapy	FALSE	Negative	AML	19.857534246575344	0:LIVING	Normal	No	No		No	No	No	No	No	No		-1	Complete Response		1	Male	UNMATCHED	FALSE	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Peripheral Blood	weak partial CD2, CD13, CD33, CD64, CD117, and  myeloperoxidase	0	0		Standard Chemotherapy	Yes	CEBPA (c.935A>G; MAF 45%, except VUS)|FLT3-ITD (c.1780_1800dup; MAF 17%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2039_BA2955	Acute Myeloid Leukemia	Acute monoblastic and monocytic leukaemia	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							21	14/24					66	66			Alive		1	Waves1+2	Yes	3+7 (Cytarabine, Daunorubicin), Bortezomib|MiDAC|Fludarabine, Cytarabine|Ibrutinib	4	Allogeneic - Sibling|Consolidation|Induction|Maintenance	4	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Ibrutinib	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M5	Positive	TRUE	FALSE	FALSE	47,XX,+6[6]/46,XX[19]	382	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Negative	AML	71.5068493150685	0:LIVING	IGH/MAF: 74/100 cells (74%) had variant abnormal 0-1 red/ 1-4 green/ 2-7 yellow signal patterns reflecting IGH/MAF fusion. The majority of cells (56%) were 0 red/ 1 green/ 3 yellow. IGH: 68/100 (68%) cells scored had signal patterns consistent with IGH re	No	No		No	No	No	No	No	No	White	6	Refractory	RUNX1 (p.P240Qfs*22; 40.0%)	1	Female	MATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dimCD4, CD11b, CD13, dimCD14, CD33, CD56, CD58, CD64, dimCD123 and HLA-DR positive; Minor subset of blasts with immunophenotype: CD13, CD33, CD34, CD58, CD117, dimCD123, HLA-DR and MPO positive.	0	0.866666667		Standard Chemotherapy	Yes	BCOR (p.G1659E MAF ~10%,)|FLT3-ITD (MAF 38%)|NRAS (p.Q61R MAF ~5%)|RUNX1 (p.P240fs*22; MAF 37%)|RUNX1 (splice site [at invariant AG (G>A) splice acceptor site at end of Intron 6];  MAF 36% ))
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2046_BA3030	Myelodysplastic/Myeloproliferative Neoplasms	Atypical chronic myeloid leukaemia, BCR-ABL1 negative	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							10	14/24					70	70	0.428571429		Dead-Disease		1	Waves1+2	No	Hydroxyurea	1	Induction	1	Targeted Therapy - Kinase Inhibitor(s)	1	Hydroxyurea	Induction		Myelodysplastic/Myeloproliferative Neoplasms	NonAML	UNKNOWN		Positive	FALSE	FALSE	FALSE	46,XX[20]	-1	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Negative	MDS/MPN	1.084931506849315	1:DECEASED	Normal	No	No		No	No	Yes	No	No	No	Unknown	-1	Unknown		1	Female	MATCHED	TRUE	Atypical chronic myeloid leukaemia, BCR-ABL1 negative	Unknown	Bone Marrow Aspirate	CD13, CD33, CD34, partial CD117, CD123, HLA-DR	0	0.5		Targeted Therapy - Kinase Inhibitor(s)	No	FLT3-ITD (MAF 45%)|IKZF1 (p.N159S ; MAF 45%)|SF3B1 (p.K666N ; MAF 45%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2052_BA2272	Acute Myeloid Leukemia	Acute myelomonocytic leukaemia	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							2	14/24					12	12	0.538461538		Alive		1	Waves1+2	Yes	Cytarabine|Sorafenib|Cytarabine, Daunorubicin, and Etoposide|Busulfan, Cyclophosphamide	4	Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction	3	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	3	Busulfan, Cyclophosphamide	Allogeneic - Mismatched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	HISPANIC	M4	Positive	TRUE	FALSE	FALSE	47,XY,+8[19]/46,XY[1]	-1	Bone Marrow Transplant	FALSE	Negative	AML	62.630136986301366	0:LIVING	RUNX1T1 signal consistent with the trisomy 8 clone	No	No		No	No	No	No	No	No	White	0	Refractory		1	Male	UNMATCHED	FALSE	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Leukapheresis	dimCD11b, dimCD13, CD14, dimCD33, CD64, variable CD123, HLA-DR CD13,dimCD33, dim variable CD34, CD117, CD123, HLA-DR	0	0.066666667		Standard Chemotherapy	Yes	FLT3-ITD (~16 amino acid insertion; MAF 11%)|FLT3-ITD (~8 amino acid insertion; MAF 20%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2074_BA2256	Acute Myeloid Leukemia	Acute myeloid leukaemia, NOS	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							4	14/24					25	26	1		Dead-Unknown		6	Waves1+2	Yes	Azacitidine, Sorafenib|7+3 (Cytarabine, Idarubicin)|HiDAC|Cladribine, Cytarabine, Idarubicin	4	Consolidation|Induction|Re-induction	3	Standard Chemotherapy	1	Azacitidine, Sorafenib	Re-induction	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	FALSE	FALSE	FALSE	46,XX,t(7;12)(q22;p13)[12]/46,XX,t(7;17)(p10;q10),-9,+mar[7]/46,XX[1]	67	Standard Chemotherapy	FALSE	Negative	AML	10.652054794520549	1:DECEASED	This test has detected a translocation between 7 and 12 in 12 cells; a translocation between 7 and 17 with loss of a chromosome 9 and a marker in 7 cells.	No	No		No	No	No	No	No	No		-1	Complete Response		1	Female	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	These are positive for CD34, CD117, HLADR, CD33 but negative for CD13 and CD11b. TdT and CD79a are partially expressed. (Bone Marrow Immunophenotyping)	49	0.1		Standard Chemotherapy	Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2097_BA2649	Acute Myeloid Leukemia	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							16	14/24					65	65			Dead-Other		1	Waves1+2	Yes	ATRA (Tretinoin)|3+7 (Cytarabine, Daunorubicin)	2	Induction	1	Standard Chemotherapy	1	3+7 (Cytarabine, Daunorubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M3	Positive	TRUE	FALSE	FALSE	46,X,der(X)add(X)(p22.1)add(X)(q22~24),add(7)(p15),der(15)t(15;17)(q22;q21),der(17)t(15;17)(q22;q21)inv(17)(q21q21)del(17)(q21)[17]/46,XX[3] (unusual PML-RARA translocation)	3	Standard Chemotherapy	FALSE	Negative	AML	0.23013698630136986	1:DECEASED	76% Unusual t(15;17), with the fusion signal on the derivative chromosome 15	No	No		No	No	No	No	No	No	White	5	Unknown		1	Female	MATCHED	FALSE	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	partial CD2, CD13, CD33, partial CD34, CD117, CD123, MPO-positive	0	0.866666667		Standard Chemotherapy	Yes	FLT3-ITD (MAF 40%)|SF3B1 (p.K66N; MAF 40%)|WT1 (rs16754; MAF 50%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2130_BA2935	Acute Myeloid Leukemia	Acute monoblastic and monocytic leukaemia	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							3	14/24					78	78	0.886792453		Dead-Disease		4	Waves1+2	Yes	Azacitidine|Sorafenib|Decitabine, Midostaurin	3	Induction|Experimental|Re-induction	3	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Sorafenib	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse		M5	Positive	TRUE	FALSE	FALSE	46,XY[25]	8	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Negative	AML	23.17808219178082	1:DECEASED		No	No		No	No	No	No	No	No		317	Refractory		1	Male	MATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood		0	0.133333333		Standard Chemotherapy	Yes	FLT3-ITD
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2140_BA2132	Acute Myeloid Leukemia	Acute myeloid leukaemia, NOS	X593_X593insDFREYEYDLKWEFPRENLEFGG	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608277	28608278	-	CCCCCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAA	13:g.28608277_28608278insCCCCCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAA	ENST00000241453.7:c.1837+1_1837+2insGGGTTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTTTGG	0.04		5	109			4	14/24					70	70	0.333333333		Alive		6	Waves1+2	Yes	Azacitidine	1	Induction	1	Standard Chemotherapy	1	Azacitidine	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse			Positive	TRUE	FALSE	FALSE	46,XX,del(5)(q22q35)[20]	37	Standard Chemotherapy	FALSE	Negative	AML	1.2164383561643834	0:LIVING	Positive for 5q deletion in 91% of cells.	No	No		No	No	No	No	No	No		37	Unknown		1	Female	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	POSITIVE FOR CD34, HLA-DR, CD117 AND CD33, AND NEGATIVE FOR MPO, TdT, CD13, CD19, CD20 AND CD10. (Bone Marrow Immunophenotyping)	0	0.133333333		Standard Chemotherapy	Yes	FLT3-ITD|MLL |U2AF1 (p.S34F; MAF 35%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2163_BA2647	Acute Myeloid Leukemia	Acute myeloid leukaemia, NOS	F612_G613insAHNEYFYVDFREYEYDLKWEFPRENLEF	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608299	28608300	-	GTGCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTAT	13:g.28608299_28608300insGTGCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTAT	ENST00000241453.7:c.1837_1837+1insCACATAATGAGTACTTCTACGTTGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTTTG	0.15		22	120			4	14/24					44	45	0.515151515		Dead-Unknown		6	Waves1+2	Yes	Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|HiDAC|3+7 (Cytarabine, Daunorubicin)|Azacitidine|Clofarabine, Cytarabine	5	Consolidation|Salvage|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction	5	Standard Chemotherapy|Bone Marrow Transplant	2	Azacitidine	Salvage	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC		Positive	FALSE	TRUE	FALSE		4	Standard Chemotherapy	FALSE	Negative	AML	25.249315068493146	1:DECEASED		No	No		No	No	No	No	No	No	White	7	Refractory	RUNX1 (p.R107C; 43.8%)|RUNX1 (p.W106*; 36.8%)	1	Female	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Relapse|Post-Chemotherapy|Post-Transplant	Bone Marrow Aspirate	POSITIVE for the FLT3 Internal Tandem Duplication (ITD)-Signal Ratio (SR) with a signal ratio of 0.045. NOT DETECTED for the FLT3 TKD Mutation.  (Bone Marrow Immunophenotyping) | POSITIVE FOR DIM CD45, CD34, HLADR, CD117, CD13, CD38, NEGATIVE FOR CD33. (B	0	0.2		Standard Chemotherapy	Yes	FLT3-ITD|IDH2 (c.419G>A; p.R140Q   MAF 39%)|NF1 (c.5225A>G; p.N17425 MAF 10%)|PHF6 (c.901T>G; p.Y301D MAF 29%)|RAD21 (c.482-3T>C; MAF 8%)|RUNX1 (c.318G>A; p.W106* MAF 37%, c.319C>T; p.R107C  MAF 37%)|SMC1A (c.3391G>A; p.G1131R  MAF 29%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2170_BA2660	Acute Myeloid Leukemia	Acute myelomonocytic leukaemia	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							11	14/24					43	43			Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Cytarabine|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Induction|Re-induction|Supportive/Palliative Care	3	Standard Chemotherapy|Supportive/Palliative Care	2	Cytarabine	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M4	Positive	TRUE	FALSE	FALSE	46,XX[20]	125	Supportive/Palliative Care	FALSE	Negative	AML	8.054794520547945	1:DECEASED	Normal	No	No		No	No	No	No	No	No	White	6	Refractory	RUNX1 (p.R250Lfs*13; 46.7%)	1	Female	MATCHED	FALSE	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Myeloid blast (52%) immunophenotype: CD13, variable CD33, CD34, variable CD38, variable CD117, HLA-DR, and TdT positive | Monocytic blast/promonocyte (28%) immunophenotype: dim CD2, CD11b, CD13, variable CD14, bright CD33, dim CD34, CD38, CD58, CD64, and 	0	0.466666667		Standard Chemotherapy	Yes	FLT3-ITD (MAF 47%)|RUNX1 (p.K110Q; MAF 38%)|SUZ12 (p.E261fs*2; MAF 52%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2179_BA2069	Acute Myeloid Leukemia	AML with t(9;11)(p22;q23); MLLT3-MLL	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							5	14/24					55	55	1.083333333		Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine	4	Consolidation|Salvage|Induction	3	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	NON-HISPANIC	M5	Positive	TRUE	FALSE	FALSE	46,XY,t(9;11)(p22;q23)[20]	4	Standard Chemotherapy	FALSE	Positive	AML	8.087671232876712	1:DECEASED	MLL rearrangement and t(9;11) (86%)	No	No		No	No	No	No	No	No	White	6	Complete Response		1	Male	MATCHED	FALSE	AML with t(9;11)(p22;q23); MLLT3-MLL	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD11b, partial CD13, CD33, CD38, CD56, CD58, CD64, partial CD117, CD123, and HLA-DR+	0	0.1		Standard Chemotherapy	Yes	No gene mutations found in the 43 genes tested
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2196_BA2399	Acute Myeloid Leukemia	Acute myeloid leukaemia, NOS	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							15	14/24					55	55	1		Alive		2	Waves1+2	Yes	HiDAC|Cyclophosphamide|Fludarabine, Cyclophosphamide, TBI |7+3 (Cytarabine, Idarubicin) plus Crenolanib	4	Consolidation|Induction|Allogeneic - Child|Maintenance	4	Standard Chemotherapy|Bone Marrow Transplant	2	Cyclophosphamide	Maintenance	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse			Positive	TRUE	FALSE	FALSE	46,XY[29]	1	Standard Chemotherapy	FALSE	Negative	AML	21.96164383561644	0:LIVING	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[199],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No		No	No	No	No	No	No	Asian	7	Complete Response		1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(-), CD4(partial dim +), CD7(-), CD11b(-), CD13(dim +), CD14(-), CD15(-/few dim +), CD16(-), CD33(+), CD34 (partial +), CD36(equivocal/small subset appears +), CD38(partial +), CD45(+), CD56(-), CD64(-/few dim +), CD117(+), HLA-DR(+ and variable), TDT(	0	0.766666667		Standard Chemotherapy	Yes	FLT3-ITD (S584_S585INSSDNEYFYVDFRE; MAF 29.0%)|IDH1 (R132H; MAF 47.0%)|MLL (Foundation; MLL-PTD Exons 2-8; not GeneTrails)|TET2 (SPLICE SITE 3500+1G>A; MAF 48.0%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2208_BA2752	Acute Myeloid Leukemia	Acute myeloid leukaemia, NOS	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							18	14/24					68	68	0.162790698		Alive		6	Waves1+2	Yes	Vidaza|Fludarabine, Melphalan|HiDAC|3+7 (Cytarabine, Daunorubicin)	4	Allogeneic - Sibling|Consolidation|Induction|Re-induction	4	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Sibling	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC		Positive	FALSE	FALSE	FALSE	46,XY[20]	0	Bone Marrow Transplant	FALSE	Negative	AML	9.830136986301369	0:LIVING		No	No		No	No	No	No	No	No	White	34	Refractory	RUNX1 (p.G170Efs*7; 32.5%)|RUNX1 (p.R162W; 36.4%)	1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Residual Disease|Post-Chemotherapy	Bone Marrow Aspirate	These are positive for CD34, CD117, HLADR, CD33, and CD13. (Bone Marrow Immunophenotyping)	0	0.8		Standard Chemotherapy	Yes	FLT3-ITD|MLL
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2210_BA2850	Acute Myeloid Leukemia	Acute myeloid leukaemia, NOS	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							15	14/24					50	50	1.5		Alive		6	Waves1+2	Yes	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling|Induction|Re-induction	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Sibling	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	FALSE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	FALSE	Negative	AML	18.936986301369863	0:LIVING		No	No		No	No	No	No	No	No	Multiracial	-1	Refractory	RUNX1 (p.E454Gfs*149; 21.4%)	4	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Residual Disease|Post-Chemotherapy	Peripheral Blood	These are postive for CD34, CD117, HLADR, CD13 and CD33. These are negative for CD3, CD20, CD4, CD11b. (Bone Marrow Immunophenotyping)	0	0.7		Standard Chemotherapy	Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2210_BA2993	Acute Myeloid Leukemia	Acute myeloid leukaemia, NOS	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							14	14/24					50	50	1.5		Alive		6	Waves1+2	Yes	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC	3	Allogeneic - Sibling|Induction|Re-induction	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Sibling	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	FALSE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	FALSE	Negative	AML	18.936986301369863	0:LIVING		No	No		No	No	No	No	No	No	Multiracial	-1	Refractory	RUNX1 (p.E454Gfs*149; MAF 51%)	4	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Residual Disease|Post-Chemotherapy	Peripheral Blood		30	0.633333333		Standard Chemotherapy	No	DNMT3A (p.r882H; MAF 45%)|FLT3-ITD|MLL |RUNX1 (p.E454Gfs*149; MAF 51%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2236_BA3011	Acute Myeloid Leukemia	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							1	14/24					32	32			Alive		1	Waves1+2	Yes	ATRA, Arsenic Trioxide	1	Consolidation|Experimental	2	Standard Chemotherapy|Targeted Therapy - Other	2	ATRA, Arsenic Trioxide	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	HISPANIC	M3	Positive	TRUE	FALSE	FALSE	46,XY,t(15;17)(q22;q21)[20]	232	Standard Chemotherapy	FALSE	Negative	AML	69.17260273972603	0:LIVING	70% PML/RARA	No	No		No	No	No	No	No	No	Multiracial				1	Male	UNMATCHED	FALSE	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD33, CD64, CD117, CD123 and  MPO-positive	0	0			Yes	FLT3-ITD (MAF 7%)|MPL (p.E484G, MAF 3%)|WT1 (p.F451C; MAF 51% )
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2248_BA2308	Acute Myeloid Leukemia	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							16	14/24					71	72	5.25		Dead-Disease		4	Waves1+2	Yes	Dasatinib|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine	4	Hypomethylating/Low Dose Cytarabine|Induction|Experimental|Maintenance	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Azacitidine	Hypomethylating/Low Dose Cytarabine	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	FALSE	FALSE	FALSE	45,XY,-7,t(3;3)[20]	-1	Standard Chemotherapy	FALSE	Negative	AML	18.246575342465754	1:DECEASED		Yes	No	Prostate Cancer	No	No	No	No	No	No		-1	Refractory		2	Male	MATCHED	FALSE	AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1	Residual Disease|Post-Chemotherapy	Peripheral Blood	CD34+ CD38, CD13,CD33, CD117, HLA-DR, DIM CD7, PARTIAL CD11C, CD2(SUBSET), CD15(MINOR SUBSET), DIM cCD79a(MINOR SUBSET), AND PARTIAL CD4	0	0.833333333		Standard Chemotherapy	Yes	FLT3-D835
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2270_BA2334	Acute Myeloid Leukemia	AML with t(6;9)(p23;q34); DEK-NUP214	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							14	14/24					30	31	2.125		Dead-Disease		2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Crenolanib|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine, Sorafenib |Quizartinib	6	Salvage|Induction|Experimental	3	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Crenolanib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	FALSE	FALSE	FALSE	47~49,XX,t(6;9)(p23;q24),+8,+13,+15[cp8]/47~49,idem,+del(13)(q12q22)[cp12]	52	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Negative	AML	18.673972602739727	1:DECEASED		No	No		No	No	No	No	No	No		-1	Refractory		2	Female	MATCHED	FALSE	AML with t(6;9)(p23;q34); DEK-NUP214	Post-Chemotherapy|Residual Disease	Peripheral Blood	CD34(partial +), CD13(+), CD14(-), CD15(few +), CD30(-), CD33(+), CD38(variably +), CD45 (moderately +), CD64(variably +), CD4(partial +), CD117(+), CD123(variably +), HLA-DR(+), CD79a(-), CD22(-), intracellular CD3(-), TdT(-), MPO(partial +), other myelo	0	0.666666667		Standard Chemotherapy	Yes	FLT3-D835|FLT3-ITD
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2295_BA2216	Acute Myeloid Leukemia	Acute myelomonocytic leukaemia	Y599_D600insGGVQVTGSSDNEYFYVDFREYEY	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608322	28608323	-	CCACCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGTACC	13:g.28608322_28608323insCCACCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGTACC	ENST00000241453.7:c.1798_1799insGTGGGGTACAGGTGACCGGCTCCTCAGATAATGAGTACTTCTACGTTGATTTCAGAGAATATGAATATG	0.32		63	133			3	14/24					74	77	0.923076923		Dead-Unknown		1	Waves1+2	Yes	Decitabine|Quizartinib|Mitoxantrone	3	Induction|Experimental|Supportive/Palliative Care	3	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	3	Mitoxantrone	Supportive/Palliative Care	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M4	Positive	FALSE	FALSE	FALSE	46,XY[17]	18	Supportive/Palliative Care	FALSE	Negative	AML	41.556164383561644	1:DECEASED	normal	No	No		No	No	No	No	No	No	White	1025	Refractory	RUNX1 (p.R166*; 40.0%)	2	Male	UNMATCHED	FALSE	Acute myelomonocytic leukaemia	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	CD2, dim CD4, partial CD7, partial/dim CD64, CD13, partial CD22, dim CD33, partial CD34, CD117, CD123, HLA-DR, partial cCD79, partial TdT,  partial PAX/5 and partial MPO positive	0	0.133333333		Standard Chemotherapy	Yes	FLT3-ITD
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2295_BA2859	Acute Myeloid Leukemia	Acute myelomonocytic leukaemia	Y599_D600insGGVQVTGSSDNEYFYVDFREYEY	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608322	28608323	-	CCACCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGTACC	13:g.28608322_28608323insCCACCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGTACC	ENST00000241453.7:c.1798_1799insGTGGGGTACAGGTGACCGGCTCCTCAGATAATGAGTACTTCTACGTTGATTTCAGAGAATATGAATATG	0.37		92	157			3	14/24					74	77	0.01010101		Dead-Unknown		1	Waves1+2	Yes	Decitabine|Quizartinib|Mitoxantrone	3	Induction|Experimental|Supportive/Palliative Care	3	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	3	Mitoxantrone	Supportive/Palliative Care	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M4	Positive	FALSE	FALSE	FALSE	46,XY[20]	18	Supportive/Palliative Care	FALSE	Negative	AML	41.556164383561644	1:DECEASED	normal	No	No		No	No	No	No	No	No	White	1025	Refractory	RUNX1 (p.R166*; 47.6%)	2	Male	UNMATCHED	FALSE	Acute myelomonocytic leukaemia	Post-Chemotherapy|Residual Disease	Peripheral Blood	CD2, dim CD4, partial CD7, partial/dim CD64, CD13, partial CD22, dim CD33, partial CD34, CD117, CD123, HLA-DR, partial cCD79, partial TdT,  partial PAX/5 and partial MPO positive	166	0.133333333		Standard Chemotherapy	No	FLT3-D835|FLT3-ITD
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2304_BA2000	Acute Myeloid Leukemia	Acute myeloid leukaemia, NOS	E611_F612insVTNEYFYVDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608297	28608298	-	TGTCACCTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATT	13:g.28608297_28608298insTGTCACCTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATT	ENST00000241453.7:c.1833_1834insGTGACAAATGAGTACTTCTACGTTGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAG	0.30		53	121			14	14/24					24	24	0.666666667		Dead-Disease	mono	3	Waves1+2	Yes	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG (Cladribine, Cytarabine, Filgrastim)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	6	Allogeneic - Sibling|Consolidation|Salvage|Induction|Re-induction	5	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse			Positive	TRUE	FALSE	FALSE	46,XX[20]	-1	Bone Marrow Transplant	FALSE	Negative	AML	20.81095890410959	1:DECEASED	Normal	No	No		No	No	No	No	No	No		-1	Refractory		1	Female	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Leukapheresis	weak CD4, partial  CD7, partial CD11b, CD13, CD33, partial CD34, weak CD64,  CD117, MPO, and HLA-DR	0	0.7		Standard Chemotherapy	Yes	CEBPA (p.Gln41fs; MAF 4%)|FLT3-ITD (p.Glu611_Phe612ins27; MAF 8%)|JAK3 (p.Gln865Glu; MAF 48.9%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2318_BA2022	Acute Myeloid Leukemia	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							1	14/24					33	33	0.923076923		Alive		3	Waves1+2	Yes	ATRA, Arsenic Trioxide	1	Consolidation|Induction	2	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable		M3	Positive	TRUE	FALSE	FALSE		-1	Standard Chemotherapy	FALSE	Negative	AML	18.378082191780823	0:LIVING	This analysis showed evidence of a PML-RARA rearrangement in 177/200 (88.5 percent) interphase cells scored.	No	No		No	No	No	No	No	No		-1	Complete Response		1	Female	UNMATCHED	FALSE	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Peripheral Blood	Large population of CD117pos, CD34neg, HLA-DR neg myeloblasts, representing 78% of leukocytes consistent w/AML.	0	0		Standard Chemotherapy	Yes	FLT3-ITD (p.Leu601_Lys602ins9; MAF 15%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2329_BA2559	Acute Myeloid Leukemia	Acute monoblastic and monocytic leukaemia	X585_X586insDNEYFYVDFREYEYDLKWEFPRENLEFGN	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608300	28608301	-	ATTACCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATC	13:g.28608300_28608301insATTACCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATC	ENST00000241453.7:c.1837+4_1837+5insTGATAATGAGTACTTCTACGTTGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTTTGGTAA	0.34		65	126			5	14/24					42	42			Alive		5	Waves1+2	Yes	HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Fludarabine, Cyclophosphamide, TBI	4	Induction|Re-induction|Double Umbilical Cord Blood Transplant (DUCBT)	3	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Cyclophosphamide, TBI	Double Umbilical Cord Blood Transplant (DUCBT)	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse		M5	Positive	TRUE	FALSE	FALSE	46,XX[20]	-1	Bone Marrow Transplant	FALSE	Negative	AML	28.865753424657534	0:LIVING	Normal	No	No		No	No	No	No	No	No		-1	Refractory		1	Female	MATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	The immature cells were positive for CD13, CD33, and many showed aberrant expression of CD7. The myeloblast portion was positive for CD34, CD117, and HLA-DR.  The immature monocyte portion was negative for CD34 and CD117, and expressed variable CD64 (incl	0	0.133333333		Standard Chemotherapy	Yes	FLT3-ITD (MAF 34.8%)|RUNX1 (p.L29S; MAF 52.7%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2352_BA2557	Acute Myeloid Leukemia	Acute myeloid leukaemia, NOS	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							20	14/24					62	62	0.923076923		Dead-Disease		1	Waves1+2	Yes	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	3	Induction|Re-induction	2	Standard Chemotherapy	1	CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M0/M1	Positive	FALSE	FALSE	TRUE		4	Standard Chemotherapy	FALSE	Negative	AML	2.663013698630137	1:DECEASED	Tetrasomy 8 (67%)	No	No		No	No	No	No	Yes	Yes	White	7	Refractory		1	Female	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	partial CD7, CD13, CD33 (variable), CD34, CD38 (variable), CD117(variable)	0	1.033333333		Standard Chemotherapy	Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2354_BA2018	Acute Myeloid Leukemia	Acute myeloid leukaemia, NOS	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							12	14/24					44	44			Dead-Disease		3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Ponatinib	6	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Re-induction	5	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Ponatinib	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	IntermediateOrAdverse			Positive	TRUE	FALSE	FALSE	46,XX[20]	-1	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Negative	AML	11.243835616438357	1:DECEASED	Normal	No	No		No	No	No	No	No	No		-1	Unknown		2	Female	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Large population of atypical CD34 positive myeloblasts (weak CD4+, weak CD33+), representing approximately 78% of the leukocytes suggestive of acute myeloid leukemia	0	0.766666667		Standard Chemotherapy	No	FLT3-ITD
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2354_BA2405	Acute Myeloid Leukemia	Acute myeloid leukaemia, NOS	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							18	14/24					44	44	0.449275362		Dead-Disease		3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Ponatinib	6	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Re-induction	5	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Ponatinib	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse			Positive	TRUE	FALSE	FALSE	46,XX[20]	-1	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Negative	AML	11.243835616438357	1:DECEASED	Normal	No	No		No	No	No	No	No	No		-1	Unknown	RUNX1 (p.Q262*; 72.4%)	2	Female	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	Large population of atypical CD34 positive myeloblasts (weak CD4+, weak CD33+), representing approximately 78% of the leukocytes suggestive of acute myeloid leukemia	0	0.933333333		Standard Chemotherapy	Yes	FLT3-ITD
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2385_BA2377	Acute Myeloid Leukemia	AML with t(9;11)(p22;q23); MLLT3-MLL	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							23	14/24					35	35	2.448275862	ASXL1 (p.D943Qfs*6; 38.5%)	Alive		2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide, Thymoglobulin	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide, Thymoglobulin	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate			Positive	TRUE	FALSE	FALSE	46,XY,der(4)t(4;9;11)(p14;p22;q23),der(9)del(9)(p13p22)t(4;9;11),der(11)t(4;9;11)[19]/46,XY[1].isht(4;9;11)(5'MLL-,3'MLL+;5'MLL-,3'MLL-;5'MLL+,3'MLL-)[1]	-1	Bone Marrow Transplant	FALSE	Positive	AML	38.00547945205479	0:LIVING	nuc ish(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL sep 3'MLLx1)[189/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198]	No	No		No	No	No	No	No	No		-1	Complete Response		1	Male	MATCHED	FALSE	AML with t(9;11)(p22;q23); MLLT3-MLL	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(-), CD4(+), CD7(-), CD11b(+), CD13(partial +), CD14(-), CD15(+), CD16(-), CD33(+), CD34(-), CD36(partial +), CD45(+), CD56(variably +), CD64(+), CD117(partial +), CD79a(-), HLA-DR(+), MPO(-), Tdt(-)	0	1.1		Standard Chemotherapy	Yes	ASXL1 (D943fs*6; MAF 25%)|FLT3-D835 (BMA)|KMT2A (MLL-AF9 fusion)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2401_BA2067	Acute Myeloid Leukemia	Acute myelomonocytic leukaemia	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							4	14/24					59	59			Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Quizartinib|Busulfan, Cyclophosphamide	5	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	IntermediateOrAdverse	NON-HISPANIC	M4	Positive	TRUE	FALSE	FALSE	47,XX,+13[18]/46,XX[2]	4	Standard Chemotherapy	FALSE	Negative	AML	17.786301369863015	1:DECEASED	trisomy 13	No	No		No	No	No	No	No	No	White	7	Complete Response		1	Female	UNMATCHED	FALSE	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Leukapheresis	Blast immunophenotype: dim CD4, variable CD11b, CD13, CD33, partial CD34, dim CD45, variable CD64, partial CD117, CD123, HLA-DR and MPO positive; Promonocyte immunophenotype: dim CD4, CD11b, CD13, CD33, CD45, bright CD64, CD123, HLA-DR, and dim MPO positi	0	0.166666667		Standard Chemotherapy	Yes	FLT3-ITD
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2403_BA2316	Acute Myeloid Leukemia	Acute monoblastic and monocytic leukaemia	X594_X595insREYEYDLKWEFPRENLEFGA	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608273	28608274	-	CGCCCCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCT	13:g.28608273_28608274insCGCCCCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCT	ENST00000241453.7:c.1837+1_1837+2insGGCGAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTTTGG	0.17		20	100			5	14/24					62	62			Dead-Disease		1	Waves1+2	No		0		0		0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M5	Positive	TRUE	FALSE	FALSE	46,XY[20]		None	FALSE	Negative	AML	0.06575342465753425	1:DECEASED	Normal	No	No		No	No	No	No	No	No	White			RUNX1 (p.X205_splice; 44.3%)	2	Male	MATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD4, CD11b, CD13, CD14, partial CD16, CD33, CD38, partial CD56, CD58, CD64, CD123, and HLA-DR positive	1	0.2			No	DNMT3A (p. R882C; MAF 50%)|DNMT3A (p.R882C; MAF 50%)|FLT3-ITD (MAF 90%)|RUNX1 (Intron 5, 3' splice site mutation; MAF 50%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2403_BA2742	Acute Myeloid Leukemia	Acute monoblastic and monocytic leukaemia	X594_X595insREYEYDLKWEFPRENLEFGA	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608273	28608274	-	CGCCCCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCT	13:g.28608273_28608274insCGCCCCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCT	ENST00000241453.7:c.1837+1_1837+2insGGCGAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTTTGG	0.08		6	70			9	14/24					62	62	15.66666667		Dead-Disease		1	Waves1+2	No		0		0		0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M5	Positive	TRUE	FALSE	FALSE	46,XY[20]		None	FALSE	Negative	AML	0.06575342465753425	1:DECEASED	Normal	No	No		No	No	No	No	No	No	White			RUNX1 (p.X205_splice; 56.7%)	2	Male	MATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Leukapheresis	CD4, CD11b, CD13, CD14, partial CD16, CD33, CD38,      partial CD56, CD58, CD64, CD123, and HLA-DR positive	0	0.366666667			Yes	DNMT3A (p. R882C; MAF 50%)|DNMT3A (p.R882C; MAF 50%)|FLT3-ITD (MAF 90%)|RUNX1 (Intron 5, 3' splice site mutation; MAF 50%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2448_BA2811	Acute Myeloid Leukemia	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	D593_G613dup	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	ACCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insACCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1777_1837+2dup	0.09		14	139			5	14/24					47	47			Alive		1	Waves1+2	Yes	ATRA, Arsenic Trioxide|APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	2	Consolidation|Induction	2	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M3	Positive	TRUE	FALSE	FALSE	46,XX,t(15;17)(q24;q21)[4]/45,idem,-22[15]/46,XX[1]	31	Standard Chemotherapy	FALSE	Negative	AML	72.23013698630137	0:LIVING		No	No		No	No	No	No	No	No	White	26	Complete Response		1	Female	MATCHED	FALSE	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2, CD13, CD33, CD34, CD56, CD58, CD64, CD117, CD123, dim/partial HLA-DR, dim/partial TdT and MPO positive	0	0.166666667		Standard Chemotherapy	Yes	FLT3-ITD (MAF 40%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2457_BA2278	Acute Myeloid Leukemia	Acute monoblastic and monocytic leukaemia	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							7	14/24					47	47	4		Dead-Disease		4	Waves1+2	Yes	HiDAC|Cytarabine|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|MEC, Lenalidomide	5	Consolidation|Induction|CNS|Re-induction|Supportive/Palliative Care	5	Standard Chemotherapy|Supportive/Palliative Care|Intrathecal	3	Hydroxyurea	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse		M5	Positive	TRUE	FALSE	FALSE	46,XY,t(11;19)(q23;p13.1)[20]	9	Supportive/Palliative Care	FALSE	Negative	AML	7.4958904109589035	1:DECEASED		No	No		No	No	No	No	No	No		7	Complete Response		2	Male	MATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD34+ BLAST POPULATION, 40%, EXPRESSING CD117, CD15 (DIM PARTIAL), CD13 (DIM PARTIAL), CD33 (DIM PARTIAL), CD38, CD4 (DIM PARTIAL), CD11C (DIM PARTIAL), CD64 (DIM PARTIAL), MPO (BRIGHT), AND ABERRANT CD7 (MINOR SUBSET DIM), WITH POSSIBLE CD19	0	0.233333333		Standard Chemotherapy	Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2457_BA3013	Acute Myeloid Leukemia	Acute monoblastic and monocytic leukaemia	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							8	14/24					47	47	0.075268817		Dead-Disease		4	Waves1+2	Yes	HiDAC|Cytarabine|SWOG S1203 (7+3 +/- Vorinostat)|Hydroxyurea|MEC, Lenalidomide	5	Consolidation|Induction|CNS|Re-induction|Supportive/Palliative Care	5	Standard Chemotherapy|Supportive/Palliative Care|Intrathecal	3	Hydroxyurea	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse		M5	Positive	TRUE	FALSE	FALSE	46,XY,t(11;19)(q23;p13.1)[20]	9	Supportive/Palliative Care	FALSE	Negative	AML	7.4958904109589035	1:DECEASED		No	No		No	No	No	No	No	No		7	Complete Response		2	Male	MATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD34+ BLAST POPULATION, 40%, EXPRESSING CD117, CD15 (DIM PARTIAL), CD13 (DIM PARTIAL), CD33 (DIM PARTIAL), CD38, CD4 (DIM PARTIAL), CD11C (DIM PARTIAL), CD64 (DIM PARTIAL), MPO (BRIGHT), AND ABERRANT CD7 (MINOR SUBSET DIM), WITH POSSIBLE CD19	0	0.266666667		Standard Chemotherapy	Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2459_BA2071	Myelodysplastic Syndromes	Myelodysplastic syndrome, unclassifiable	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							14	14/24					40	39	0.333333333		Alive		2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|Clofarabine, Cytarabine	4	Hypomethylating/Low Dose Cytarabine|Salvage|Consolidation|Induction	4	Standard Chemotherapy	1	HiDAC	Consolidation		Myelodysplastic Syndromes	NonAML			Positive	FALSE	FALSE	FALSE	46,XX[20]	5	Standard Chemotherapy	FALSE	Negative	MDS	12.887671232876713	0:LIVING	nuc ish(D4Z1,D10Z1)x2[200],(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[199],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[	No	No		Yes	Yes	No	No	No	No		5			1	Female	MATCHED	TRUE	Myelodysplastic syndrome, unclassifiable		Bone Marrow Aspirate		0	0.766666667		Standard Chemotherapy	No	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2467_BA2047	Acute Myeloid Leukemia	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							3	14/24					69	69	0.851851852		Alive		1	Waves1+2	Yes	ATRA, Idarubicin|ATRA, Arsenic Trioxide	2	Consolidation|Induction	2	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M3	Positive	TRUE	FALSE	FALSE	46,XX,t(15;17)(q24;q21)[20]	-1	Standard Chemotherapy	FALSE	Negative	AML	50.69589041095891	0:LIVING	PML/RARA fusion	No	No		No	No	No	No	No	No	White	-1	Complete Response		1	Female	MATCHED	FALSE	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Peripheral Blood	dim CD2, CD13, dim CD15, CD33, CD38, CD58, CD64, CD117, CD123, variable HLA-DR and bright MPO positive	1	0.066666667		Standard Chemotherapy	Yes	FLT3-ITD (MAF 42%)|NOTCH1 (p.P2438L ; MAF 47%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2487_BA2374	Acute Myeloid Leukemia	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							12	14/24					36	36			Alive		1	Waves1+2	Yes	ATRA, Arsenic Trioxide|APML4 Protocol (ATRA, Arsenic Trioxide, Idarubicin)	2	Induction|Experimental	2	Standard Chemotherapy|Targeted Therapy - Other	2	ATRA, Arsenic Trioxide	Experimental	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M3	Positive	TRUE	FALSE	FALSE	46,XX,der(15)t(15;17)(q22;q21),der(17)t(15;17)del(17)(q21)[15]/46,XX[1]	-1	Targeted Therapy - Other	FALSE	Negative	AML	71.67123287671232	0:LIVING	95% of cells had a variant abnormal signal pattern with PML/RARA fusion.  PML (15q22) (SO) / RARA (17q21) (SG) t(15;17)	No	No		No	No	No	No	No	No	Black	27	Complete Response		1	Female	MATCHED	FALSE	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Immunophenotype: CD13, CD33, partial CD34, CD64, CD117, CD123 and MPO positive	0	0.466666667		Standard Chemotherapy	Yes	FLT3-ITD (MAF 50%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2549_BA2442	Acute Myeloid Leukemia	Acute myeloid leukaemia, NOS	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							2	14/24					66	66	0.428571429		Dead-Treatment		3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate			Positive	TRUE	FALSE	FALSE	47,XX,+8[18]	6	Standard Chemotherapy	FALSE	Negative	AML	0.4273972602739726	1:DECEASED	Normal	No	No		No	No	No	No	No	No		6	UNKNOWN		1	Female	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood	Large population of CD117 pos myeloblasts, representing 80% of leukocytes, consistent w/ AML.	0	0.033333333		Standard Chemotherapy	Yes	FLT3-ITD (p.Tyr591_Val592ins16; MAF 10%)|WT1 (p.Val379fs; MAF 13%)|ZRSR2 (p.Arg415Trp; MAF 48.9%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2551_BA2265	Acute Myeloid Leukemia	Acute myelomonocytic leukaemia	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT	0.06		7	101			3	14/24					69	69	0.851851852		Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea|AC220 (Ambit)	4	Consolidation|Induction|Experimental|Re-induction	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Hydroxyurea	Re-induction	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M4	Positive	FALSE	TRUE	FALSE	47,XY,+8[cp20]	3	Standard Chemotherapy	FALSE	Negative	AML	13.775342465753425	1:DECEASED	trisomy 8	No	No		No	No	No	No	No	No	White	4	Complete Response		3	Male	UNMATCHED	FALSE	Acute myelomonocytic leukaemia	Relapse|Post-Chemotherapy	Peripheral Blood	CD7, CD13, CD33, CD34, CD117, CD123, HLA-DR, and MPO-positive	163	0.1		Standard Chemotherapy	No	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2551_BA2460	Acute Myeloid Leukemia	Acute myelomonocytic leukaemia	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT	0.14		14	85			3	14/24					69	70			Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea|AC220 (Ambit)	4	Consolidation|Induction|Experimental|Re-induction	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Hydroxyurea	Re-induction	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M4	Positive	FALSE	FALSE	FALSE	47,XY,+8[cp20]	3	Standard Chemotherapy	FALSE	Negative	AML	13.775342465753425	1:DECEASED	trisomy 8	No	No		No	No	No	No	No	No	White	4	Complete Response		3	Male	UNMATCHED	FALSE	Acute myelomonocytic leukaemia	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	CD7, CD13, CD33, CD34, CD117, CD123 and HLA-DR positive	333	0.066666667		Standard Chemotherapy	No	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2551_BA2643	Acute Myeloid Leukemia	Acute myelomonocytic leukaemia	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT	0.08		9	100			3	14/24					69	69	0.960784314		Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea|AC220 (Ambit)	4	Consolidation|Induction|Experimental|Re-induction	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Hydroxyurea	Re-induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M4	Positive	TRUE	FALSE	FALSE	47,XY,+8[cp9]/46,XY[11]	3	Standard Chemotherapy	FALSE	Negative	AML	13.775342465753425	1:DECEASED	Signal copy for CEP 8 and ETO	No	No		No	No	No	No	No	No	White	4	Complete Response		3	Male	UNMATCHED	FALSE	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Leukapheresis	dim CD4, partial CD7, CD13, CD33, CD34, dim CD45, dim CD56, variable CD64, CD117, CD123, HLA-DR and MPO positive	0	0.1		Standard Chemotherapy	Yes	FLT3-ITD
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2558_BA2962	Acute Myeloid Leukemia	Acute monoblastic and monocytic leukaemia	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							5	14/24					75	75			Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Cytarabine|Fludarabine, TBI|Decitabine	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, TBI	Allogeneic - Mismatched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	IntermediateOrAdverse	NON-HISPANIC	M5	Positive	TRUE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	FALSE	Negative	AML	10.75068493150685	1:DECEASED	Normal	No	No		No	No	No	No	No	No	White	6	Refractory		1	Male	MATCHED	FALSE	Acute monoblastic and monocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	dim partial CD11b, dim variable CD13, CD33, CD34, CD38, CD58, partial CD64, CD117, CD123, HLA-DR, partial TdT, dim MPO positive	0	0.133333333		Standard Chemotherapy	Yes	DNMT3A (intron 7 splice site (at invariant AG splice donor); MAF 50% )|DNMT3A (p.P777L; MAF 50%)|FLT3-ITD (MAF 40%)|IDH2 (p.R140Q; MAF 45%)|MLL (PTD; no MAF available)|WT1 (Intron 1 splice site (at invariant AG splice donor); MAF 90% )
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2589_BA3064	Acute Myeloid Leukemia	Acute myeloid leukaemia, NOS	X595_X596insEYEYDLKWEFPRENLEFGR	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608270	28608271	-	CCTCCCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTC	13:g.28608270_28608271insCCTCCCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTC	ENST00000241453.7:c.1837+1_1837+2insGAGGGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTTTGG	0.08		8	90			2	14/24					38	40	4		Dead-Disease		3	Waves1+2	Yes	Azacitidine, Sorafenib|Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|Gilteritinib (ASP2215)|Sorafenib|Cladribine, Cytarabine, Idarubicin	6	Allogeneic - Sibling|Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Experimental|Intensification|Re-induction	7	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	Sorafenib	Experimental	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	FALSE	TRUE	FALSE		38	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Negative	AML	23.57260273972603	1:DECEASED	Normal	No	No		No	No	No	No	No	No		-1	Refractory		1	Male	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Relapse|Post-Chemotherapy|Post-Transplant	Peripheral Blood	CD4,  CD11b, dim CD13, variable CD15, CD33, partial CD34  (approximately 25%), variable CD64 (dim to bright), CD117,  HLA-DR, and myeloperoxidase	0	0.066666667		Standard Chemotherapy	Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2596_BA3128	Acute Myeloid Leukemia	Acute myeloid leukaemia, NOS	X597_X598insEYDLKWEFPRENLEFGKNGMCRL	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608264	28608265	-	GAGCCGGCACATTCCATTCTTACCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTC	13:g.28608264_28608265insGAGCCGGCACATTCCATTCTTACCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTC	ENST00000241453.7:c.1837+18_1837+19insGGCTCGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTTTGGTAAGAATGGAATGTGCC	0.23		39	131			4	14/24					33	33			Alive		8	Waves3+4	Yes	5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|CECA (Cyclophosphamide, Etoposide, Carboplatin, Cytosine)|Cytarabine, OXi4503	4	Salvage|Induction|Re-induction	3	Standard Chemotherapy	1	Cytarabine, OXi4503	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC		Positive	FALSE	FALSE	FALSE	Normal	-1	Standard Chemotherapy	FALSE	Negative	AML	8.383561643835616	0:LIVING	Normal	No	No		No	No	No	No	No	No	White	-1	Refractory		1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Peripheral Blood		0	0.166666667		Standard Chemotherapy	Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2603_BA3264	Acute Myeloid Leukemia	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							3	14/24					41	41	1.127659574		Alive		1	Waves3+4	Yes	ATRA, Arsenic Trioxide, Idarubicin|ATRA, Arsenic Trioxide	2	Consolidation|Induction	2	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M3	Positive	TRUE	FALSE	FALSE	46,XY,t(15;17)(q24;q21)[20]	200	Standard Chemotherapy	FALSE	Negative	AML	41.19452054794521	0:LIVING	PML/RARA (92% of  cells had the dual fusion signal pattern consistent with PML/RARA fusion and t(15;17).)	No	No		No	No	No	No	No	No	White	26	Complete Response		1	Male	UNMATCHED	FALSE	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	partial CD11b, CD13, CD33, CD34, CD38, CD58, variable  CD64, CD117, CD123, partial HLA-DR and bright MPO	0	0.066666667		Standard Chemotherapy	Yes	FLT3-ITD (Mutant Allele Ratio:  0.85)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2623_BA3351	Acute Myeloid Leukemia	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							4	14/24					72	72	0.03092784		Alive		1	Waves3+4	Yes	ATRA, Arsenic Trioxide	1	Induction	1	Standard Chemotherapy	1	ATRA, Arsenic Trioxide	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M3	Positive	TRUE	FALSE	FALSE	46,XX,t(15;17)(q22;q21)[20]	-1	Standard Chemotherapy	FALSE	Negative	AML	30.476712328767125	0:LIVING	positive for PML/RARA fusion	No	No		No	No	No	No	No	No	White	-1	Complete Response		1	Female	MATCHED	FALSE	Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD7, CD11b, CD13, CD15, CD16, CD33, CD38, CD56, CD64, CD117, CD123, and MPO positive	0	0.2		Standard Chemotherapy	Yes	FLT3-ITD (allelic ratio 0.03; VAF 3.09%)|NRAS (p.A146T; VAF 19%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2624_BA3217	Acute Myeloid Leukemia	Acute myeloid leukaemia, NOS	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							7	14/24					60	60	0.960784314		Alive		5	Waves3+4	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)	2	Allogeneic - Sibling|Induction	2	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse			Positive	TRUE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	FALSE	Negative	AML	9.632876712328768	0:LIVING	Normal	No	No		No	No	No	No	No	No	White	-1	Complete Response		1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Positive (CD38, CD33, CD34, MPO, HLA-DR) | Negative (CD19, CD22, Cyt CD79a, Cyt CD3, CD7, CD56, CD13, CD14, CD15, CD117, TdT) | Dim (CD11b, CD45, CD64)	0	0.266666667		Standard Chemotherapy	Yes	FLT3-ITD (ITD, c.1769_1770ins42; p.Y589_F590insl4 (MAF 38%))|IDH2 (c.419G>A; p.R140Q (MAF 48%))|STAG2 (c.3034delC; p.R1012fs (MAF 92%))
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2632_BA3216	Acute Myeloid Leukemia	Acute myeloid leukaemia, NOS	L601_K602insSSSDNEYFYVDFREYEYDL	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608308	28608309	-	TGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGC	13:g.28608308_28608309insTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGC	ENST00000241453.7:c.1748_1804dup	0.12		19	144			6	14/24					73	73	0.428571429		Dead-Disease	mono	5	Waves3+4	No		0		0		0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate			Positive	TRUE	FALSE	FALSE			None	FALSE	Negative	AML	0.526027397260274	1:DECEASED		No	No		No	No	No	No	No	No	White				1	Female	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood		0	0.233333333			Yes	FLT3-ITD (suspicious for D835 as well)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2690_BA3419	Acute Myeloid Leukemia	Acute myeloid leukaemia, NOS	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							5	14/24					87	87	0.639344262		Dead-Disease		5	Waves3+4	Yes	Entospletinib	1	Supportive/Palliative Care	1	Standard Chemotherapy	1	Entospletinib	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	HISPANIC		Positive	TRUE	FALSE	FALSE		-1	Standard Chemotherapy	FALSE	Negative	AML	1.3150684931506849	1:DECEASED		No	No		No	No	No	No	No	No					1	Male	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	positive for dim CD7, CD11b, CD13, CD33, CD34, CD38, CD45, dim CD64, CD117, HLA-DR, and MPO	0	0.233333333			Yes	FLT3-ITD
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2762_BA3409	Acute Myeloid Leukemia	Acute myeloid leukaemia, NOS	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							7	14/24					64	65	1		Dead-Disease		2	Waves3+4	Yes	J1219, quizartinib|7+3 (Cytarabine, Idarubicin)|Crenolanib|Azacitidine|Sorafenib|Valproic Acid|E1906, topotecan, carboplatin	7	Induction|Experimental|Re-induction|Maintenance	4	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	Crenolanib	Experimental	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M4	Positive	FALSE	FALSE	FALSE	46,XX[20]	21	Targeted Therapy - Kinase Inhibitor(s)	FALSE	Negative	AML	8.810958904109588	1:DECEASED		No	No		No	No	No	No	No	No	White	-1	Refractory		1	Female	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Peripheral Blood		0	0.333333333		Standard Chemotherapy	Yes	FLT3-ITD
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2766_BA3380	Acute Myeloid Leukemia	Acute myeloid leukaemia, NOS	S618_G619insSDNEYFYVDFREYEYDLKWEFPRENLEFGKNGMCQMFLQHFFSIGKSLKCTYSPFVFAGKVLGS	OncoKB: Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608310	28608311	-	AGTACCTTCCCTGCAAAGACAAATGGTGAGTACGTGCATTTTAAAGATTTTCCAATGGAAAAGAAATGCTGCAGAAACATTTGGCACATTCCATTCTTACCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCG	13:g.28608310_28608311insAGTACCTTCCCTGCAAAGACAAATGGTGAGTACGTGCATTTTAAAGATTTTCCAATGGAAAAGAAATGCTGCAGAAACATTTGGCACATTCCATTCTTACCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCG	ENST00000241453.7:c.1746_1847dup	0.38		123	200			2	14/24					21	23	5.666666667		Alive		7	Waves3+4	No		0		0		0	NONE	NONE	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	HISPANIC		Positive	FALSE	FALSE	FALSE	Normal		None	FALSE	Negative	AML	17.0958904109589	0:LIVING		No	No		No	No	No	No	No	No					1	Male	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Post-Chemotherapy|Residual Disease	Peripheral Blood		0	0.033333333			Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2784_BA3173	Acute Myeloid Leukemia	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							5	14/24					45	46	0.075268817		Dead-Unknown		6	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	3	Consolidation|Salvage|Induction	3	Standard Chemotherapy	1	CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	FALSE	FALSE	FALSE	46,XX,t(8;21)(q22;q22)[15]/46-47,sl,+6,add(13)(p11.2),add(15)(q26),-16,+19,+22[cp5]	4	Standard Chemotherapy	FALSE	Positive	AML	15.024657534246575	1:DECEASED		No	No		No	No	No	No	No	No	Black	7	Complete Response		1	Female	UNMATCHED	FALSE	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Residual Disease	Peripheral Blood		0	0.133333333		Standard Chemotherapy	Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2796_BA3406	Acute Myeloid Leukemia	Acute myeloid leukaemia, NOS	E611_F612insLDFREYEYDLKWEFPRENLE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608279	28608280	-	TAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	13:g.28608279_28608280insTAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATC	ENST00000241453.7:c.1835_1836insAGATTTCAGAGAATATGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTT							6	14/24					33	33	0.492537313		Alive		3	Waves3+4	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate			Positive	TRUE	FALSE	FALSE	46, XY[20]	6	Standard Chemotherapy	FALSE	Negative	AML	0.9863013698630136	0:LIVING	Normal	No	No		No	No	No	No	No	No		6	UNKNOWN		1	Male	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood		0	0.233333333		Standard Chemotherapy	Yes	BCOR (p.G1n1626; MAF 62.2%)|FLT3-ITD (p.Glu598_Tyr599ins9)|WT1 (p.Arg370fs; MAF 27.7%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2815_BA3251	Acute Myeloid Leukemia	Acute myeloid leukaemia, NOS	R596_I618dup	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608271	28608272	-	ATTCCATTCTTACCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCT	13:g.28608271_28608272insATTCCATTCTTACCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCT	ENST00000241453.7:c.1785_1837+13dup	0.03		5	149			6	14/24					75	75	0.5625		Dead-Disease		5	Waves3+4	Yes	Venetoclax (ABT-199), Azacitidine	1	Induction	1	Standard Chemotherapy	1	Venetoclax (ABT-199), Azacitidine	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse			Positive	TRUE	FALSE	FALSE	46,XX[20]	4	Standard Chemotherapy	FALSE	Negative	AML	0.4602739726027397	1:DECEASED	Normal	No	No		No	No	No	No	No	No	White	4	Unknown		1	Female	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Positive (CD38, CD13, CD33, CD117, MPO, HLA-DR) | Negative (CD19, CD22, Cyt CD79a, Cyt CD3, CD7, CD56, CD11b, CD14, CD15, CD34, CD64, TdT, Glyc A) | DIM (CD45, CD71)	0	0.233333333		Standard Chemotherapy	Yes	FLT3-ITD (c.1829_1830ins51; p.N609_L610ins17; MAF 19%)|IDH2 (c.419G>A; p.R140Q; MAF 48%)|RUNX1 (c.1041G>A; p.M347I; MAF 50%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2007_BA2918	Acute Myeloid Leukemia	AML with mutated NPM1	I836del	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Del	DEL		NA	NA	NA	13	28592635	28592637	ATG	-	13:g.28592635_28592637del	ENST00000241453.7:c.2508_2510del	0.18		23	104			21	20/24					53	53	0		Dead-Disease		1	Waves1+2	Yes	Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)	5	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant	2	Fludarabine, Melphalan	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M1	Negative	TRUE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	FALSE	Positive	AML	24.328767123287673	1:DECEASED	Normal	No	No		No	No	No	No	No	No	White	23	Complete Response		1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Leukapheresis	partial CD7, CD13, CD33, CD117, CD123, dim HLA-DR, and MPO positive	0	1.2		Standard Chemotherapy	Yes	FLT3 (FLT3 I836 deletion)|NPM1 (An insertion mutation is present in exon 12 (near the C-terminus) of NPM
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2028_BA2144	Acute Myeloid Leukemia	AML with myelodysplasia-related changes	A680V	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: medium, score: 5.843439386046834;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.951;AlphaMissense: pathogenicity: pathogenic, score: 0.8871	Missense_Mutation	SNP		NA	NA	NA	13	28602329	28602329	G	A	13:g.28602329G>A	ENST00000241453.7:c.2039C>T	0.29		16	39			31	16/24				0.00023	56	56	0	ASXL1 (p.G645Vfs*58; 14.3%)	Alive		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|ME (Etoposide, Mitoxantrone)|Busulfan, Cyclophosphamide	4	Salvage|Consolidation|Induction|Allogeneic - Matched Unrelated Donor	4	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M2	Negative	FALSE	FALSE	TRUE	46,XX[20]	-1	Bone Marrow Transplant	FALSE	Negative	AML	56.9095890410959	0:LIVING	Normal	No	No		No	No	Yes	Yes	No	No	White	-1	Refractory	RUNX1 (p.R201*; 45.8%)	1	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD13, CD34, CD38, CD117, and dim HLA-DR +.	0	1.6		Standard Chemotherapy	Yes	ASXL1 (p.T601A; MAF 45%)|BCOR (p.Y1350fs*1; MAF 43%)|DNMT3A (p.R882H; MAF 46%)|FLT3 (p.A680V; MAF 37%)|IDH2 (p.R140Q; MAF 43%)|NRAS (p.Q61K; MAF 9%)|PRDM1 (p.I117M; MAF 49%)|RUNX1 (p.N434fs*166; MAF 37%)|RUNX1 (p.R201*; MAF 45%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2066_BA2066	Acute Myeloid Leukemia	AML with myelodysplasia-related changes	A680V	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: medium, score: 5.843439386046834;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.951;AlphaMissense: pathogenicity: pathogenic, score: 0.8871	Missense_Mutation	SNP		NA	NA	NA	13	28602329	28602329	G	A	13:g.28602329G>A	ENST00000241453.7:c.2039C>T	0.21		13	49			4	16/24				0.00023	62	62	0	ASXL1 (p.R693*; 19.8%)	Dead-Other		1	Waves1+2	Yes	3+7 (Cytarabine, Daunorubicin)|MiDAC|Hydroxyurea|Fludarabine, Melphalan, TBI, ATG	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Child	4	Standard Chemotherapy|Bone Marrow Transplant|Other	3	Fludarabine, Melphalan, TBI, ATG	Allogeneic - Child	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M5	Negative	TRUE	FALSE	FALSE	46,XX,t(1;11)(p36.1;q23),add(9)(p22)[13]/46,sl,del(2)(p21p23),del(20)(q11.2-13.1)[4]/46,sl,add(12)(p11.2)[2]	-1	Bone Marrow Transplant	FALSE	Negative	AML	10.421917808219177	1:DECEASED	MLL: 85%  The t(1;11) with these breakpoints in not common, but has been associated with monoblastic leukemia	No	No		No	No	No	No	No	No	White	7	Complete Response		1	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD4, partial CD11b, CD15, CD33, CD38, moderate CD45, partial CD56, CD64, CD123, partial CD117, and HLA-DR	0	0.233333333		Standard Chemotherapy	Yes	ASXL1 (p.R693*; MAF 19%)|BCOR (p.S209L (possibly a benign germline polymorphism); MAF 48%)|FLT3 (p.A680V; MAF 17%)|FLT3 (p.I836delI (in-frame deletion of one amino acid in TK domain); MAF 11%)|NRAS (p.G12S; MAF 19%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2066_BA2066	Acute Myeloid Leukemia	AML with myelodysplasia-related changes	I836del	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Del	DEL		NA	NA	NA	13	28592635	28592637	ATG	-	13:g.28592635_28592637del	ENST00000241453.7:c.2508_2510del	0.09		9	94			4	20/24					62	62	0	ASXL1 (p.R693*; 19.8%)	Dead-Other		1	Waves1+2	Yes	3+7 (Cytarabine, Daunorubicin)|MiDAC|Hydroxyurea|Fludarabine, Melphalan, TBI, ATG	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Child	4	Standard Chemotherapy|Bone Marrow Transplant|Other	3	Fludarabine, Melphalan, TBI, ATG	Allogeneic - Child	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC	M5	Negative	TRUE	FALSE	FALSE	46,XX,t(1;11)(p36.1;q23),add(9)(p22)[13]/46,sl,del(2)(p21p23),del(20)(q11.2-13.1)[4]/46,sl,add(12)(p11.2)[2]	-1	Bone Marrow Transplant	FALSE	Negative	AML	10.421917808219177	1:DECEASED	MLL: 85%  The t(1;11) with these breakpoints in not common, but has been associated with monoblastic leukemia	No	No		No	No	No	No	No	No	White	7	Complete Response		1	Female	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD4, partial CD11b, CD15, CD33, CD38, moderate CD45, partial CD56, CD64, CD123, partial CD117, and HLA-DR	0	0.233333333		Standard Chemotherapy	Yes	ASXL1 (p.R693*; MAF 19%)|BCOR (p.S209L (possibly a benign germline polymorphism); MAF 48%)|FLT3 (p.A680V; MAF 17%)|FLT3 (p.I836delI (in-frame deletion of one amino acid in TK domain); MAF 11%)|NRAS (p.G12S; MAF 19%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2134_BA2524	Acute Myeloid Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Y572C	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: medium, score: 5.851119593087318;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.975;AlphaMissense: pathogenicity: ambiguous, score: 0.4718	Missense_Mutation	SNP		NA	NA	NA	13	28608341	28608341	T	C	13:g.28608341T>C	ENST00000241453.7:c.1715A>G	0.11		6	49			13	14/24					51	51	0		Alive		4	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Stanford Protocol 9022 (BU/CY)	4	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Stanford Protocol 9022 (BU/CY)	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable		M4eo	Negative	TRUE	FALSE	FALSE	46,XX,inv(16)(p13q22)[20]	-1	Bone Marrow Transplant	FALSE	Negative	AML	27.58356164383562	0:LIVING		No	No		No	No	No	No	No	No		7	Complete Response		1	Female	MATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD34+ EXPRESSING CD38, CD13, CD33, PARTIAL DIM CD2, PARTIAL CD64; DIM PARTIAL CD11C, PARTIAL DIM CD4, COEXPRESSION OF CD117 AND CD15, HLA-DR, MPO, AND PARTIAL DIM TDT	0	0.7		Standard Chemotherapy	Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2169_BA2086	Acute Myeloid Leukemia	AML with mutated NPM1	N676T	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: medium, score: 5.851706792215288;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.959;AlphaMissense: pathogenicity: pathogenic, score: 0.7399	Missense_Mutation	SNP		NA	NA	NA	13	28602341	28602341	T	G	13:g.28602341T>G	ENST00000241453.7:c.2027A>C	0.08		7	79			17	16/24					69	69	0		Dead-Disease		4	Waves1+2	Yes	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine, Midostaurin|FLAG-IDA, Gemtuzumab|MEC, Lenalidomide	4	Salvage|Induction|Re-induction	3	Standard Chemotherapy	1	MEC, Lenalidomide	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Negative	FALSE	FALSE	FALSE	46,XY[22]	5	Standard Chemotherapy	FALSE	Positive	AML	9.994520547945205	1:DECEASED		No	No		No	No	No	No	No	No		79	Refractory		2	Male	MATCHED	FALSE	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Peripheral Blood		0	0.833333333		Standard Chemotherapy	No	FLT3-ITD|IDH1
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2169_BA2086	Acute Myeloid Leukemia	AML with mutated NPM1	S451F	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: low, score: 4.404621318037968;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: benign, score: 0.155;AlphaMissense: pathogenicity: benign, score: 0.1185	Missense_Mutation	SNP		NA	NA	NA	13	28610138	28610138	G	A	13:g.28610138G>A	ENST00000241453.7:c.1352C>T	0.11		17	137			17	11/24					69	69	0		Dead-Disease		4	Waves1+2	Yes	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine, Midostaurin|FLAG-IDA, Gemtuzumab|MEC, Lenalidomide	4	Salvage|Induction|Re-induction	3	Standard Chemotherapy	1	MEC, Lenalidomide	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Negative	FALSE	FALSE	FALSE	46,XY[22]	5	Standard Chemotherapy	FALSE	Positive	AML	9.994520547945205	1:DECEASED		No	No		No	No	No	No	No	No		79	Refractory		2	Male	MATCHED	FALSE	AML with mutated NPM1	Residual Disease|Post-Chemotherapy	Peripheral Blood		0	0.833333333		Standard Chemotherapy	No	FLT3-ITD|IDH1
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2169_BA2756	Acute Myeloid Leukemia	AML with mutated NPM1	N676T	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: medium, score: 5.851706792215288;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.959;AlphaMissense: pathogenicity: pathogenic, score: 0.7399	Missense_Mutation	SNP		NA	NA	NA	13	28602341	28602341	T	G	13:g.28602341T>G	ENST00000241453.7:c.2027A>C	0.11		7	54			11	16/24					69	69			Dead-Disease		4	Waves1+2	Yes	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine, Midostaurin|FLAG-IDA, Gemtuzumab|MEC, Lenalidomide	4	Salvage|Induction|Re-induction	3	Standard Chemotherapy	1	MEC, Lenalidomide	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	FALSE	FALSE	FALSE	46,XY[22]	5	Standard Chemotherapy	FALSE	Negative	AML	9.994520547945205	1:DECEASED		No	No		No	No	No	No	No	No		79	Refractory		2	Male	MATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate		0	0.6		Standard Chemotherapy	Yes	FLT3-ITD|IDH1
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2169_BA2756	Acute Myeloid Leukemia	AML with mutated NPM1	S451F	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: low, score: 4.404621318037968;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: benign, score: 0.155;AlphaMissense: pathogenicity: benign, score: 0.1185	Missense_Mutation	SNP		NA	NA	NA	13	28610138	28610138	G	A	13:g.28610138G>A	ENST00000241453.7:c.1352C>T	0.13		17	112			11	11/24					69	69			Dead-Disease		4	Waves1+2	Yes	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine, Midostaurin|FLAG-IDA, Gemtuzumab|MEC, Lenalidomide	4	Salvage|Induction|Re-induction	3	Standard Chemotherapy	1	MEC, Lenalidomide	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial			Positive	FALSE	FALSE	FALSE	46,XY[22]	5	Standard Chemotherapy	FALSE	Negative	AML	9.994520547945205	1:DECEASED		No	No		No	No	No	No	No	No		79	Refractory		2	Male	MATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate		0	0.6		Standard Chemotherapy	Yes	FLT3-ITD|IDH1
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2172_BA2483	Acute Myeloid Leukemia	AML with myelodysplasia-related changes	F594I	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: medium, score: 5.849353846696582;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.932;AlphaMissense: pathogenicity: pathogenic, score: 0.6723	Missense_Mutation	SNP		NA	NA	NA	13	28608276	28608276	A	T	13:g.28608276A>T	ENST00000241453.7:c.1780T>A	0.35		52	95			22	14/24					63	64	0		Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Cytarabine|Azacitidine|Sorafenib|Decitabine|Hydroxyurea	6	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Supportive/Palliative Care	5	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Other	3	Hydroxyurea	Supportive/Palliative Care	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC		Negative	FALSE	FALSE	FALSE	48,XX,+8,+21[16]/46,XX[4]	29	Supportive/Palliative Care	FALSE	Negative	AML	11.441095890410958	1:DECEASED	RUNX1/RUNX1T1/CEP8: 81% of cells had three signals for all probes, consistent with +8 and +21, as seen on metaphase analysis.  MLL: 68% of cells had a split signal pattern consistent with MLL (11q23) rearrangement. Disruption of MLL was not apparent on ba	Yes	No	Cervical Cancer	No	No	No	No	No	No	White	-1	Complete Response		2	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Residual Disease	Peripheral Blood	CD4, partial CD11b, partial CD13, CD33, CD34, CD38,  partial CD56, CD64, partial CD117, CD123, and dim HLA-DR positive | CD4, partial CD11b, partial CD13, CD33, CD34, CD38, partial CD56, CD64, partial CD117, CD123, and dim HLA-DR positive	44	1.233333333		Standard Chemotherapy	Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2172_BA3002	Acute Myeloid Leukemia	AML with myelodysplasia-related changes	F594I	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: medium, score: 5.849353846696582;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.932;AlphaMissense: pathogenicity: pathogenic, score: 0.6723	Missense_Mutation	SNP		NA	NA	NA	13	28608276	28608276	A	T	13:g.28608276A>T	ENST00000241453.7:c.1780T>A	0.08		10	108			31	14/24					63	64	0		Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|Cytarabine|Azacitidine|Sorafenib|Decitabine|Hydroxyurea	6	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Supportive/Palliative Care	5	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Other	3	Hydroxyurea	Supportive/Palliative Care	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC		Negative	FALSE	FALSE	FALSE	48,XX,+8,+21[16]/46,XX[4]	29	Supportive/Palliative Care	FALSE	Negative	AML	11.441095890410958	1:DECEASED	RUNX1/RUNX1T1/CEP8: 81% of cells had three signals for all probes, consistent with +8 and +21 MLL: 68% of cells had a split signal pattern consistent with MLL (11q23)	Yes	No	Cervical Cancer	No	No	No	No	No	No	White	-1	Complete Response		2	Female	MATCHED	FALSE	AML with myelodysplasia-related changes	Residual Disease	Peripheral Blood	CD4, partial CD11b, partial CD13, CD33, CD34, CD38, partial CD56, CD64, partial CD117, CD123, and dim HLA-DR positive	58	1.866666667		Standard Chemotherapy	No	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2197_BA2301	Acute Myeloid Leukemia	AML with mutated NPM1	S451F	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: low, score: 4.404621318037968;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: benign, score: 0.155;AlphaMissense: pathogenicity: benign, score: 0.1185	Missense_Mutation	SNP		NA	NA	NA	13	28610138	28610138	G	A	13:g.28610138G>A	ENST00000241453.7:c.1352C>T	0.28		39	101			10	11/24					42	42	0		Alive		5	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable			Negative	TRUE	FALSE	FALSE	46,XX[19]	-1	Standard Chemotherapy	FALSE	Positive	AML	22.126027397260273	0:LIVING	Normal	No	No		No	No	No	No	No	No	White	-1	Complete Response		1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Positive (A large blastic population is noted, positive for CD45 and CD64. A small subset of blasts also express CD13 and CD14. The blasts are negative for CD10, CD16, CD19, CD34 and CD117.)	0	0.466666667		Standard Chemotherapy	Yes	NPM1 (c.859_860insTCTG; p.W288fs)|WT1 (c.933_934ins10; p.R312fs; c.938_939insCGGTC; p.A314fs)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2219_BA3089	Acute Myeloid Leukemia	AML with mutated NPM1	V592D	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: low, score: 4.663439094112067;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: benign, score: 0.007;AlphaMissense: pathogenicity: pathogenic, score: 0.6658	Missense_Mutation	SNP		NA	NA	NA	13	28608281	28608281	A	T	13:g.28608281A>T	ENST00000241453.7:c.1775T>A	0.37		45	77			6	14/24					67	68	0		Dead-Other		1	Waves3+4	Yes	AG-120|Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC	5	Consolidation|Salvage|Induction|Experimental|Allogeneic - Mismatched Unrelated Donor	5	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	3	Fludarabine, Melphalan	Allogeneic - Mismatched Unrelated Donor	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M4	Negative	FALSE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	FALSE	Positive	AML	28.405479452054795	1:DECEASED	Normal	No	No		No	No	No	No	No	No	White	6	Complete Response		3	Male	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Bone Marrow Aspirate	CD7, CD13, CD33, CD38, CD58, CD117, CD123, partial MPO+	429	0.366666667		Standard Chemotherapy	No	DNMT3A (p.R882H; MAF 46%)|FLT3 (p.V592D; MAF 39%)|IDH1 (p.R132H, MAF 39%)|IDH2 (p.R140Q; MAF 39%)|NPM1 (p.W288fs*12; MAF 41%)|NRAS (p.Q61P; MAF 40%)|SETBP1 (p.K459E; MAF 40%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2221_BA2087	Acute Myeloid Leukemia	AML with t(9;11)(p22;q23); MLLT3-MLL	S451F	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: low, score: 4.404621318037968;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: benign, score: 0.155;AlphaMissense: pathogenicity: benign, score: 0.1185	Missense_Mutation	SNP		NA	NA	NA	13	28610138	28610138	G	A	13:g.28610138G>A	ENST00000241453.7:c.1352C>T	0.27		44	119			1	11/24					40	40	0		Alive		2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide	3	Allogeneic - Sibling|Consolidation|Induction	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate			Negative	TRUE	FALSE	FALSE	46,XX,t(9;11)(p22;q23)[20]	-1	Bone Marrow Transplant	FALSE	Negative	AML	47.178082191780824	0:LIVING	nuc ish(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL sep 3'MLLx1) [179/200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No		No	No	No	No	No	No	Unknown	-1	Complete Response		1	Female	UNMATCHED	FALSE	AML with t(9;11)(p22;q23); MLLT3-MLL	Initial Acute Leukemia Diagnosis	Peripheral Blood	brightCD4, partialCD11b, brightCD15, brightCD33, partialCD36, partialCD38, CD45, brightCD64, partialCD117, HLA-DR (86% population of cells)	0	0.066666667		Standard Chemotherapy	Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2231_BA2561	Acute Myeloid Leukemia	Acute myelomonocytic leukaemia	I836del	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Del	DEL		NA	NA	NA	13	28592635	28592637	ATG	-	13:g.28592635_28592637del	ENST00000241453.7:c.2508_2510del	0.16		21	110			2	20/24					75	75	0		Dead-Disease		3	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|CLAG (Cladribine, Cytarabine, Filgrastim)|MiDAC|ODSH (2 O, 3-O Desulfated Heparin) |SGN-CD33A	5	Consolidation|Induction	2	Standard Chemotherapy	1	CLAG (Cladribine, Cytarabine, Filgrastim)	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate		M4	Negative	TRUE	FALSE	FALSE	46,XY,add(8)(p21),t(8;19)(p11.2;q13.3)[18]/46,XY[2]	-1	Standard Chemotherapy	FALSE	Negative	AML	11.013698630136986	1:DECEASED	Normal	No	No		No	No	No	No	No	No		21	Complete Response		3	Male	UNMATCHED	FALSE	Acute myelomonocytic leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	Large population of atypical myelomonocytic cells (CD4+, bright CD64+, MPO positive, partial CD14), representing 85% of the total leukocytes	0	0.066666667		Standard Chemotherapy	Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2292_BA2386	Acute Myeloid Leukemia	AML with mutated NPM1	A680V	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: medium, score: 5.843439386046834;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.951;AlphaMissense: pathogenicity: pathogenic, score: 0.8871	Missense_Mutation	SNP		NA	NA	NA	13	28602329	28602329	G	A	13:g.28602329G>A	ENST00000241453.7:c.2039C>T	0.17		6	29			5	16/24				0.00023	52	52	0		Dead-Disease		2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)	3	Consolidation|Salvage|Induction	3	Standard Chemotherapy	1	MEC (Cytarabine, Etoposide, Mitoxantrone)	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable		M1	Negative	TRUE	FALSE	FALSE	46,XX[20]	-1	Standard Chemotherapy	FALSE	Positive	AML	20.81095890410959	1:DECEASED	nuc ish(D4Z1,D10Z1)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No		No	No	No	No	No	No	Unknown	7	Complete Response		3	Female	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD2(-), CD4(dim +), CD7(-), CD11b(-), CD13(+ and dim +), CD14(-), CD15(+), CD16(-), CD25(-), CD33(slightly bright +), CD34(-), CD36(-), CD38(variably +), CD45(+), CD56(small subset +), CD64(-), CD117(dim and variably +), CD123(variably +), HLA-DR(+), TdT(	0	0.233333333		Standard Chemotherapy	Yes	FLT3 (Foundation; A680V; MAF 6%)|FLT3 (Foundation; Y842C; MAF 2%)|KDM6A (Foundation; P738fs*2;MAF 31%)|NPM1 (Foundation; W288fs*10+; MAF 25%)|TET2 (Foundation; Q742*; MAF 45%)|TET2 (Foundation; R1712fs*6;MAF 44%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2369_BA2631	Acute Myeloid Leukemia	AML with mutated NPM1	I836del	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Del	DEL		NA	NA	NA	13	28592635	28592637	ATG	-	13:g.28592635_28592637del	ENST00000241453.7:c.2508_2510del	0.19		20	86			5	20/24					60	60	0		Alive		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|MiDAC	2	Consolidation|Induction	2	Standard Chemotherapy	1	MiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M2	Negative	TRUE	FALSE	FALSE	46,XY[21]	114	Standard Chemotherapy	FALSE	Positive	AML	91.03561643835616	0:LIVING	Normal	No	No		No	No	No	No	No	No	White	6	Complete Response		1	Male	UNMATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD7, CD13, CD33, partial CD34, CD38, CD58, CD117, CD123,HLA-DR, and MPO positive	0	0.166666667		Standard Chemotherapy	Yes	CEBPA (p. Q83fs*27 (c.245?246insTGTTCCA); MAF 50%)|FLT3 ( p.N841I; MAF 12%)|FLT3 (p.I836delI; MAF 25%)|NPM1 (p.W288fs*>9; MAF 40%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2372_BA3036	Acute Myeloid Leukemia	Acute myeloid leukaemia, NOS	E596_Y597insCQLQMVQVTGSSDNEYFYVDFRE	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608335	28608336	-	ATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGTACCATCTGTAGCTGGC	13:g.28608335_28608336insATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGTCACCTGTACCATCTGTAGCTGGC	ENST00000241453.7:c.1721_1789dup	0.28		55	141			2	14/24					43	43	0.492537313		Alive		2	Both	Yes	7+3 (Cytarabine, Idarubicin)	1	Induction	1	Standard Chemotherapy	1	7+3 (Cytarabine, Idarubicin)	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate			Positive	FALSE	FALSE	TRUE	46,XX[20]	6	Standard Chemotherapy	FALSE	Negative	AML	1.1506849315068493	0:LIVING	nucish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]	No	No		No	No	No	No	Yes	Yes	Black	6	Unknown		1	Female	UNMATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Peripheral Blood		0	0.033333333		Standard Chemotherapy	No	FLT3-D835
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2453_BA2930	Acute Myeloid Leukemia	AML with myelodysplasia-related changes	I836del	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Del	DEL		NA	NA	NA	13	28592635	28592637	ATG	-	13:g.28592635_28592637del	ENST00000241453.7:c.2508_2510del	0.10		11	102			18	20/24					76	77	0		Dead-Unknown		1	Waves1+2	Yes	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Decitabine|Incyte trial (azacitidine and JAK 1 inhibitor)	3	Consolidation|Induction	2	Standard Chemotherapy	1	Incyte trial (azacitidine and JAK 1 inhibitor)	Induction	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	M0	Negative	FALSE	FALSE	FALSE	47,XY,+8[cp15]/47,sl,der(22)t(1;22)(q11;p11.2)[2]/46,XY,dup(1)(q21q42)[cp2]	77	Standard Chemotherapy	FALSE	Negative	AML	17.0958904109589	1:DECEASED	60/100 (60%) interphase cells scored had a signal pattern reflecting trisomy 8.	Yes	No	Basal Cell Carcinoma	No	No	No	No	No	No	White	35	Complete Response	RUNX1 (p.A338Rfs*256; 76.9%)	3	Male	MATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood	Positive (The myeloid blasts are CD13, CD34, CD38, CD117, and HLA-DR;Atypical monocytic cells comprise approximately 41% of analyzed events and are CD11b, CD13, CD14, CD64, and dim HLA-DR positive. T cells show a CD4:CD8 ratio of 6.9:1 without aberrant an	472	0.866666667		Standard Chemotherapy	No	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2479_BA2012	Acute Myeloid Leukemia	AML with mutated NPM1	A680V	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: medium, score: 5.843439386046834;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.951;AlphaMissense: pathogenicity: pathogenic, score: 0.8871	Missense_Mutation	SNP		NA	NA	NA	13	28602329	28602329	G	A	13:g.28602329G>A	ENST00000241453.7:c.2039C>T	0.85		40	7			6	16/24				0.00023	60	61	2.448275862		Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Quizartinib	5	Salvage|Consolidation|Induction|Experimental|Supportive/Palliative Care	5	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	3	Etoposide, Mitoxantrone	Supportive/Palliative Care	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NOS	Positive	FALSE	TRUE	FALSE	46,XX[20]	0	Supportive/Palliative Care	FALSE	Positive	AML	12.953424657534246	1:DECEASED	normal	No	No		No	No	No	No	No	No	White	6	Complete Response		3	Female	UNMATCHED	FALSE	AML with mutated NPM1	Relapse	Bone Marrow Aspirate	partial CD7, CD13, CD33, partial CD34, partial dim CD64, CD117, and CD123 positive	0	0.233333333		Standard Chemotherapy	Yes	FLT3-ITD|NPM1
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2479_BA2352	Acute Myeloid Leukemia	AML with mutated NPM1	A680V	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: medium, score: 5.843439386046834;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.951;AlphaMissense: pathogenicity: pathogenic, score: 0.8871	Missense_Mutation	SNP		NA	NA	NA	13	28602329	28602329	G	A	13:g.28602329G>A	ENST00000241453.7:c.2039C>T	0.96		75	3			6	16/24				0.00023	60	61	7.333333333		Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Quizartinib	5	Salvage|Consolidation|Induction|Experimental|Supportive/Palliative Care	5	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	3	Etoposide, Mitoxantrone	Supportive/Palliative Care	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NOS	Positive	FALSE	FALSE	FALSE	46,XX[20]	0	Supportive/Palliative Care	FALSE	Positive	AML	12.953424657534246	1:DECEASED	normal	No	No		No	No	No	No	No	No	White	6	Complete Response		3	Female	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood	partial CD7, CD13, CD33, partial CD34, CD58, CD64, CD117, and CD123 positive	138	0.266666667		Standard Chemotherapy	No	FLT3-ITD|NPM1
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2479_BA2630	Acute Myeloid Leukemia	AML with mutated NPM1	A680V	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: medium, score: 5.843439386046834;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.951;AlphaMissense: pathogenicity: pathogenic, score: 0.8871	Missense_Mutation	SNP		NA	NA	NA	13	28602329	28602329	G	A	13:g.28602329G>A	ENST00000241453.7:c.2039C>T	0.98		53	1			6	16/24				0.00023	60	61	19		Dead-Disease		1	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Quizartinib	5	Salvage|Consolidation|Induction|Experimental|Supportive/Palliative Care	5	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	3	Etoposide, Mitoxantrone	Supportive/Palliative Care	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC	NOS	Positive	FALSE	FALSE	FALSE	46,XX[20]	0	Supportive/Palliative Care	FALSE	Positive	AML	12.953424657534246	1:DECEASED	normal	No	No		No	No	No	No	No	No	White	6	Complete Response		3	Female	UNMATCHED	FALSE	AML with mutated NPM1	Post-Chemotherapy|Residual Disease	Peripheral Blood		181	0.233333333		Standard Chemotherapy	No	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2481_BA2456	Acute Myeloid Leukemia	AML with mutated NPM1	I836del	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Del	DEL		NA	NA	NA	13	28592635	28592637	ATG	-	13:g.28592635_28592637del	ENST00000241453.7:c.2508_2510del	0.17		13	63			17	20/24					65	65	0		Dead-Unknown		2	Waves1+2	Yes	Cytarabine	1	Supportive/Palliative Care	1	Standard Chemotherapy	1	Cytarabine	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable			Negative	FALSE	FALSE	FALSE		-1	Standard Chemotherapy	FALSE	Positive	AML	0.06575342465753425	1:DECEASED	nuc ish (PML,RARA)x2[199]	Yes	No	Skin cancer	No	No	No	No	No	No	White				1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood		0	0.833333333			Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2481_BA2456	Acute Myeloid Leukemia	AML with mutated NPM1	V592G	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: low, score: 4.663439094112067;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: benign, score: 0.145;AlphaMissense: pathogenicity: ambiguous, score: 0.5083	Missense_Mutation	SNP		NA	NA	NA	13	28608281	28608281	A	C	13:g.28608281A>C	ENST00000241453.7:c.1775T>G	0.10		10	93			17	14/24					65	65	0		Dead-Unknown		2	Waves1+2	Yes	Cytarabine	1	Supportive/Palliative Care	1	Standard Chemotherapy	1	Cytarabine	Supportive/Palliative Care	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable			Negative	FALSE	FALSE	FALSE		-1	Standard Chemotherapy	FALSE	Positive	AML	0.06575342465753425	1:DECEASED	nuc ish (PML,RARA)x2[199]	Yes	No	Skin cancer	No	No	No	No	No	No	White				1	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood		0	0.833333333			Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2514_BA2103	Acute Myeloid Leukemia	AML with mutated NPM1	I836del	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Del	DEL		NA	NA	NA	13	28592635	28592637	ATG	-	13:g.28592635_28592637del	ENST00000241453.7:c.2508_2510del	0.18		20	91			16	20/24					54	54	0		Alive		2	Waves1+2	Yes	HiDAC|7+3 (Cytarabine, Idarubicin) plus Crenolanib	2	Consolidation|Induction	2	Standard Chemotherapy	1	HiDAC	Consolidation	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable			Negative	TRUE	FALSE	FALSE		88	Standard Chemotherapy	FALSE	Positive	AML	22.06027397260274	0:LIVING	nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[196],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[198] (MDS Fish Panel) | nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con	No	No		No	No	No	No	No	No	White	-1	Complete Response		1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	CD2(-), CD4(dim +), CD7(-), CD11b(-), CD13(-), CD14(-), CD15(-), CD16(-), CD33(variably +), CD34(-), CD36(-), CD38(variably +), CD45(+), CD56(partial +), CD64 (partial +), CD117(variably +), HLA-DR(-).	0	0.8		Standard Chemotherapy	Yes	FLT3 (I836DEL; MAF 18.0%)|FLT3 (N841I; MAF 8.0%)|FLT3 (V491L; MAF 3.0%)|FLT3 (V592A; MAF 1.0%)|IDH2 (R140Q; MAF 47.0%)|NPM1 (W288FS*10+; MAF 35.0%)|SRSF2 (P95L; MAF 41.0%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2559_BA2427	Acute Myeloid Leukemia	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Y572C	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: medium, score: 5.851119593087318;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.975;AlphaMissense: pathogenicity: ambiguous, score: 0.4718	Missense_Mutation	SNP		NA	NA	NA	13	28608341	28608341	T	C	13:g.28608341T>C	ENST00000241453.7:c.1715A>G	0.17		17	84			2	14/24					53	60	0		Alive		4	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|3+7 (Cytarabine, Daunorubicin)|Azacitidine, Gemtuzumab|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Cytarabine	5	Induction|Re-induction	2	Standard Chemotherapy	1	Azacitidine, Gemtuzumab	Re-induction	Relapse	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial		M4eo	Negative	FALSE	TRUE	FALSE	47,XX,t(16;16)(p13;q22),+22[20]	-1	Standard Chemotherapy	FALSE	Negative	AML	82.91506849315068	0:LIVING	CBFB inv(16)	No	No		No	No	No	No	No	No		-1	Refractory		1	Female	UNMATCHED	FALSE	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Post-Chemotherapy|Relapse	Peripheral Blood	Positive (ABNORMAL CD34+ BLAST POPULATION, 11%, EXPRESSING CD117, CD15,CD13, CD33 (DIM), AND HLA-DR, WITH ABERRANT EXPRESSION OF CD19(DIM-PARTIAL) AND CD22 (DIM-PARTIAL)ABNORMAL MONOCYTIC POPULATION EXPRESSING CD64, CD14, CD34(DIM), CD2 (DIM), CD7 (DIM), 	0	0.1		Standard Chemotherapy	Yes	FLT3-D835
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2606_BA3379	Acute Leukemias of Ambiguous Lineage	Acute undifferentiated leukaemia	I836del	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Del	DEL		NA	NA	NA	13	28592635	28592637	ATG	-	13:g.28592635_28592637del	ENST00000241453.7:c.2508_2510del	0.12		26	190			5	20/24					34	34	0.041666667		Alive		1	Waves3+4	Yes	Cyclophosphamide, TBI|7+3 (Cytarabine, Idarubicin)|HAM-VD (Cytarabine, Mitoxantrone, Vincristine, Dexamethasone)	3	Allogeneic - Sibling|Consolidation|Induction|Re-induction	4	Standard Chemotherapy|Bone Marrow Transplant	2	Cyclophosphamide, TBI	Allogeneic - Sibling	Initial Diagnosis	Acute Leukaemias Of Ambiguous Lineage	Intermediate	NON-HISPANIC		Positive	TRUE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	FALSE	Negative	ALAL	99.35342465753425	0:LIVING	cryptic t(14;21) (54.5% of cells had three signals for AML1)	No	No		No	No	No	No	No	No	White	-1	Refractory		1	Male	UNMATCHED	FALSE	Acute undifferentiated leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2 , CD7 , CD13 , CD34 , dim CD45 , CD117 , HLA-DR , TdT positive	0	0.166666667		Standard Chemotherapy	Yes	FLT3-D835|FLT3-ITD
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2669_BA3447	Acute Myeloid Leukemia	AML without maturation	I836del	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Del	DEL		NA	NA	NA	13	28592635	28592637	ATG	-	13:g.28592635_28592637del	ENST00000241453.7:c.2508_2510del	0.32		38	79			6	20/24					67	67	0		Dead-Disease		7	Waves3+4	No		0		0		0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate		M1	Negative	TRUE	FALSE	FALSE	46XY		None	FALSE	Negative	AML	8.186301369863013	1:DECEASED		No	No		No	No	No	No	No	No	White				1	Male	UNMATCHED	FALSE	AML without maturation	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	positive for CD13, CD33, CD34, CD38, CD117, HLA-DR, cytoplasmic myeloperoxidase (subset), and TdT (subset)	0	0.3			Yes	FLT3-ITD|NRAS|U2AF1
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2713_BA3110	Acute Myeloid Leukemia	Acute Myeloid Leukemia	A680V	OncoKB: Likely Oncogenic, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: medium, score: 5.843439386046834;SIFT: impact: deleterious, score: 0;Polyphen-2: impact: probably_damaging, score: 0.951;AlphaMissense: pathogenicity: pathogenic, score: 0.8871	Missense_Mutation	SNP		NA	NA	NA	13	28602329	28602329	G	A	13:g.28602329G>A	ENST00000241453.7:c.2039C>T	0.39		34	54			4	16/24				0.00023	51	51	0		Dead-Unknown		2	Waves3+4	No		0		0		0	NONE	NONE	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate	HISPANIC		Negative	unknown	FALSE	unknown	46,XY[20]		None	FALSE	Negative	AML	3.978082191780822	1:DECEASED	Normal	No	No		No	No	No	No	No	No					1	Male	MATCHED	FALSE	Unknown	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate		0	0.233333333			Yes	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2606_BA3379	Acute Leukemias of Ambiguous Lineage	Acute undifferentiated leukaemia	Q640_V641insTGSSDNEYFYVDFREYEYDLKWEFPRENLEFGKNGMCQMFLQHFFSIGKSLKCTYSPFVFAGKVLGSGAFGKVMNATAYGISKTGVSIQ	OncoKB: Unknown, level NA, resistance NA;CIViC: NA;CancerHotspot: yes;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28608312	28608313	-	CTGGATTGAGACTCCTGTTTTGCTAATTCCATAAGCTGTTGCGTTCATCACTTTTCCAAAAGCACCTGATCCTAGTACCTTCCCTGCAAAGACAAATGGTGAGTACGTGCATTTTAAAGATTTTCCAATGGAAAAGAAATGCTGCAGAAACATTTGGCACATTCCATTCTTACCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGT	13:g.28608312_28608313insCTGGATTGAGACTCCTGTTTTGCTAATTCCATAAGCTGTTGCGTTCATCACTTTTCCAAAAGCACCTGATCCTAGTACCTTCCCTGCAAAGACAAATGGTGAGTACGTGCATTTTAAAGATTTTCCAATGGAAAAGAAATGCTGCAGAAACATTTGGCACATTCCATTCTTACCAAACTCTAAATTTTCTCTTGGAAACTCCCATTTGAGATCATATTCATATTCTCTGAAATCAACGTAGAAGTACTCATTATCTGAGGAGCCGGT	ENST00000241453.7:c.1744_1920dup	0.17		67	333			5	14/24					34	34	0.041666667		Alive		1	Waves3+4	Yes	Cyclophosphamide, TBI|7+3 (Cytarabine, Idarubicin)|HAM-VD (Cytarabine, Mitoxantrone, Vincristine, Dexamethasone)	3	Allogeneic - Sibling|Consolidation|Induction|Re-induction	4	Standard Chemotherapy|Bone Marrow Transplant	2	Cyclophosphamide, TBI	Allogeneic - Sibling	Initial Diagnosis	Acute Leukaemias Of Ambiguous Lineage	Intermediate	NON-HISPANIC		Positive	TRUE	FALSE	FALSE	46,XY[20]	-1	Bone Marrow Transplant	FALSE	Negative	ALAL	99.35342465753425	0:LIVING	cryptic t(14;21) (54.5% of cells had three signals for AML1)	No	No		No	No	No	No	No	No	White	-1	Refractory		1	Male	UNMATCHED	FALSE	Acute undifferentiated leukaemia	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2 , CD7 , CD13 , CD34 , dim CD45 , CD117 , HLA-DR , TdT positive	0	0.166666667		Standard Chemotherapy	Yes	FLT3-D835|FLT3-ITD
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2304_BA2000	Acute Myeloid Leukemia	Acute myeloid leukaemia, NOS	V491L	OncoKB: Unknown, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: low, score: 4.385167788796637;SIFT: impact: tolerated, score: 0.21;Polyphen-2: impact: benign, score: 0.077;AlphaMissense: pathogenicity: benign, score: 0.1111	Missense_Mutation	SNP		NA	NA	NA	13	28609758	28609758	C	G	13:g.28609758C>G	ENST00000241453.7:c.1471G>C	0.10		8	73			14	12/24					24	24	0.666666667		Dead-Disease	mono	3	Waves1+2	Yes	Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG (Cladribine, Cytarabine, Filgrastim)|Azacitidine|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)	6	Allogeneic - Sibling|Consolidation|Salvage|Induction|Re-induction	5	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Fludarabine	Allogeneic - Sibling	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse			Positive	TRUE	FALSE	FALSE	46,XX[20]	-1	Bone Marrow Transplant	FALSE	Negative	AML	20.81095890410959	1:DECEASED	Normal	No	No		No	No	No	No	No	No		-1	Refractory		1	Female	MATCHED	FALSE	Acute myeloid leukaemia, NOS	Initial Acute Leukemia Diagnosis	Leukapheresis	weak CD4, partial  CD7, partial CD11b, CD13, CD33, partial CD34, weak CD64,  CD117, MPO, and HLA-DR	0	0.7		Standard Chemotherapy	Yes	CEBPA (p.Gln41fs; MAF 4%)|FLT3-ITD (p.Glu611_Phe612ins27; MAF 8%)|JAK3 (p.Gln865Glu; MAF 48.9%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2366_BA2714	Acute Myeloid Leukemia	AML with mutated NPM1	V491L	OncoKB: Unknown, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: low, score: 4.385167788796637;SIFT: impact: tolerated, score: 0.21;Polyphen-2: impact: benign, score: 0.077;AlphaMissense: pathogenicity: benign, score: 0.1111	Missense_Mutation	SNP		NA	NA	NA	13	28609758	28609758	C	G	13:g.28609758C>G	ENST00000241453.7:c.1471G>C	0.35		18	33			16	12/24					60	60	0		Dead-Disease		1	Waves1+2	Yes	FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)	3	Salvage|Induction|Re-induction	3	Standard Chemotherapy	1	Azacitidine	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable	NON-HISPANIC	M4	Negative	TRUE	FALSE	FALSE	46,XY[20]	6	Standard Chemotherapy	FALSE	Positive	AML	28.6027397260274	1:DECEASED	Normal	No	No		No	No	No	No	No	No	White	167	Complete Response		2	Male	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Peripheral Blood	dim CD4, dim CD7, dim CD11b, CD13, CD33, variable CD34, CD38, CD58, variable CD64, CD117, CD123, dim HLA-DR, MPO, and dim TdT	0	0.766666667		Standard Chemotherapy	Yes	FLT3-V491L (p.V491L; MAF 51%)|NPM1 (p.W288fs*12; MAF 50%)|SF3B1 (p.K666Q; MAF 47%)|WT1 (p.Y395fs*51; MAF 49%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2385_BA2377	Acute Myeloid Leukemia	AML with t(9;11)(p22;q23); MLLT3-MLL	L442_A443dup	OncoKB: Unknown, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: NA;SIFT: NA;Polyphen-2: NA;AlphaMissense: NA	In_Frame_Ins	INS		NA	NA	NA	13	28610161	28610162	-	GCGAGC	13:g.28610161_28610162insGCGAGC	ENST00000241453.7:c.1323_1328dup	0.28		25	65			23	11/24					35	35	2.448275862	ASXL1 (p.D943Qfs*6; 38.5%)	Alive		2	Waves1+2	Yes	7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide, Thymoglobulin	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	3	Standard Chemotherapy|Bone Marrow Transplant	2	Busulfan, Cyclophosphamide, Thymoglobulin	Allogeneic - Matched Unrelated Donor	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Intermediate			Positive	TRUE	FALSE	FALSE	46,XY,der(4)t(4;9;11)(p14;p22;q23),der(9)del(9)(p13p22)t(4;9;11),der(11)t(4;9;11)[19]/46,XY[1].isht(4;9;11)(5'MLL-,3'MLL+;5'MLL-,3'MLL-;5'MLL+,3'MLL-)[1]	-1	Bone Marrow Transplant	FALSE	Positive	AML	38.00547945205479	0:LIVING	nuc ish(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL sep 3'MLLx1)[189/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198]	No	No		No	No	No	No	No	No		-1	Complete Response		1	Male	MATCHED	FALSE	AML with t(9;11)(p22;q23); MLLT3-MLL	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate	CD2(-), CD4(+), CD7(-), CD11b(+), CD13(partial +), CD14(-), CD15(+), CD16(-), CD33(+), CD34(-), CD36(partial +), CD45(+), CD56(variably +), CD64(+), CD117(partial +), CD79a(-), HLA-DR(+), MPO(-), Tdt(-)	0	1.1		Standard Chemotherapy	Yes	ASXL1 (D943fs*6; MAF 25%)|FLT3-D835 (BMA)|KMT2A (MLL-AF9 fusion)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2619_BA3138	Acute Myeloid Leukemia	AML with myelodysplasia-related changes	V491L	OncoKB: Unknown, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: low, score: 4.385167788796637;SIFT: impact: tolerated, score: 0.21;Polyphen-2: impact: benign, score: 0.077;AlphaMissense: pathogenicity: benign, score: 0.1111	Missense_Mutation	SNP		NA	NA	NA	13	28609758	28609758	C	G	13:g.28609758C>G	ENST00000241453.7:c.1471G>C	0.13		60	396			6	12/24					56	56	0	ASXL1 (p.G646Wfs*12; 31.3%)	Dead-Disease		1	Waves3+4	Yes	HAM (Cytarabine, Mitoxantrone)|Azacitidine|Vyxeos (Daunorubicin, Cytarabine - liposomal)|MBG453 (TIM-3 inhibitor)|Decitabine, Ruxolitinib	5	Salvage|Induction|Maintenance|Re-induction	4	Standard Chemotherapy|Targeted Therapy - Other	2	Decitabine, Ruxolitinib	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC		Negative	FALSE	FALSE	TRUE	49,XY,+10,+13,+21[1]/51,sl,+9,+15[1]/49,sl,+8,-10[12]/46,XY[6]	-1	Standard Chemotherapy	FALSE	Negative	AML	5.391780821917808	1:DECEASED	Chromosome 9:  With all chromosome 9 probes (ABL, ASS and NUP214) ~20% of cells had three signals, consistent with trisomy 9.  | PML (15q24): 17% of cells had three signals, consistent with trisomy 15.  | RUNX1 (21q22):  69% of cells had three signals, co	No	No		No	No	Yes	Yes	No	No	White	5	Refractory	RUNX1 (p.S322*; 17.2%)	3	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood		48	0.3		Standard Chemotherapy	No	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2619_BA3229	Acute Myeloid Leukemia	AML with myelodysplasia-related changes	V491L	OncoKB: Unknown, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: low, score: 4.385167788796637;SIFT: impact: tolerated, score: 0.21;Polyphen-2: impact: benign, score: 0.077;AlphaMissense: pathogenicity: benign, score: 0.1111	Missense_Mutation	SNP		NA	NA	NA	13	28609758	28609758	C	G	13:g.28609758C>G	ENST00000241453.7:c.1471G>C	0.48		182	198			4	12/24					56	56	0	ASXL1 (p.G646Wfs*12; 37.6%)	Dead-Disease		1	Waves3+4	Yes	HAM (Cytarabine, Mitoxantrone)|Azacitidine|Vyxeos (Daunorubicin, Cytarabine - liposomal)|MBG453 (TIM-3 inhibitor)|Decitabine, Ruxolitinib	5	Salvage|Induction|Maintenance|Re-induction	4	Standard Chemotherapy|Targeted Therapy - Other	2	Decitabine, Ruxolitinib	Salvage	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Adverse	NON-HISPANIC		Negative	FALSE	FALSE	TRUE	49,XY,+10,+13,+21[6]/51,idem,+9,+15[14]	-1	Standard Chemotherapy	FALSE	Negative	AML	5.391780821917808	1:DECEASED	Chromosome 9:  With all chromosome 9 probes (ABL, ASS and NUP214) ~20% of cells had three signals, consistent with trisomy 9.  | PML (15q24): 17% of cells had three signals, consistent with trisomy 15.  | RUNX1 (21q22):  69% of cells had three signals, co	No	No		No	No	Yes	Yes	No	No	White	5	Refractory	RUNX1 (p.S322*; 49.8%)	3	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Peripheral Blood	partial CD11b, CD13, partial CD25, CD33, CD34, CD38, partial CD56, CD117 and HLA-DR positive	0	0.233333333		Standard Chemotherapy	Yes	ASXL1 (p.G646fs*12; VAF 36%)|BRAF (p.G469R; VAF 36%)|CREBBP (p.F1703fs*33; VAF 12%)|CSF3R (p.T618I; VAF 5%)|EZH2 (p.F672L; VAF 73%)|FLT3 (p.V491L; VAF 53%)|NRAS (p.G12D; VAF 10%)|RUNX1 (p.G199E; VAF 7%)|RUNX1 (p.S322*; VAF 52%)
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2619_BA3388	Acute Myeloid Leukemia	AML with myelodysplasia-related changes	V491L	OncoKB: Unknown, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: low, score: 4.385167788796637;SIFT: impact: tolerated, score: 0.21;Polyphen-2: impact: benign, score: 0.077;AlphaMissense: pathogenicity: benign, score: 0.1111	Missense_Mutation	SNP		NA	NA	NA	13	28609758	28609758	C	G	13:g.28609758C>G	ENST00000241453.7:c.1471G>C	0.14		64	401			5	12/24					56	56	0	ASXL1 (p.G646Wfs*12; 37.2%)	Dead-Disease		1	Waves3+4	Yes	HAM (Cytarabine, Mitoxantrone)|Azacitidine|Vyxeos (Daunorubicin, Cytarabine - liposomal)|MBG453 (TIM-3 inhibitor)|Decitabine, Ruxolitinib	5	Salvage|Induction|Maintenance|Re-induction	4	Standard Chemotherapy|Targeted Therapy - Other	2	Decitabine, Ruxolitinib	Salvage	Residual	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	NonInitial	NON-HISPANIC		Negative	FALSE	FALSE	TRUE	49,XY,+10,+13,+21[1]/51,sl,+9,+15[1]/49,sl,+8,-10[12]/46,XY[6]	-1	Standard Chemotherapy	FALSE	Negative	AML	5.391780821917808	1:DECEASED	Chromosome 9:  With all chromosome 9 probes (ABL, ASS and NUP214) ~20% of cells had three signals, consistent with trisomy 9.  | PML (15q24): 17% of cells had three signals, consistent with trisomy 15.  | RUNX1 (21q22):  69% of cells had three signals, co	No	No		No	No	Yes	Yes	No	No	White	5	Refractory	RUNX1 (p.S322*; 17.2%)	3	Male	UNMATCHED	FALSE	AML with myelodysplasia-related changes	Post-Chemotherapy|Residual Disease	Peripheral Blood		55	0.266666667		Standard Chemotherapy	No	
FLT3	Acute Myeloid Leukemia (OHSU, Cancer Cell 2022)	aml_ohsu_2022_2636_BA3422	Acute Myeloid Leukemia	AML with mutated NPM1	M659V	OncoKB: Unknown, level NA, resistance NA;CIViC: NA;CancerHotspot: no;3DHotspot: no			MutationAssessor: impact: low, score: 4.944609790369212;SIFT: impact: deleterious, score: 0.01;Polyphen-2: impact: benign, score: 0.114;AlphaMissense: pathogenicity: benign, score: 0.2658	Missense_Mutation	SNP		NA	NA	NA	13	28602393	28602393	T	C	13:g.28602393T>C	ENST00000241453.7:c.1975A>G	0.34		37	73			7	16/24					72	72	0		Alive		5	Waves3+4	Yes	Venetoclax (ABT-199), Azacitidine	1	Induction	1	Standard Chemotherapy	1	Venetoclax (ABT-199), Azacitidine	Induction	Initial Diagnosis	Acute Myeloid Leukaemia (AML) And Related Precursor Neoplasms	Favorable			Negative	TRUE	FALSE	FALSE	46,XX[20]	-1	Standard Chemotherapy	FALSE	Positive	AML	17.128767123287673	0:LIVING	Normal	No	No		No	No	No	No	No	No	Black	-1	Complete Response		1	Female	MATCHED	FALSE	AML with mutated NPM1	Initial Acute Leukemia Diagnosis	Bone Marrow Aspirate		0	0.333333333		Standard Chemotherapy	Yes	GATA2 (A372T; VAF 48%)|NPM1 (W288Cfs*12; VAF 39%)|TET2 ( E843*; VAF 47%)|TET2 (T1726Lfs*19; VAF 51%)
